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Opioid use disorder (OUD) is a debilitating, chronic psychiatric disorder. Opioid 
substitution treatment (OST) is associated with the suppression of illicit drug use, 
criminal offending and improved health. Efficacy trials estimate the response to short 
interventions and follow-ups but may not reflect outcomes from routinely delivered 
OST. National administrative databases circumvent this limitation. This thesis 
addresses the impact of publicly funded treatment for OUD using the English National 
Drug Treatment Monitoring System (NDTMS). 
Aims  
The thesis has three aims: to identify sub-populations of OUD patients at treatment 
admission and estimate their likelihood of completing treatment successfully over the 
next five years; to identify longitudinal sub-populations among those continuously 
enrolled in OST for five years based on heroin use and estimate their likelihood of 
completing treatment successfully; to identify longitudinal sub-populations based on 
alcohol and other drug use and estimate whether membership modifies the likelihood 
of completing treatment successfully. 
Design and method 
National, five-year, prospective, observational cohort studies of community specialist 
treatment for OUD by data linkage with NDTMS and fatal drug-related poisoning data 
from the Office for National Statistics. The population for Study 1 was adults who 
entered treatment between 1 April 2008 and 31 March 2009 (n=54,347). The cohort for 
Study 2 and Study 3 was a subset of Study 1 who were continuously enrolled in 
treatment for five years (n=7,719). An objective summative outcome measure was 
used, comprised of Successful Completion of treatment (clinician-verified) with No Re-
presentation (SCNR) to treatment in the following six months. Analysis was by Latent 
 iii 
Class Analysis, Multilevel Latent Class Growth Analysis, Multinomial Logistic 
Regression and Multilevel Logistic Regression. 
Findings 
One fifth of discharged patients in Study 1 achieved remission from OUD. Of the four 
sub-populations of heroin users identified from their co-presenting substance use 
disorder at admission, heroin and crack cocaine users were less likely to recover. 
Those continuously in treatment for over two years were more likely to recover. Five 
longitudinal sub-populations (trajectories) of heroin users were identified for Study 2. 
Patients whose heroin use tended towards abstinence were more likely to recover in 
Year 6 and Year 7. Adjunctive psychosocial intervention during OST increased the 
likelihood of remission. Study 3 identified between three and five trajectory classes for 
crack cocaine, alcohol, cannabis and unspecified drug use. The continued high-level 
heroin use trajectory class during OST was associated with high-level crack cocaine 
and alcohol use and increasing unspecified drug use. Increasing use of crack cocaine 
was associated with a decreased likelihood that long-term OST was completed 
successfully. 
Conclusions 
This thesis presents the first national long-term evaluations of the impact of publicly 
funded treatment for OUD in England. As relapse requiring treatment is relatively 
common in the first six months following treatment completion, these studies highlight 
the importance of incorporating re-presentation to treatment in the assessment of 
remission. Sub-population analysis is an important facet in evaluating patients’ 
progress through treatment, produces novel insights into the effectiveness of routinely 
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Chapter 1  INTRODUCTION 
This thesis investigates the long-term effectiveness of treatment interventions for illicit 
drug addiction. The focus is on heroin, a powerful euphoric analgesic associated with 
high risk of morbidity and mortality. Data for the thesis comes from an England-wide 
administrative database from which a cohort is identified of approximately 50,000 
people seeking treatment from specialist clinics in the National Health Service (NHS) 
and non-governmental organisations (NGO) for heroin addiction (formal diagnosis: 
opioid use disorder [OUD]). The thesis has an applied goal – to identify and 
characterise differential response to treatment to and inform clinical practice and policy 
on the treatment of drug addiction. 
Throughout this thesis, I use the term ‘opiates’ to refer to heroin and all organic 
compounds which derive from the poppy plant. Opioids, on the other hand, refer to all 
drugs that act on the opioid receptor system in the brain, including synthetic drugs that 
bear little resemblance to the molecular structure of organic opiates. While OUD is a 
term that incorporates the misuse of all opioid drugs, this thesis is concerned only with 
individuals for whom heroin poses a significant problem. Throughout, the terms heroin, 
opiate and opioid are used synonymously unless otherwise stated. Further, the term 
OUD is utilised as the preferred terminology for those individuals accessing specialist 
addiction treatment services in England for heroin addiction problems. 
The thesis is presented in six chapters. In Chapter 1, I provide a brief historical 
overview of the development of heroin as a medical problem in England and describe 
the nature and symptoms of OUD. Heroin (diamorphine) was discovered approximately 
150 years ago. Since that time, when pharmaceutical diamorphine was largely confined 
to a small group of people prescribed the drug by a physician, problematic use of illicitly 
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manufactured heroin has increased to a widely recognised problem exerting a 
significant effect on contemporary society. Over time, the national strategic response 
has also shifted: penal and medical policies have been implemented and adapted; 
information systems providing critical evidence on the effectiveness of treatment have 
been established and disestablished; and funding and policy support for treatment has 
waxed and waned. Today, one of the most significant public health indicators of the 
heroin epidemic – fatal overdose – is at an all-time high.  
Large scale treatment effectiveness studies consistently demonstrate that exposure to 
treatment interventions is associated with suppression in the use of heroin, a reduction 
in the cost to society in terms of criminal offending and criminal justice-related costs, 
and a reduction in the risk of death and the transmission of blood-borne viruses. These 
studies are, however, expensive, time consuming, necessarily formed of only a sample 
of those affected and are not designed to capture change in the context of ongoing, 
continuous, treatment. National administrative databases circumvent these limitations, 
and provide near real-time performance management reports to treatment services, 
treatment commissioners and those public bodies responsible for overseeing the 
delivery and effectiveness of treatment. 
In Chapter 2, I provide an overview of the methodologies employed in three 
interconnected analyses for the thesis – each published in a scientific journal during the 
course of my studies for a PhD. Taken together, these studies shine light on the 
effectiveness of treatment for OUD over five-years. Follow-up studies over this time 
frame are rare in addiction science. Using latent cross-sectional and longitudinal 
statistical procedures, I identify sub-groups of heroin users at the start of treatment and 
over time while enrolled in treatment. 
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In Study 1, reported in Chapter 3, I selected all individuals accessing treatment for 
OUD in England in 2008/09 and followed them over a five-year period (until the end of 
2013/14). Heroin users presenting to treatment are far from homogenous, and four 
sub-populations are identified according to the concurrent problematic psychoactive 
substances with which they present to treatment using Latent Class Analysis (LCA). I 
introduce an objective summative (proxy) measure of treatment effectiveness (i.e. the 
successful completion with no re-presentation to treatment within six months). From 
this analysis, I demonstrate that presenting to treatment with concurrent cocaine (a 
powerful, addictive stimulant) is negatively associated with the likelihood of recovery 
from OUD.  
In Chapter 4, I present Study 2, which contains a detailed assessment of those 
patients who had been continuously enrolled in opioid substitution treatment (OST; with 
oral liquid methadone or sublingual tablet buprenorphine) for the five-year period. Sub-
populations are identified based on their relative longitudinal response to treatment. 
Using Latent Class Growth Analysis (LCGA), I show that patients whose heroin use 
trajectory places them on a course towards abstinence are those most likely to be 
found to have overcome OUD in the subsequent Year 6 and Year 7 phase of follow-up. 
Study 3 is reported in Chapter 5. Here, I again use LCGA to model the frequency of 
use of other drugs and alcohol during heroin treatment. By examining the relationship 
between heroin and other drug and alcohol change trajectories, I demonstrate that 
those patients who make the least improvement in terms of heroin are generally those 
clients for whom crack cocaine is also a persistently used substance. 
Chapter 6 explores the clinical and policy implications of the three studies presented in 
this thesis. It integrates the findings within the wider literature and sets out the 
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implications of these findings for the ongoing utilisation and development of the English 
National Drug Treatment Monitoring System (NDTMS). The strengths and limitations of 
the studies are reviewed and limitations of the national monitoring system are 
considered. Chapter 6 concludes with the next immediate research question using the 
cohort described throughout this thesis.  
1.1 HEROIN 
1.1.1 A BRIEF HISTORY OF HEROIN 
Heroin is a derivative of the poppy plant Papaver somniferum, and was first 
synthesised almost 150 years ago in the United Kingdom (Wright, 1874). Heroin was 
not the first drug to come from this plant. Opium had been used for centuries by this 
point, and morphine was isolated from the poppy extract in 1805 (Krishnamurti and 
Rao, 2016). Diacetylmorphine, as it was then known, was later synthesised by simple 
acetylisation of morphine at St. Mary’s, London, in 1874. This innovation went largely 
unnoticed until it was rediscovered twenty years later, apparently independently, at 
which point the seeds of the modern-day epidemic were planted. In 1898, the German 
pharmaceutical company, Bayer & Company, marketed the drug as a cough 
suppressant and it was used in medicine in many countries around the world. The 
name ‘heroin’ was coined by Bayer & Co., and alludes to an ancient Greek hero 
honoured on account of his deeds (Sneader, 1998).  
The addictive liability of heroin was not recognised in the early years of availability. It 
was proactively advertised in medical journals as preferential to morphine as it was not 
habit forming (Phillips, 1912). Nonetheless, the non-therapeutic – or illicit use – of 
heroin soon emerged. Heroin pills could be crushed and sniffed into the nose, much 
like snuff tobacco, and reports of smoking heroin pills began to emerge from Shanghai 
in the 1920s (Phillips, 1912; Strang et al., 1997a). The smoking of pills involved gently 
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heating a pill inserted into a hole drilled into a porcelain vase and smoking the fumes 
through a bamboo tube. This process was later refined in Hong Kong during the 1950s 
into a technique that came to be known as ‘chasing the dragon’. This new technique 
involved heating heroin powder over tin foil and inhaling the sublimated vapours. 
Chasing the dragon quickly spread out from Hong Kong. Its use was noted in Thailand 
in the 1960s; then in Singapore, Burma, Malaysia and the Netherlands in the 1970s; 
and in India and the UK in the 1980s, and Switzerland and Spain in the 1990s (Strang 
et al., 1997a). 
While addiction to morphine and heroin was a recognised problem in England during 
the 1920s, the prevalence of the problem was considered rare and diminishing 
(Berridge, 1980; Rolleston, 1926). The first epidemic of illicit heroin use in England 
appears to have begun in London in the early 1960s, at a time when virtually all 
available heroin came in the form of pharmaceutical tablets (Strang et al., 1997b). By 
1966 it had spread beyond London (James, 1969). This was England’s first heroin 
‘epidemic’ – ‘epidemic’ in the sense that the heroin habit (a learned behaviour) was 
spread by users to friends and acquaintances (Reuter and Stevens, 2008). One 
patient, for example, was reported to have introduced 11 other people to heroin 
addiction (Chapple and Marks, 1965). The increase in heroin addiction during the 
1960s coincided with an arrival of ‘fifty’ (James, 1969) or ‘hundreds’ (Strang et al., 
1993) of injecting addicts from the United States (US) and Canada seeking to capitalise 
on England’s propensity to prescribe heroin to addicts and growth of an injecting 
subculture in London emerged. It was thought at the time that the rise in the number of 
new addicts was due in large part to doctors prescribing heroin in greater amounts than 
required by patients, enabling patients to sell the surplus (Edwards, 1969; Patricia, 
1965). The profile of users also changed during the 1960s. No longer were they 
middle-aged and older, who had developed the condition through prescribing for 
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legitimate medical problems, they were younger people who had acquired their 
addiction through illicit means. The ratio of therapeutic to illicit acquisition of addiction 
had altered substantially, from 5:1 to 1:4 (James, 1969). 
There were two further epidemics in England during the first half of the 1980s and the 
first half of the 1990s (Strang and Taylor, 1997). The epidemic of the 1980s was 
probably influenced by the increased imports of illicit heroin from South East Asia in the 
early 1970s and from South West Asia in the late 1970s (Strang et al., 1997b). The 
difference between the decades is stark. In 1989 heroin was concentrated in the North 
West of England, East of England and in London, but by 1997 the majority of the 
country had witnessed new outbreaks (Parker et al., 1998).  
England was not alone among the countries of Great Britain in experiencing a rapid 
onset of heroin addiction within its population. There were what were considered minor 
waves of heroin use in Glasgow (Scotland) in 1967, 1971 and 1976, but the major shift 
occurred between 1980 and 1981 when referrals to the two available drug clients 
increased by more than 500% to 174 individuals (Ditton and Speirits, 1982). By 1984, 
almost 300 Scots were being treated for opioid addiction (Drummond, 1986). Heroin is 
now recognised as the most harmful type of drug in health terms, and there are now an 
estimated 17.7 million users worldwide (United Nations Office on Drugs and Crime, 
2017). 
1.1.2 OPIOID USE DISORDER 
Heroin addiction is a debilitating and often chronic bio-behavioural disorder. It is 
contemporaneously diagnosed as opioid use disorder (OUD, herein) in the American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5; American Psychiatric Association, 2013), or opioid dependence under 
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the World Health Organization’s International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10; World Health Organization, 2016). 
OUD is characterised by a set of cognitive, behavioural and physiological symptoms, 
and chronic consumption of heroin is usually accompanied by several negative 
consequences. One of the earliest definitions described a heroin addict as “[a] person 
who, not requiring the continued use of a drug for the relief of the symptoms of organic 
disease, has acquired, as a result of repeated administration, an overpowering desire 
for its continuance, and in whom withdrawal of the drug leads to definite symptoms of 
mental or physical distress or disorder" (Rolleston, 1926, p392).  
Both the nosology (i.e. how a disorder is classified) and the nomenclature (i.e. how a 
disorder is named) of addiction has changed markedly in the 60 years since DSM-1 
was first published in 1952 (Nathan et al., 2016; Robinson and Adinoff, 2016). The first 
DSM used the term ‘drug addiction’ and categorised it under sociopathic personality 
disorder (American Psychiatric Association, 1952). Sixteen years later, DSM-II applied 
the term ‘drug dependence’ and shifted the categorisation to that of ‘personality 
disorder and certain other non-psychotic mental disorders’ (American Psychiatric 
Association, 1968). From DSM-III to DSM-5, the disorder was classified independently 
although the name given to it changed from ‘substance use disorders’ (American 
Psychiatric Association, 1980) to ‘psychoactive substance use disorders’ (American 
Psychiatric Association, 1987) to ‘substance-related disorders’ (American Psychiatric 
Association, 1994) and, finally, to its current form of ‘substance-related and addictive 
disorders’ (American Psychiatric Association, 2013).  
DSM-III drew a distinction between opioid abuse and opioid dependence, and this 
terminology continued through DSM-IV. Just as the term ‘addiction’, however, was 
8  
supplanted with the term ‘dependence’, the latest version of the manual (DSM-5) has 
now adopted to the term ‘opioid use disorder’ (OUD). In doing so, the DSM system has 
removed the concept of heroin ‘abuse’. OUD is now conceptualised as falling on a 
severity continuum, ranging from mild, when two or three criteria are met to moderate 
(four or five criteria) and severe (six or more criteria) (see Table 1.1). 
Table 1.1 Diagnostic criteria for opioid use disorder (DSM-5) 
 
1. Opioids are often taken in larger amounts or over a longer period than was 
intended.  
2. There is a persistent desire or unsuccessful efforts to cut down or control 
opioid use.  
3. A great deal of time is spent in activities necessary to obtain the opioid, use the 
opioid, or recover from its effects.  
4. Craving, or a strong desire or urge to use opioids.  
5. Recurrent opioid use resulting in a failure to fulfil major role obligations at work, 
school, or home.  
6. Continued opioid use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of opioids.  
7. Important social, occupational, or recreational activities are given up or 
reduced because of opioid use.  
8. Recurrent opioid use in situations in which it is physically hazardous.  
9. Continued opioid use despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or 
exacerbated by the substance.  
10. Tolerance, as defined by either of the following:  
a. A need for markedly increased amounts of opioids to achieve intoxication or 
desired effect.  
b. A markedly diminished effect with continued use of the same amount of an 
opioid.  
11. Withdrawal, as manifested by either of the following:  
a. The characteristic opioid withdrawal syndrome  
b. Opioids (or a closely related substance) are taken to relieve or avoid 
withdrawal symptoms. 
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Similar evolutionary changes can be seen in the ICD (Aggarwal et al., 2008; Maddux 
and Desmon, 2000; Saunders, 2006). It was not until publication of the seventh edition 
of the ICD, ICD-7, in 1967 that substance-related problems were incorporated into this 
classification system (World Health Organization, 1967). The current edition, the ICD-
10, was first published in 1992 and subject to several iterations (World Health 
Organization, 1992; 2016) and uses the term harmful use for those whose opioid use is 
causing damage to their physical or mental health. The term opioid dependence is 
applied to those individuals with at least three symptoms present of those listed in 
Table 1.2. 
Table 1.2 Diagnostic criteria for opioid dependence (ICD-10) 
 
(a) a strong desire or sense of compulsion to take the substance; 
(b) difficulties in controlling substance-taking behaviour in terms of its onset, 
termination, or levels of use; 
(c) a physiological withdrawal state when substance use has ceased or been 
reduced, as evidenced by: the characteristic withdrawal syndrome for the 
substance; or use of the same (or a closely related) substance with the intention 
of relieving or avoiding withdrawal symptoms; 
(d) evidence of tolerance, such that increased doses of the psychoactive 
substances are required in order to achieve effects originally produced by lower 
doses (clear examples of this are found in alcohol- and opiate-dependent 
individuals who may take daily doses sufficient to incapacitate or kill non-tolerant 
users); 
(e) progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time necessary to obtain or 
take the substance or to recover from its effects; 
(f) persisting with substance use despite clear evidence of overtly harmful 
consequences 
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1.1.3 THE LIFE COURSE OF OPIOID USE 
The life-course epidemiology of heroin use has been described by Darke (2011). There 
is a logic sequence of events in the development of OUD: a person must first be 
exposed to the opportunity to take the drug and, subsequently, the person must 
actually use the drug, and then take it repeatedly. In the case of opioids, it has been 
estimated that around 5% of the population are exposed to the opportunity to consume 
heroin, with males having greater exposure than females (7.8% versus 3.2%; Van 
Etten and Anthony, 1999). The same study indicated that around 20% of those 
exposed subsequently took the drug, with males and females having the same 
propensity to do so. 
Simply using the drug, however, does not inevitably lead to the development of OUD. It 
has been reported that around one quarter of opioid users will develop OUD in their 
lifetime (Anthony et al., 1994; Ashton, 2002; Degenhardt and Hall, 2012; Gable, 1993). 
This indicates that opioids confer the greatest dependence liability of all psychoactive 
substances – second only to nicotine. Initiating heroin use at an early age (before 21 
years), appears to be strongly associated with a more rapid progression to regular use, 
a longer lifetime duration of heroin use and more negative drug-related health and 
social consequences (Woodcock et al., 2015). 
Once established, OUD typically follows a chronic course, causing substantial health, 
social and economic problems. OUD is now the single largest contributor to the global 
burden of disease attributable to illicit drug use (Degenhardt et al., 2013). Over a 30 
year period, between 20% and 25% of heroin users will not demonstrate any 
appreciable decrease in consumption (Grella and Lovinger, 2011; Hser et al., 2001). 
They are likely to suffer extensive and worsening physical health and mental health 
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issues and – due to the illicit nature of heroin distribution and personal cost of addiction 
– some people also have involvement with the criminal justice system (Darke, 2011).  
1.1.4 NEUROBIOLOGY OF HEROIN 
The primary receptors in the brain involved in the reinforcing and rewarding properties 
of opioids are the mu opioid receptors, although opioids also have an affinity to delta 
and kappa receptors (Negus et al., 1993). Once the opioid is linked with the mu 
receptor, it activates the reward circuitry of the brain, the mesolimbic dopamine system. 
The ventral tegmental area in the mesolimbic system triggers the release of dopamine 
in the nucleus accumbens, generating feeling of pleasure, and appears to be the 
primary motivating reason for chronic opioid use (Kosten and George, 2002). In time, 
the release of dopamine in response to the continued administration of opioids is 
attenuated. A number of mechanisms for receptor attenuation have advanced, 
including: down-regulation (a reduction in the number of receptors); desensitisation (a 
reduced receptor response); phosphorylation (the chemical addition of phosphoryl to 
receptors), and endocytosis (internalising material from outside the receptor)(Allouche 
et al., 2014). As OUD develops, a desired ‘high’ becomes harder to achieve due to 
tolerance while at the same time the ‘low’ or ‘come down’ becomes more unpleasant, 
adding a further motivation for continued drug taking – alleviation of negative 
withdrawal symptoms.   
The consequences of this attenuation are twofold: the person is likely to need greater 
quantities of the drug to achieve the same effect and the brain’s reward system no 
longer activates (or is under-activated) in the presence of previously rewarding 
activities (Volkow et al., 2016). The latter of these may be the reason many individuals 
with OUD no longer engage in important social, occupational or recreational activities, 
one of the defining features of the disorder (American Psychiatric Association, 2013). 
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To place the impact of tolerance in context, the administration of 10mg of 
pharmaceutical diamorphine may induce respiratory failure in persons unaccustomed 
to the drug, but one patient with OUD was observed to self-administer 1,140mg of 
pharmaceutical diamorphine in 24-hours (Stimson and Oppenheimer, 1982). 
Another consequence of repeated stimulation of the dopaminergic pathway is that 
adaptations occur in the amygdala and forebrain structures. These changes induce 
negative emotions – such as dysphoria, anxiety and irritability – and particularly when 
drug supply is no longer available. The person’s negative reactivity to stressful 
situations also increase (Volkow et al., 2016).  
In the absence of opioids, people with OUD experience a set of physical withdrawal 
symptoms, including diarrhoea, sweats, chills, dilated pupils, nausea, vomiting, and 
increased heart rate or blood pressure – described as a subjectively severe but 
objectively mild set of symptoms (Farrell, 1994). Neurologically, these symptoms are 
associated with a surge of noradrenergic activity in the locus coeruleus. The locus 
coeruleus is a noradrenergic centre in the brain. It is also the anatomical intersection of 
opioid and stress signalling (Scavone et al., 2013). Alpha-2 adrenergic receptor 
agonists such as clonidine and lofexidine can be prescribed to regulate this 
hyperactivity (Gossop, 1988; Strang et al., 1999), with the latter associated with fewer 
side effects. 
1.1.5 THE EMERGENCE OF CRACK COCAINE 
Cocaine hydrochloride (usually referred to as powder cocaine) is usually snorted, but it 
can also be mixed with water and injected. This form of cocaine cannot be smoked as 
the salt is destroyed by heating (Cornish and O’Brien, 1996). ‘Crack’ cocaine is a 
colloquial name for a base form of cocaine hydrochloride that can be smoked. There 
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are two methods for creating crack cocaine from powder cocaine, the simpler of which 
involves combining it with sodium bicarbonate and heating until a solid is formed 
(Cornish and O’Brien, 1996). 
The development of crack cocaine is unclear and may have emerged by accident. As 
outlined by Streatfeild (2002), at some point during the 1970s an American trafficker 
became aware that Peruvian growers of cocaine were smoking a sulphate form they 
called ‘basé’ (a name which had nothing to do with the chemical itself). Nonetheless, 
this trafficker may have had contacts in the chemistry world and realised that cocaine 
could be separated from the hydrochloride by adding a strong alkali and creating 
cocaine crystals. The result was quite different from than the crude cocaine sulphate 
the Peruvians were smoking. It was still technically the same drug, but it was much 
refined. For those used to snorting cocaine powder, with only the relatively small 
surface area of the nasal cavity to cross slowly into the bloodstream, the combined 
surface area of both lungs were now available resulting in a very fast and powerful ‘hit’. 
The first outbreak of a crack cocaine epidemic was probably in the Bahamas in 1979 
(Streatfeild, 2002) and by the late 1980s crack cocaine began to emerge in the US 
where it was quickly seen as a major risk to public health (Minyard, 1986; Thomas, 
1989; Washton et al., 1986). There were significant concerns that cocaine would have 
an immediate and significant impact on the health of the UK population. Cocaine was 
declared to be “the most serious peace-time threat to our national wellbeing” (House of 
Commons, 1985 cited in Strang et al., 1990). The potential for crack cocaine to be 
readily subsumed into the lifestyle of a heroin addicts seems obvious in retrospect. In 
1886 the phenomenon of ‘cocomania’, the combined addiction to cocaine and 
morphine, had been described by Erlenmeyer (James, 1969). The modern day 
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equivalent, ‘speedballing’, involves the simultaneous exposure to both crack cocaine 
and heroin (Leri et al., 2003a). 
Early reports from treatment services in England showed that the prevalence of 
cocaine use among people addicted to heroin rose from 13% to 29% between 1987 
and 1989. Detailed examination of those reporting past-month cocaine use showed, 
however, that crack cocaine rose from 15% to 75% over the same period, and of those 
reporting cocaine use, 95% were consuming it alongside heroin (Strang et al., 1990). In 
a sample of 500 opioid injectors in London, most of whom were recruited from the 
community as opposed to treatment services, the use of crack cocaine rose from 1% in 
1990 to 27% in 1993 (Hunter et al., 1995). Latest statistics from England report that 
more than half (54%) of patients who entered treatment in 2017/18 for OUD also 
reported a concurrent crack cocaine problem (Public Health England, 2018a). 
There is wide recognition that crack cocaine is a substantial public health problem. 
Crack cocaine accelerates the progression of HIV/AIDS (Baum et al., 2009) andis 
associated with high criminal involvement (Pierce et al., 2015b). Cocaine is also 
associated with reduced effectiveness of treatment for OUD in that the frequency of 
heroin use is substantially higher in those who also use cocaine (Hartel et al., 1995; 
Heidebrecht et al., 2018; Marsden et al., 2009).  
1.1.6 THE MEDICO-LEGAL RESPONSE 
Restrictions on the availability of ‘hard’ drugs had already been imposed by the time 
heroin was first synthesised. The first attempt to control ‘the sale of poisonous drugs’ in 
Britain came in the form of the Poisons Bill in 1819, which failed to become law 
(Stimson and Oppenheimer, 1982). It was only with the passing of the Arsenic Act in 
1851 that some form of regulation began to emerge. The Arsenic Act also positioned 
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the Pharmaceutical Society of Great Britain to successfully lobby for further restrictions 
on those eligible to sell (and make money from) drugs. Prior to the introduction of the 
Pharmacy Act in 1868, when certain drugs were restricted to being dispensed by 
pharmacies, opium was readily available in apothecaries, herbalists and retail shops 
(Berridge, 1982). Between 1868 and 1920, an addict could still obtain opium from a 
pharmacy without prescription (Merry, 1975). It was only with the passing of the 
Defence of the Realm Act in 1916, specifically regulation 40B generally referred to as 
DORA 40B, that a doctor’s prescription was required by law for the acquisition of 
certain substances, mostly notably cocaine. 
The Dangerous Drugs Act was introduced in 1920 to meet Britain’s obligations under 
the 1912 International Opium Convention at The Hague, obligations which were further 
reinforced under Article 295 of the Treaty of Versailles in 1919 (Ashton, 2002). 
Followed by the Dangerous Drugs and Poisons Acts of 1923, 1925 and 1928, the 
manufacture, sale, possession, import and export were criminalised, although 
allowances were made for legitimate use. The penal emphasis and police search 
powers were also increased during the 1920s. 
At the same time, the Dangerous Drugs Act allowed medical practitioners to prescribe 
heroin for legitimate reasons. Contemporary legitimate uses include the treatment of 
myocardial infarction, palliative care, pulmonary oedema and post-operative pain 
(Gossop et al., 2005a). The Rolleston Report of 1926 reaffirmed doctors’ rights to 
prescribe heroin to persons addicted, even while acknowledging that heroin addiction 
was rare in Britain at the time. The report was clear that heroin addiction “should be 
regarded as a manifestation of a morbid state, and not as a mere form of vicious 
indulgence” and that it would be legitimate to prescribe heroin to “…those who are 
undergoing treatment for cure of the addiction by the gradual withdrawal method; and 
16  
persons for whom, after every effort has been made for the cure of the addiction, the 
drug cannot be completely withdrawn…” (Rolleston, 1926, p392-393). This unique 
approach, which is to say an approach with a legitimate medical structure within a 
penal framework, became known as the ‘British system’. 
In 1958, after press reports of a new form of heroin use by young people, the Ministry 
of Health convened the Interdepartmental Committee on Drug Addiction. Headed by Sir 
Russell Brain, the ‘Brain Committee’ first reported in 1961 and effectively concluded 
that there was no real increase in drug use in Britain at the time (Interdepartmental 
Committee on Drug Addiction, 1961). It did not take long for this optimistic view of 
events to be superceded. Thirty-five years had passed between the Rolleston Report 
and the report from the First Brain Committee, yet a second review was convened only 
three years following the publication of the latter, again headed by Sir Russell Brain. 
This time round, a significant increase in the heroin using population was noted, 
alongside recommendations to tackle the growing problem (Interdepartmental 
Committee on Drug Addiction, 1965). 
Dedicated treatment centres, known as ‘Clinics’, started to open from April 1968 
onwards (Stimson and Oppenheimer, 1982) and by the autumn of that year there were 
39 Clinics providing treatment. By October 1968, there was a total of 904 patients 
accessing these Clinics. Alongside the opening of the new Clinics in 1968, the 
Dangerous Drugs (Supply to Addicts) Regulations came into force across the country. 
One of the aims of the British system was to prevent patients from accessing heroin on 
the black market. These regulations, however, stipulated that doctors should be certain 
a patient arriving at the clinic was indeed an addict and that the amount of heroin 
prescribed should be conservative. As pointed out at the time, however, these 
intentions were beset by unexpected consequences: an addict refused a prescription, 
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or prescribed too little, would be motivated to seek out supply on the black market 
(Edwards, 1969). Indeed, by the end of the 1960s, the black market for heroin was 
flourishing in Britain, although it should be noted that this was an illicit market in 
pharmaceutical diamorphine and not an illicit market of the illicitly-manufactured heroin 
of today (Stimson, 1987). 
It only became apparent in 1986 that injecting drug users were at a particular risk of 
contracting and transmitting HIV through the sharing of injecting equipment (Robertson 
et al., 1986). The United Kingdom was not alone in this as many countries in Europe 
and beyond had particularly high prevalence rates of HIV in the injecting drug user 
population during the 1980s (Hamers et al., 1997), An influential report at the time by 
the Advisory Council on the Misuse of Drugs noted that ‘HIV is a greater threat to 
public and individual health than drug misuse’ (Advisory Council on the Misuse of 
Drugs, 1988). This report prompted a national strategic focus on preventing injecting 
drug users from acquiring and transmitting the virus. What is important to note is that 
abstinence from opioid use was not the only recognised means of achieving these 
goals; risk reduction strategies were also promoted for those who could not achieve 
abstinence. Needle and syringe provision became widespread as funding allocated to 
this preventive measure escalated from around £1.3million in 1987/88 to £16.1million in 
1993/94 (Stimson, 1995). Crucially, a greater clarity around the purpose of changing 
injecting behaviour among treatment providers was brought to the fore (Strang, 1998). 
Clinicians could target intermediary steps away from high-risk behaviours such that, for 
example, cessation of sharing equipment could precede cessation of injecting entirely. 
The strategy was effective, at least until recently when there a rapid re-emergence of 
HIV among injecting drug users was reported in Glasgow: HIV rates in this population, 
usually very low, increased from 0.1% in 2011 to 4.9% in 2018 (McAuley et al., 2019). 
While this is still in the estimated range of HIV prevalence in the injecting population in 
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Western Europe (3.2-6.0%), it is higher than Australasia (0.8-1.4%) and much lower 
than the global estimate of 10.8-24.8% (Degenhardt et al., 2017). 
1.1.7 INFORMATION SYSTEMS IN ENGLAND 
Accurately capturing the extent of the heroin addiction population is crucial to the 
formulation of a strategic response. By far the easiest approach is to simply tally the 
numbers of unique patients coming into contract with treatment centres. Initial efforts 
began in the 1930s and since then there has been a general shift from informal 
methods of capturing this information towards more formal and, latterly, computerised 
methods. A mandatory obligation was placed on all doctors from 1968 onwards to 
record and to notify the ‘Addicts Index’ (see below) when they treated or otherwise 
attended a heroin addict. The late 1980s and early 1990s saw the introduction of 
computerised information gathering systems in each region of Great Britain. With the 
dawn of the new millennium, the English regional systems were integrated into a 
national drug treatment monitoring system. 
1.1.7.1 HOME OFFICE ADDICTS INDEX 
From around 1935 there was an informal arrangement to notify the Home Office of 
persons addicted (Corkery, 2002). The number of addicts known to the Home Office 
was relatively small, reinforcing Rolleston’s statement that addiction was rare at this 
time. There were around 700 known addicts in 1935 and there was a general decline 
until 1953 when only 290 people were recorded on the index (Stimson and 
Oppenheimer, 1982). Relatively small increases followed in the following years and in 
1960 there was a total of 437 people on the index. Rapid increases were witnessed in 
the mid-1960s and by 1968 there were 2,782 recorded addicts. 
It is interesting to note that the rise in the 1960s seems almost entirely due to changes 
in the recording of males on the index. In 1936, when gender could be disaggregated, 
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there were 313 males and 300 females on the index. By 1968, there were 2,161 males 
and 621 females, indicating that while the population of known females doubled in this 
period, the male addict population had increased seven-fold (Figure 1.1). 
The recording of heroin, specifically, on the index did not emerge until 1954 when only 
57 (18%) of those on the index were so recorded (Figure 1.2). This had changed 
substantially by 1968, when 2,240 (81%) of those on the index were notified as ‘heroin 
addicts’. This dramatic increase was the background to the 1968 Dangerous Drugs 
(Notification of Addicts) Regulations. From 1968, doctors prescribing heroin had to be 
specially licenced by the Home Secretary, the licence was only valid at a named 
hospital, and doctors had a statutory duty to report patients to the Home Office Addicts 
Index. The notification of addicts to the Home Office was entirely straightforward. For 
some General Practitioners, for example, re-notifying the index about a particular 
individual each year was prone to under-reporting and the clarity (or interpretation) of 
the addiction diagnosis could lead to discrepancies between those being treatment and 
those being notified (Robertson and Bucknall, 1985). Nonetheless, the number of 
individuals recorded on the index kept accelerating and by 1996, the year before the 
index was closed, there were 43,372 individuals on the system, 30,573 (70%) of whom 
were addicted to heroin (Morgan, 2014).  
The Addicts Index was not without its critics. There was an apparent lack of investment 
in analysis of the data and the shifting profile of users was only noticed in retrospect, 
leading the authors to conclude that “…our new data-collecting power now needs to be 
accompanied by at least some investment in time for academic study of these collected 
data, so that information may be translated into knowledge and so that science may 
better serve the policy-making process” (Strang and Taylor, 1997, p47). 
20  
1.1.7.2 REGIONAL DRUG MISUSE DATABASE 
Regional Drug Misuse Databases (RDMD) were set up in England, Wales and 
Scotland in 1990 to monitor the demand for treatment (Donmall, 1999). These 
overlapped with the Home Office Addicts Index until the index was closed in 1997, 
although doctors were still expected to continue to report anonymous data to the 
RDMD (Tregoning, 1998). The rationale behind this decision was that the Home Office 
Addicts Index did not provide a comprehensive picture of addicts accessing treatment. 
It only captured those individuals being treated by doctors with the result that non-
medical treatments were not captured. It also did not capture individuals who were 
addicted to certain substances, such as amphetamines and benzodiazepines, which 
doctors were not required to notify (Government Statistical Service, 1994).  
Statistics from the RDMD were published by the Department of Health, and cover the 
six-month period ending 31st March or 30th September from 1993 to 2001. Between 
March 1993 and March 2001, the number of individuals accessing treatment increased 
86%, from 17,822 to 33,200 (Figure 1.3). Throughout the same period, the proportion 
of individuals reporting heroin as their primary drug increased from 47% to 67%. It is 
interesting to note given the arguments given for closing down the Addicts Index – 
specifically with regards the idea that the index did not provide comprehensive 
reporting of all addicts being treatment – that data from the RDMD on 31 March 1996 
point to 23,313 individuals being in receipt of treatment compared with the 43,372 
recorded on the index. 
1.1.7.3 NATIONAL DRUG TREATMENT MONITORING SYSTEM 
The RDMD was replaced by the National Drug Treatment Monitoring System (NDTMS) 
in 2001 when the National Treatment Agency for Substance Misuse was formed and 
took charge of treatment in England. Comprehensive reporting from the NDTMS was 
not, however, available until 2005/06. As can be seen in Figure 1.4, the first year 
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reported 216,802 individuals accessing treatment in that year, 65% of whom were 
treated for opiates. In the latest year of reporting (2017/18), there were 268,390 
individuals accessing treatment, 53% (n=141,189) of whom were being treated for 
opiates (Public Health England, 2018a). 
1.1.8 PREVALENCE ESTIMATES 
A more difficult task than counting those accessing treatment services is to estimate 
the total population of persons with OUD in the country. The prevalence of OUD in the 
general population aged 15-64 have been estimated several times in England, starting 
in 2004/05 (Figure 1.5). As can be seen, the estimates of the number of opioid users 
have shown a decline from a peak of 286,566 (95% Confidence Interval [CI] 281,668-
299,394) in 2005/06 to 261,294 (95% CI 259,018-271,403) in 2016/17 (Hay et al., 
2019). By cross-referencing these estimates with the number of individuals accessing 
treatment, it has been concluded that 49% of the OUD population in England accessed 
treatment in 2005/06, and this proportion increased to 56% at the time of the latest 
prevalence estimates in 2016/17.  
To put these prevalence estimates in context, it is useful to look at the rate of 
individuals with OUD per 1000 population. In the US, it is estimated that 2.6 people per 
1,000 aged 12 and above used heroin in the past year (Jones et al., 2015). In Europe, 
the estimated annual heroin use prevalence is 4 per 1,000 aged 15-64 and this ranges 
between 1 and 8 per 1,000 (EMCDDA, 2016). In England, the current estimates 7.4 per 
1,000 among people aged 15-64 in England (Hay et al., 2017), making the rate in 
England one of the highest of Western counties. There is wide regional variation in the 
rate of opioid users per 1,000 population within England. In the northern parts of the 




Figure 1.1 The number of males and females recorded on the Home Office Addicts Index, 1936-1968 





























































































































































Figure 1.2 The number and proportion of heroin addicts recorded on the Home Office Addicts Index, 1954-1968  
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1.2 SEQUELAE OF OPIOID USE DISORDER 
As outlined in Table 1.1 and Table 1.2 above, the consequences of OUD are manifold. 
Aside from the expensive daily cost of paying for heroin – which generally requires 
significant time spent in illicit activities to fund the purchase of the drug – the person 
continues to use despite the numerous and persistent social, occupational, physical 
and psychological problems that are caused or exacerbated by such continuation. The 
Heroin Use Consequences Survey, for example, lists 21 negative sequalae arising 
from heroin use (Woodcock et al., 2015). While these sequalae have recently been 
shown to exist in five distinct domains (Moses et al., 2018), the following section will 
touch briefly on three main categories: criminal offending, morbidity and mortality. 
1.2.1 CRIMINAL OFFENDING 
The cost of maintaining a heroin addiction is substantial, with estimates of around 
£900-£1,000 per month in England (Hayhurst et al., 2013; Luty et al., 2009). Similar 
expenditure, around $1,100, has been noted in Manhattan (Golub and Johnson, 2004). 
More recently, it has been estimated that the average monthly expenditure on heroin in 
the United States increased from $1,240 in 2006 to $1,450 in 2016 (Midgette et al., 
2019). With less than 20% of patients with OUD in gainful employment in England 
(Public Health England, 2017a), many turn to acquisitive crime to pay for the drug. In a 
recent linkage study combining the NDTMS with the Police National Computer, more 
than a quarter of male opioid uses had a recent criminal conviction for shoplifting, 
which increased to more than a third of their female counterparts (Pierce et al., 2015b). 
Other forms of offending, such as burglary and handling stolen goods were also 
prevalent in men. For females opioid users, a little over 2% were convicted of 
prostitution, rising to almost 7.5% in those using both opioids and crack cocaine (ibid). 
It is important to note that these are proven offences only; many offences go 
undetected or do not result in criminal convictions. Indeed, 40% of patients self-
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reported offending behaviour in the past 30 days alone (Hayhurst et al., 2013). While 
accurately capturing the degree to which individuals with OUD engage in criminal 
activity is an inherently difficult endeavour, it is interesting to note that as of 31st March 
2018 there were 11,453 individuals in receipt of prison-based specialist addiction 
treatment for heroin addiction problems out of a population of 83,263 prisoners 
(Ministry of Justice, 2018; Public Health England, 2018b). In other words, more than 
one in eight of the prison population were being treated for heroin addiction problems 
on that particular date.  
1.2.2 MORBIDITY 
Recurrent use of opioids is associated with an increased risk of developing a number of 
physical and mental health conditions, which contribute significantly to the burden of 
disease associated with OUD (Degenhardt and Hall, 2012). In this section, a brief 
overview of the main areas of morbidity is provided.  
1.2.2.1 INFECTIONS 
Opioid users, as a result of sharing injecting equipment, are at increased risk of 
contracting a number of infections, which, left untreated, can lead to compromised 
physical health. Fungal infections, though rare, have been reported (Hadley et al., 
2017; Jensenius et al., 1999; Melnychuk and Sole, 2017). Bacterial infections can 
include endocarditis, wound botulism, tetanus, bacterial pneumonia and tuberculosis 
(Anderson et al., 1997; Beeching and Crowcroft, 2005; Duberstein and Kaufman, 1971; 
Frontera and Gradon, 2000; Hahné et al., 2006; Iqbal, 2001; Kalka-Moll et al., 2007; 
Louria, 1967; Neufeld et al., 1976; Passaro et al., 1998; Wang et al., 2006; Warner-
Smith et al., 2001; Yuan et al., 2011). It has been estimated that 34,000 injecting drug 
users in England need care for injecting-related wounds, such as abscesses, and that 
around 18,000 need hospitalisation costing £19-30 million (Hope et al., 2008). 
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Injecting drug users are also at heightened risk of contracting viral infections, such as 
hepatitis B (HBV), hepatitis C (HCV) and HIV (Alshomrani, 2015; Garten et al., 2004; 
Mwatelah et al., 2015; Sepúlveda-Arias et al., 2014; Vallejo et al., 2015). HCV attacks 
the liver and can cause serious complications such as cirrhosis and liver cancer, 
although the virus can prove asymptomatic until the liver is severely damaged (Public 
Health England, 2018c). Globally, it is estimated that around 1% of the total population 
is living with HCV, equating to some 71 million people, while an estimated 257 million 
people are living with HBV (World Health Organization, 2017). In England, it is 
estimated that 203,000 (0.67%) people aged 15-59 have HCV (Harris et al., 2012) 
although the prevalence, at 22% in 2017, is much higher in injecting drug users (Public 
Health England, 2018c). Chronic infection occurs in around 85% of those with acute 
HCV (Hoofnagle, 1997). Individuals living with HCV can also experience fatigue, which 
appears to be multidimensional in nature and encompasses physical, cognitive, and 
affective dimensions (Glacken et al., 2003). Significantly, there were 1.34 million 
deaths estimated to have occurred as a result of viral hepatitis in 2015, 96% of which 
were due to HBV and HCV (World Health Organization, 2017). To put this in context, 
hepatitis caused around 300,000 more deaths than HIV (World Health Organization, 
2017), yet hepatitis C is now a curable condition. The cost of treatment has fallen 
dramatically in recent years, from £35,000 in England per patient to £5,000 per patient 
(Hurley, 2018). With this cost reduction, the goal of eliminating hepatitis as a public 
health threat by 2030 (World Health Organization, 2016b) may well be achievable. 
1.2.2.2 MENTAL ILLNESS 
Prolonged heroin use is also associated with significant comorbid mental health 
disorders, including anxiety, depression and post-traumatic stress disorder (Darke et 
al., 2009; Han et al., 2010; Rosen et al., 2008; Sordo et al., 2012). It is likely these 
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underlying mental health issues play a significant role in the high rates of self-harming 
behaviour associated with OUD (Darke et al., 2010; Pérez de los Cobos et al., 2009). 
1.2.2.3 NON-FATAL OVERDOSE 
While overdose is clearly a major cause of death, non-fatal overdose can also 
engender long lasting consequences in the form of brain damage and cognitive 
impairment through prolonged hypoxia (Darke et al., 2007a). Other complications can 
include oedema, pneumonia, cardiac and muscular effects (Warner-Smith et al., 2001). 
The likelihood of users experiencing such an overdose is high. In an 11-year follow up 
of an Australian cohort, two-thirds had experienced at least one overdose and a quarter 
had experienced five or more overdoses (Darke et al., 2015). 
1.2.3 MORTALITY 
Globally, the estimated number of deaths attributed to OUD rose from 94,200 (95% CI 
90,500-99,700) in 2005 to 121,100 (95% CI 109,500-129,700) in 2015, representing 
over 70% of deaths attributed to drug use disorders (GBD 2015 Mortality and Causes 
of Death Collaborators, 2016). It has been estimated that opioid use leads to the loss of 
18 years of life (Smyth et al., 2007). In England and Wales, drug-related deaths (DRD) 
have been rising steadily since 2012, and deaths recorded in 2017 (n=3,765) are the 
highest recorded since comparable recording began in 1993 (n=2,178)(Office for 
National Statistics, 2018a). Opiates are the predominant substance (53%) recorded on 
the death certificate, with heroin/morphine accounting for 31% of the recorded DRD in 
2017. OUD is also associated with an increased risk of suicide (Darke et al., 2010; 
Darke and Ross, 2002; Degenhardt and Hall, 2012; Pan et al., 2014). 
Large-scale national linkage studies demonstrate that opioid users face a substantially 
increased likelihood of mortality. The standardised mortality ratio (SMR) is a measure 
of the extent to which a given population is at an increased risk of death relative to 
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what is expected from the general population sharing the same age and gender 
distribution. In a meta-analysis of 58 studies, Degenhardt et al. (2011) report a pooled 
SMR of 14.7 (95% CI 12.8-16.5), indicating that opioid users are almost 15 times more 
likely to die than would otherwise be expected. 
In one study of nearly 200,000 opioid users (Pierce et al., 2015a), it was estimated that 
males have an SMR of 5.5 (95% CI 5.3-5.6) and females have an SMR of 6.9 (95% CI 
6.5-7.4). The same study showed that while drug-related poisonings (i.e. fatal 
overdose) accounted for 43% of all deaths, opioid users were at a heightened risk of 
death from numerous causes, including: infectious/parasitic diseases (SMR 12.6, 95% 
CI 10.8-14.8); liver cancer (SMR 9.2, 95% CI 6.7-12.7); respiratory system (SMR 8.9, 
95% CI 7.9-10.1); musculoskeletal system and connective tissue (SMR 4.5, 95% CI 
2.6-7.9), and the circulatory system (SMR 3.1, 95% CI 2.8-3.4). Opioid users are also 
more susceptible to death by homicide (SMR 12.2, 95% CI 9.8-15.3). The increased 
risk of all-cause mortality has been documented in several countries, including: Spain 
(Jimenez-Treviño et al., 2011); Israel (Rosca et al., 2012); Taiwan (Huang and Lee, 
2013), and the U.S. (Evans et al., 2015; Lopez-Quintero et al., 2015). Comorbid 
personality disorder and alcohol use disorder increase the risk of all-cause mortality 
(Bogdanowicz et al., 2015). Given the multitude of cause-specific mortality risks, it is 
not surprising that approximately half of opioid users are dead within 30 years (Grella 
and Lovinger, 2011; Hser Y et al., 2001). 
One particular concern involves prisoners with OUD who face a substantially increased 
risk of fatal overdose on release. While there is some evidence of an increased risk 
across the first year (Kinner et al., 2013), the heightened risk is most notable in the first 
four weeks following release (Farrell and Marsden, 2008; Merrall et al., 2010). 
Physiologically, the most likely mechanism involves the partial or complete eradication 
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of opioid tolerance during the incarceration period. Should an ex-prisoner administer a 
‘normal’ pre-incarceration dose i.e. a dose they can no longer tolerate, there is a high 
probability that respiratory depression will set in leading to hypoxia and death. A return 
to injecting behaviour would further increase opioid bioavailability and thereby increase 
the risk of respiratory depression. The concurrent use of alcohol (Hill et al., 2016) and 
benzodiazepines (McCowan et al., 2009) may also exacerbate this effect. 
Another area for concern is the relationship between age and methadone-specific 
mortality. The first study to demonstrate this effect was based on a Scottish cohort of 
more than 30,000 patients (Gao et al., 2016) and showed that, relative to those aged 
25-34, those aged 45 or more had an adjusted hazard ratio (aHR) of 2.9 (95% CI 2.1-
3.9). These results were confirmed in a large linkage study of 130,000 patients in 
England, which showed an increased risk of methadone-specific mortality for this age 
group (aHR 5.1; 95% CI 3.6-7.2) but no increased risk was identified for heroin-specific 
mortality (aHR: 1.1; 95% CI 0.8-1.5; Pierce et al., 2018). 
Further complications associated with age have recently been reported (Advisory 
Council on the Misuse of Drugs, 2019). Ageing opioid users suffer from an 
accumulated burden of physical impairments and mental health problems, which 
exacerbates and complicates the effects of ageing. Older opioid users are, for 
example, at increased risk of mortality due to circulatory and digestive diseases (Gao 
et al., 2019). The report also highlights that ageing opioid patients are more difficult to 
treat, have entrenched problems, their dependence is harder to overcome and they are 
less able to access other services such as housing, dental care and counselling. 
Recognising that the ageing cohort is rapidly growing as a proportion of patients 
accessing treatment, the report also recommends that treatment provision needs to be 
adapted to meet the increasingly complex needs of this group. 
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1.3 TREATING OPIOID USE DISORDER 
The provision of treatment for persons involved in the “abuse of drugs” is set out in 
Article 38 of the Single Convention on Narcotic Drugs (United Nations, 1961), but it 
was not until 1968 that the first dedicated treatment centres were established in Great 
Britain (Merry, 1975). In the fifty years since then, the majority of countries with a high 
prevalence of OUD have developed an array of treatment services. The opioid 
medication methadone has been a front-line treatment since the establishment of 
treatment centres in Great Britain and, since the late 1990s, buprenorphine has also 
become a front-line treatment (Mattick et al., 2014, 2009). Both medications are 
randomised-controlled trial supported pharmacotherapies which are typically provided 
by specialist community, primary care and hospital providers. Inpatient withdrawal 
management and drug-free residential rehabilitation services are also available. In 
addition to case management, national clinical guidelines recommend additional 
psychosocial interventions to address cognitive and behavioural symptoms of OUD 
(e.g. National Institute for Clinical Excellence, 2007). Some OUD patients receive 
psychosocial interventions without an opioid medication.  
1.3.1 A NOTE ON SPONTANEOUS RECOVERY 
Spontaneous recovery, or natural recovery, refers to the process of overcoming OUD 
in the absence of treatment. The first report of this phenomenon emerged in the early 
1960s when it was suggested, from examination of records submitted to the US 
Federal Bureau of Narcotics, that registered addicts tended to disappear from records 
after the age of 35-40 (Winick, 1962). At the time, Winick claimed that “…it is almost 
impossible for a regular user of narcotics to avoid coming to the attention of the 
authorities within a period of about two years”, although this claim was shown to be 
largely inaccurate a decade later when it was demonstrated that a quarter of active 
users can quite readily avoid the official register (Vaillant, 1973). 
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Nonetheless, several small-scale studies were published in the 1960s and 1970s that 
suggested that spontaneous recovery was possible (Waldorf and Biernacki, 1979). 
Perhaps the most compelling evidence for spontaneous recovery involved following up 
soldiers returning from the Vietnam war (Robins, 1974; Robins et al., 1975, 1974). 
Robins and her team took a sample of around 900 soldiers from the 14,000 who 
returned from Vietnam in September 1971. Over 40% had tried either opium or heroin 
during their tour, and approximately 20% could be said to have OUD (although this 
diagnostic term was not in use at this time). A year after their return, however, only 2% 
were using heroin on a weekly basis. Numerous factors played a role in facilitating 
such dramatic recovery rates, including purity, price, route of administration, social 
norms, education and life circumstances (Hall and Weier, 2016).   
For some drug users – usually those not deeply engrained in the drug using world – 
spontaneous recovery can be instigated when their central point of contact for 
accessing drugs is no longer available, for example when a spouse is imprisoned or 
dies (Biernacki, 1990). For others, they first need to develop a sense of resolve to stop 
using drugs and develop alternative social connections or coping strategies. This 
resolve can develop in response to hitting ‘rock bottom’ or experiencing an existential 
crisis, but these are not in themselves pre-requisites for change (Waldorf and 
Biernacki, 1981).  
This resolve, or motivation to change, followed by active participation in the decision to 
change, as well as maintaining the change are three stages of change outlined by 
Klingemann (1991). Other models of change include two precursor stages, 
precontemplation and contemplation (Prochaska et al., 1992), which describe a stage 
in which there is no desire to change, or indeed see the need for change, and a stage 
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in which the problem is recognised and action is probably required but a firm decision 
to change has not yet been reached. 
While recovery in the absence of treatment is possible, it has recently been shown, at 
least in the case of heroin, that almost all (~90%) individuals who recover have utilised 
treatment services (Cunningham, 2000). Comparisons between those who have and 
have not undergone treatment in their process of recovery show that those recovering 
without treatment tend to have experienced fewer difficulties in high school, were 
incarcerated less since leaving high school, more likely to have a college education 
and less likely to be unemployed (Graeven and Graeven, 1983). Those accessing 
treatment also appear to have more mental health issues (Rounsaville and Kleber, 
1985). In other words, those seeking treatment are more chaotic. Other researchers 
(Power et al., 1992) have reported that those in treatment have similar levels of heroin 
use to those not seeking help, but the former group had significantly more concerns 
across a range of issues, such as finance and health. Power et al. concluded that this 
provided evidence for the need for low-threshold outreach programs to engage heroin 
users not yet engaged in treatment. 
1.3.2 LARGE-SCALE COHORT STUDIES 
In their seminal work outlining the case for methadone treatment, Dole and Nyswander 
(1965) assessed a sample of just 22 patients in New York. In the 50 years since then, 
large scale national prospective cohort studies have consistently demonstrated that 
treatment is associated with reductions in opioid use, drug injecting and criminal 
offending, together with improvements in employment, health and social functioning.   
The US initiated these OUD cohort studies (Craddock et al., 1997; Hubbard et al., 
1989; Sells et al., 1976) and were followed, in turn, by England (Gossop et al., 1997), 
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Australia (Ross et al., 2002), Scotland (McKeganey et al., 2008) and Ireland (Comiskey 
et al., 2009). Commonly, a large cohort of patients accessing treatment is identified and 
recruited into a long-term prospective follow-up study. All, or a sample of, patients are 
re-interviewed at various points following recruitment. Crucially, participation in the 
follow up interviews is not contingent on being continuously enrolled in treatment.  
It is important to note that while the randomised control trials (RCTs) are often held as 
the pinnacle of research designs (Concato et al., 2000; Sacks et al., 1982), it can also 
be argued that the design is inappropriate or unethical in the context of researching 
drug treatment effectiveness should this require the randomisation of treatment 
seekers to a no treatment condition. That said, there are a number of variants of the 
RCT design. RCTs designed to determine whether or not a new treatment has a 
different degree of efficacy than the current standard (or placebo) is known as a 
‘superiority trial’ while RCTs designed to determine whether or not a new treatment 
yields similar efficacy as the current treatment standard is known as an ‘equivalence 
trial’ (Christensen, 2007). The equivalence trial is appropriate when the new treatment 
is associated with fewer side effects, or is simpler to administer or is perhaps cheaper 
to deliver, and it is not expected to deliver a larger effect than the control treatment 
being compared against. Related to the equivalence trial is the ‘non-inferiority trial’ 
(Christensen, 2007). Whereas the equivalence trial aims to determine whether the new 
treatment falls within plus or minus a certain level of efficacy as that obtained from the 
current treatment standard, the non-inferiority trial is concerned only with testing 
whether the new treatment is at least as good as minus a certain level of efficacy. The 
advantage the non-inferiority trial design has over the equivalence design is that it 
requires fewer participants and is therefore cheaper to run.  
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Regardless of the type of RCT, it is relevant at this point to highlight that ‘efficacy’ is the 
term used to describe the performance of a given intervention under the idealised RCT 
conditions (Singal et al., 2014). That is to say, RCTs often benefit from particularly 
stringent inclusion/exclusion criteria and can be, in the case of a psychosocial 
intervention for example, staffed with more experienced or more highly trained 
individuals than one would normally expect under routine conditions. Performance of 
an intervention under these routine conditions is referred to as treatment effectiveness 
and it is often the case that efficacy surpasses effectiveness (Singal et al., 2014). 
Nonetheless, it remains problematic for cohort studies to attribute changes in patient 
behaviour wholly to the treatment exposure as there may be a number of self-selection 
or other unmeasured biases affecting outcomes. Replication of treatment effectiveness 
outcomes across large scale multinational multisite studies do, however, lend credence 
to a general finding that ‘treatment works’ (Hubbard et al., 1989; McKeganey et al., 
2008). 
1.3.2.1 DRUG ABUSE REPORTING PROGRAM 
The Drug Abuse Reporting Program (DARP) was the first in a series of global 
longitudinal cohort studies examining the effectiveness of treatment under routine 
conditions. A cohort of almost 44,000 people were recruited from 52 sites across the 
US between 1969 and 1974.  Numerous post-treatment follow-up studies were 
conducted between one and three years (Sells et al., 1976; Sells and Simpson, 1980; 
Simpson, 1981, 1980, 1979; Simpson et al., 1979; Simpson and Sells, 1982), and 
culminated in a 6-year (Simpson et al., 1982) and 12-year follow-up (Simpson and 
Sells, 1990). 
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1.3.2.2 TREATMENT OUTCOME PROSPECTIVE STUDY 
The Treatment Outcome Prospective Study (TOPS) recruited 11,750 patients between 
1979 and 1981 across 41 drug treatment programs in the US (Hubbard et al., 1989). 
Patients were interviewed at intake, at regular intervals during treatment and then at a 
number of periods following treatment, including three months, one year, two years and 
three-five years. Detoxification only patients were dropped from treatment effectiveness 
reporting, yielding a final sample of 9,989 patients accessing outpatient methadone 
(n=4,186), residential (n=2,891) and outpatient drug-free (n=2,914) services.  
1.3.2.3 DRUG ABUSE TREATMENT OUTCOME STUDY 
The Drug Abuse Treatment Outcome Study (DATOS), again in the US, recruited 
10,010 patients across 91 programs and 11 sites between 1991 and 1993. As DATOS 
was specifically designed to utilise many of the same measures as captured in TOPS, 
as well as similar outpatient methadone, outpatient drug-free and residential programs, 
comparisons between the two studies can be drawn (Craddock et al., 1997). Across all 
three treatment modalities, there were significant increases in the weekly use of 
cocaine and there was a lower proportion of patients engaged in full time employment. 
Interestingly, the findings of these three cohort studies are still relevant today. Public 
Health England continue to monitor engagement in ‘effective treatment’, which is 
defined by patients being continually enrolled in treatment for at least three months. 
This is directly influenced by DARP, TOPS and DATOS, which showed that patients 
who experienced at least 12 weeks of treatment experienced more favourable one-year 
outcomes, although it should be noted that few significant differences by treatment 
duration were noted at five-years (Hubbard et al., 2003; Simpson, 1979). 
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1.3.2.4 NATIONAL TREATMENT OUTCOME RESEARCH STUDY 
The National Treatment Outcome Research Study (NTORS) was commissioned by a 
Department of Health Task Force in 1994 to investigate whether, and to what degree, 
the outcomes reported by the U.S. studies would apply to patients accessing treatment 
in the United Kingdom. A total of 1,075 patients were recruited in 1995 across 54 
treatment agencies. Treatment outcomes were reported at six months, 1 year, 2 year 
and 4-5 years following intake (Gossop et al., 2003, 2002, 2000, 1997). The NTORS 
project was influential in instigating similar research endeavours in Scotland, Ireland 
and Australia, and the research played a key role in the drug treatment policy making 
of the late 1990s and early 2000s (Gossop, 2015). 
1.3.2.5 DRUG OUTCOME RESEARCH IN SCOTLAND 
The Drug Outcome Research in Scotland (DORIS) study recruited a sample of 1,033 
drug users from 28 community and five prison treatment agencies across Scotland in 
2001-2002 (McKeganey et al., 2008). In a similar manner as TOPS, patients who were 
recruited from needle exchange only agencies were dropped from outcomes reporting 
(n=26). Patients were followed up at eight, 16 and 33 months. 
1.3.2.6 RESEARCH OUTCOME STUDY IN IRELAND 
The Research Outcome Study in Ireland (ROSIE) study is the smallest of the national 
cohort studies, having recruited 404 patients from 44 treatment agencies. Alongside 
drug use outcomes, ROSIE also examined the effectiveness of treatment for health, 
social functioning, harm, mortality and crime outcomes. Patients were followed up at 1-
year and 3-years, and 72% completed all three interview assessments. 
1.3.2.7 AUSTRALIAN TREATMENT OUTCOME STUDY 
The Australian Treatment Outcomes Study (ATOS) recruited 615 heroin users between 
2001 and 2002. Participants were selected from the following four main treatment 
modalities: methadone/buprenorphine maintenance (n=201), detoxification (n=201), 
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residential rehabilitation(n=133) and a non-treatment group (n=80). Originally 
envisaged to examine treatment outcomes and costs at three and 12 months, the 
project was extended to capture further outcomes at 2-years, 3-years and 11-years 
(Ross et al., 2002; Teesson et al., 2015). 
1.3.3 LONG TERM HEROIN USE OUTCOMES 
Presented in Figure 1.8 is the proportion of patients reporting opioid use in each of the 
large-scale national studies. Of note is the variability opioid use reported at baseline. 
The four cohorts reporting approximately 30% of opioid use or less were from the 
TOPS and DATOS studies, and reflect patients accessing either residential or drug-
free treatment programs. Both DARP and ATOS report almost 100% of their cohorts as 
using opioids in the period preceding study enrolment.  
To a varying extent, each study demonstrates a general reduction in opioid use over 
time, with the most change occurring in the first 6-12 months. This trend has been 
referred to as the ‘rush and trickle’ of treatment outcome (Finch, 2003). Part of the 
variability is attributable to the length of time at the assessment points for which opioid 
use prevalence is measured. The various studies examine heroin use across 30 day 
(ATOS), 90 day (NTORS, DORIS, ROSIE) or full year (DARP, TOPS, DATOS) periods. 
1.4 OUTCOME MONITORING SYSTEMS 
It has been suggested that the conceptualisation, treatment and evaluation of addiction 
needs to shift from an acute-care model to a chronic-care one (McLellan et al., 2005). 
McLellan’s conceptualisation sees drug addiction closely resemble the course of other 
chronic illnesses such as diabetes, asthma and hypertension. Assessing completion 
rates and status post-treatment for some interventions such as residential rehabilitation 
or in-patient treatment is appropriate, but some community setting interventions require 
an evaluation approach which needs to look beyond the short-term and include longer-
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term follow-up during which patients may flow in and out of the treatment system. This 
can be achieved through an integrated, standardised, and electronic outcomes 
monitoring system (OMS). 
This composition of treatment interventions delivered in England, with more than 90% 
of treatment delivered under outpatient conditions (Public Health England, 2016a) is 
similar to that of the US (McLellan et al., 2005). England is, however, in the unique 
position of having a national OMS currently in place. 
OMS “reflects a fundamental organizational and professional value, namely, a 
commitment to quality, fact-based treatment” (Brown et al., 2003). The OMS becomes 
a positive feedback loop where the impact of routine treatment on outcomes is 
monitored, reported, and informs future clinical and commissioning decision making. 
Successfully implemented OMS allow for the early detection of problems in key 
performance indicators, expose opportunities for service improvement, and improve 
outcomes. 
In 1998, the US funded the development and automation of OMS in 19 states (Evans 
and Hser, 2004), including California (ibid), Iowa (Hedden et al., 2012), Minnesota 
(Harrison and Asche, 2001), and Washington (Luchansky et al., 2000), and Canada 
implemented an OMS in Ontario (Rotondi and Rush, 2012). In England, all individuals 
accessing publically funded drug treatment are asked to share a core dataset with the 
National Drug Treatment Monitoring System (NDTMS), held by Public Health England 
(PHE), and over 98% consent to do so (Marsden et al., 2009). 
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1.5 DEVELOPMENT OF THE TREATMENT OUTCOMES PROFILE 
NDTMS was originally designed to capture intelligence on the number of people in 
treatment, interventions received, substances targeted for treatment, together with 
measures of process such as waiting times and the successful completion of treatment, 
a proxy outcome of recovery. In 2006, however, at the request of national stakeholders 
in England, the then National Treatment Agency for Substance Misuse sought to 
include a minimum set of behavioural indicators that would be measured throughout a 
patient’s time in treatment. A team of clinicians, academics and policy makers was 
convened, including me as a research assistant, and it was decided that a new 
instrument was justified to adequately reflect the priorities of the then national drug 
strategy. 
In total, more than 1,000 patients were recruited from 113 specialist treatment services 
that delivered OST, psychosocial and residential-based interventions. From a pool of 
around 80 potential items to be included on the new instrument, 38 were considered to 
be the most relevant following discussions with patients, service providers and other 
professionals. These items concerned four principal domains including substance use, 
health risk behaviours, offending and health and social functioning. The procedure 
included three interviews: an initial assessment, a 7-day retest (involving a different 
keyworker) and a 1-month follow up. This enables the psychometric evaluation of test-
retest reliability, concurrent validity and change sensitivity. The final result was the 20-
item Treatment Outcomes Profile (TOP: Marsden et al., 2008). The TOP is a short, 
structured, clinically-administered set of twenty questions which measures substance 
use, health and social functioning information recorded as part of on-going delivery of 
care.  The TOP was incorporated into NDTMS in October 2007, the point at which 
NDTMS evolved into an outcomes monitoring system. Since then, other countries have 
followed suit and, at the time of writing, there now exists a locally validated version of 
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the TOP in Chile, China and Australia (Castillo-Carniglia et al., 2015; Ryan et al., 
2014a; Wang et al., 2017) 
Research using NDTMS-based TOP data has, to date, focused on developing methods 
to capture change in the treatment seeking population (Marsden et al., 2011), 
evaluating performance while statistically adjusting for heterogeneity in the population 
(Marsden et al., 2012b), and reporting early (six-month) in-treatment reductions in 
opioid and crack-cocaine use (Marsden et al., 2009). 
1.6 SUCCESSFUL COMPLETION OF TREATMENT 
Treatment outcome studies can be expensive and time consuming and the 
commissioners of publicly funded treatment systems want regular reports on the 
effectiveness of services. While unsanctioned discharge (drop-out) from treatment and 
retention have been used (Brorson et al., 2013; Stark, 1992; Faggiano et al., 2003), a 
frequently used measure in the literature on human services research is the proportion 
of patients treated who complete treatment successfully (Alterman et al., 2001). 
Successful completion of treatment is associated with reduced drug use (Evans et al., 
2009; Kornør and Waal, 2005), increased employment (Evans et al., 2009; Sung and 
Chu, 2011; TOPPS-II Interstate Cooperative Study Group, 2003; Zarkin et al., 2002; 
Lang and Belenko, 2000; Finnigan, 1996), lower arrests and incarceration (Gifford et 
al., 2014; Evans et al., 2009; Campbell et al., 2007; Finnigan, 1996), and a reduced 
likelihood of readmission to treatment services (Luchansky et al., 2000). These 
indicators of treatment system effectiveness can reveal differential response between 
populations. For example, drop-out is more likely in those with greater psychiatric 
severity and those with more arrests in the year preceding treatment, and less likely in 
those living with dependent children and those receiving residential treatment (Evans et 
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al., 2009). Ethnic minority populations may have a lower rate of treatment episode 
completion than their white counterparts (Mennis and Stahler, 2016). 
Successful completion of treatment captures only one facet of the OUD recovery 
process. Relapse is common (e.g. for 60% within six months after leaving treatment in 
one US study; McLellan et al., 2005). The process of achieving a stable recovery can 
involve several treatment cycles over the course of a decade (Dennis et al., 2005; Hser 
et al., 1997). To fully assess the effectiveness of treatment systems, national 
administrative databases need to be able to capture this process, but the requirements 
of such systems are difficult to implement.  In the US, the absence of patient consent 
prevents linkage across consecutive treatment episodes in the Treatment Episode 
Data Set, operated by the Substance Abuse and Mental Health Services 
Administration. The impact of this is twofold: it is not possible to objectively assess 
whether an individual has previously engaged in treatment (an indicator of patient-level 
complexity; Marsden et al., 2012b); it is also not possible to determine whether a 
patient’s successful completion status is enduring or transient. 
1.7 SUB-POPULATION ANALYSIS 
In 1967 the Addiction Research Unit was established at the Institute of Psychiatry in 
London at the behest of the then Minister of Health. This multidisciplinary team 
instigated a 10-year follow up study of patients accessing the new treatment Clinics in 
1969. They took a sample of 128 patients, which represented around 12% of all 
patients accessing treatment at the time (Stimson and Oppenheimer, 1982). Although 
still relatively small in number, this study was the first in-depth analysis of treatment 
effectiveness in England. A typological approach was undertaken using cluster analysis 
and patients were identified as belonging to one of four behavioural categories: 
‘stables’, ‘junkies’, ‘loners’ and ‘two-worlders’ (Stimson, 1972). These groups differed 
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significantly on a number of domains, including employment, criminal involvement, 
hospitalisations and social connections with other addicts. 
Unlike the variable-centred approach adopted by Stimson (1972), sophisticated 
person-centred methods to empirically derive sub-populations within cross-sectional 
and longitudinal data have been emerging in recent years (Asparouhov and Muthén, 
2014; McCutcheon, 1987; McLachlan and Peel, 2000; Muthén and Muthén, 2000; 
Nagin, 2005). In the case of cross-sectional data, Latent Class Analysis (LCA) is a 
useful tool used to assign patients to a sub-group of patients who, more or less, share 
the same characteristics over several indicators which are collected at the same point 
in time.   
At the start of treatment, an assessment of any given patient yields substantial 
information about their clinical history including, for example, concurrent substance 
use. Concurrent substance use typically involves the use of one or more of the 
following substances alongside heroin: alcohol, cocaine powder, smokeable (crack) 
cocaine and benzodiazepines (Darke and Hall, 1995; Harrell et al., 2012; Kuramoto et 
al., 2011; Monga et al., 2007). Identification of sub-populations is important as certain 
groups may vary with respect to drug-related harm. For example, heroin smokers who 
use crack cocaine are substantially less likely to be infected with Hepatitis C virus than 
those who inject heroin (Harrell et al., 2012). Opioid users with concurrent substance 
use have been observed to have greater health and social problems (Leri et al., 2003) 
and a relatively poorer response to OUD treatment (Williamson et al., 2006; Marsden et 
al., 2011, 2009).  
Application of sub-population analyses to longitudinal data may distinguish between a 
sub-group of patients who respond well to treatment and another that does not. 
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Generally, studies examine longitudinal change at the cohort level in the aggregate, 
and tend to report a progressive response to treatment. In the national Australian 
study, the rate of heroin abstinence across one-, three- and 11-year follow-up was 
59%, 66% and 75%, respectively (Teesson et al., 2015). Patients accessing 
methadone treatment in England also demonstrated growth in abstinence rates, albeit 
at a lower rate than the Australian study, rising from 14.1% at Year 1 to 24.3% at Year 
2 and 25.7% by 4-5 years (Gossop et al., 2003). In the same study, patients accessing 
residential treatment appeared to make more substantial gains by Year 1 (46.5% 
abstinent), and then slowed in the rate of growth, with 48.6% abstinent by 4-5 years. In 
the US, abstinence actually reduced from 75.9% at one-year to 68.9% at five-years for 
patients accessing outpatient methadone treatment and from 97.5% to 90.3% for 
patients accessing long-term residential care (Hubbard et al., 2003).   
These population averaged estimates, however, can mask differential response during 
treatment among OUD sub-populations. For example, in a large-scale English national 
study, 37% of adults with OUD achieved abstinence from opioid use within six months 
of initiating treatment while 31% improved, 3% deteriorated, and the remaining 29% did 
not reliably change their opioid use from admission (Marsden et al., 2009). 
Disaggregation of response in treatment can also been approached longitudinally as a 
study of developmental trajectories. Employing latent growth statistical techniques with 
a sample of 471 male heroin users studied over 16-years, Hser and colleagues 
identified three classes (Hser et al., 2007). The majority were classified as ‘stably high-
level’ users of opioids (59%), while a third (32%) were ‘late-decelerated users’ and a 
minority (9%) were ‘early-quitters’. In a further 10-year study of heroin, cocaine and 
methamphetamine users five drug use trajectories were identified among 1,797 
patients: ‘high use’ (30.3%); ‘increasing use’ (14.5%); ‘decreasing use’ (14.1%); 
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‘moderate use’ (35.5%), and ‘low use’ (5.6%)(Hser et al., 2008b). The authors noted 
that heroin users were disproportionally represented in the ‘high use’ group.  
In an important study of change across 30 years, Grella and Lovinger (2011) reported 
that nearly half of their OUD cohort had died, and among survivors (n=486), four drug 
use trajectories were identified: approximately a quarter were classified as a ‘no 
decrease’ group; quarter comprised the ‘rapid decrease’ group; 35% formed a ‘gradual 
decrease’ group and the remaining 15% had a ‘moderate decrease’ response. In a 
recent report from Hser’s group, four groups were identified in a cohort of 795 patients 
enrolled in a treatment trial and followed up after 4.5 years (Hser et al., 2017). The 
majority formed a ‘low use’ group (42.0%), followed by ‘high use’ (22.3%), ‘decreasing 
use’ (18.6%) and ‘increasing use’ (17.1%) groups. Participants in the ‘decreasing use’ 
group spent more time in treatment across the follow up period than those in the ‘high 
use’ group. Comparable groups have been reported in Australian research. Teeson 
and colleagues identified six distinctive trajectories among 428 OUD patients (Teesson 
et al., 2017a). The largest group demonstrated ‘no decrease’ (22.1%), followed by 
‘gradual decrease’ (21.5%), ‘gradual decrease to near abstinence’ (17.1%), ‘rapid 
decrease to maintained abstinence’ (16.1%). ‘rapid decrease with late relapse’ 
(15.8%), and ‘rapid decrease with rapid relapse’ (7.5%). 
Several patient-level characteristics have been linked to developmental trajectories 
associated with a poor treatment response, including: males and people from some 
ethnic minorities, and among those with less educational achievement, greater 
behavioural problems, earlier involvement with the criminal justice system, earlier onset 
of drug use (Grella and Lovinger, 2011; Hser et al., 2008b, 2007). Membership of less 
responsive trajectories is associated with worse outcomes in terms of substance use, 
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mental health, physical health and mortality (Hser et al., 2007; Teesson et al., 2017a; 
Hser et al., 2017).  
1.8 THESIS AIMS 
This thesis presents a series of three linked analyses of the National Drug Treatment 
Monitoring System (NDTMS). Overall, this thesis will contribute to the evidence base 
for OUD treatment by examining a national cohort of patients admitted to treatment in 
England. It applies modern statistical techniques to identify sub-populations of OUD 
patients and estimates whether or not sub-populations at treatment entry or sub-
populations over the course of treatment exhibit a differential likelihood of recovering 
from OUD. 
AIM 1 
To identify sub-populations of OUD patients at the start of treatment, using Latent 
Class Analysis, and to investigate whether, and to what degree, these sub-populations 
differ in completing treatment successfully over five years. 
AIM 2 
To identify longitudinal sub-populations of OUD patients based on their self-reported 
heroin use, through Latent Class Growth Analysis, in patients who have been 
continuously enrolled in opioid substitution treatment for five years and to estimate 
whether or not these sub-populations are predictive of eventually completing treatment 
successfully. 
AIM 3 
To identify sub-populations according to use of other substances routinely monitored in 
the course of treatment in England, including: alcohol, cannabis, crack cocaine, 
cocaine powder, amphetamines, and ‘other drugs’, to examine how these trajectories 
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relate to heroin use trajectories, and to estimate whether or not membership modifies 
the likelihood of completing treatment successfully.  
  
52  
Chapter 2  DESIGN AND METHODS 
2.1 OVERVIEW 
This thesis is based on data extracted from the National Drug Treatment Monitoring 
System (NDTMS). Patients included in this thesis were from all the local treatment 
systems in England and all the operational specialist community agencies in the NHS 
and third-sector providing pharmacotherapies, psychosocial interventions and 
adjunctive support services for OUD in community, in-patient (short-term medically 
supervised withdrawal), and residential (drug-free rehabilitation) settings. All adults 
(≥18 years) diagnosed with OUD who presented for treatment in England between 1 
April 2008 and 31 March 2009 were selected. 
As shown in Figure 2.1, 56,156 patients were referred to treatment in 2008/09. There 
were 1,799 patients (3.2%) who did not commence a single treatment intervention by 
31 March 2014 and were therefore excluded from all analyses. The final cohort for 
Study 1 were those patients who were discharged from their index treatment journey 
during the five-year observational period (n=45,467; 85.5%). The remaining 7,890 
patients (14.5%) were continuously enrolled in treatment for the five-year period. Of 
these, 171 patients were removed from further analysis as they had not completed the 
heroin use frequency item on the Treatment Outcomes Profile throughout the entire 
five-year period (n=158) or had not been continuously enrolled in OST for the five-year 
period, yielding a cohort of 7,719 patients for Study 2. For Study 3, two patients were 
removed due to missing data on all other substances on the TOP throughout the study 
period, leaving a final cohort of 7,717 patients.
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Figure 2.1 Data flow for studies 
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2.2 NDTMS 
NDTMS is the England national core dataset of all clients accessing drug and alcohol 
treatment. All publically funded treatment agencies are required to submit data to 
NDTMS on a monthly basis. The system started in 2001 and has been operational 
since 2005. It has been managed by Public Health England (PHE) since 2013. Patient 
consent is required for data to be submitted to PHE, and over 98% of patients provide 
this consent (Marsden et al., 2009). As part of the consent process, patients also 
empower PHE to conduct research on treatment effectiveness (Public Health England, 
2018d, 2018e). 
NDTMS is designed to capture key information at each stage of the treatment process. 
A referral to treatment marks the start of the treatment process. Referrals into the 
treatment system can broadly be categorised into self-referrals, referrals from the 
criminal justice system and other referrals, such as accident and emergency 
departments or psychiatric units. During the first face-to-face meeting, an initial triage 
assessment is conducted by clinical staff. Where a treatment need is clinically 
indicated, the substance(s) and patient demographics are recorded on NDTMS and an 
appointment for a treatment intervention is arranged. For OUD patients, the average 
waiting time for the first intervention is 1.7 days and approximately 98% of patients start 
an intervention within three weeks (Public Health England, 2018a). All treatment 
interventions are recorded on NDTMS. Ongoing treatment is available for as long as is 
clinically indicated, until recovery from OUD is achieved, or a patient declines to 
partake in further treatment. 
2.3 TREATMENT EPISODES AND JOURNEYS 
Following the NDTMS reporting protocol, each patient-level ‘treatment journey’ 
comprised a single episode of pharmacotherapy or psychosocial intervention provided 
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by a clinic, enrolment in concurrently delivered medication and psychosocial 
interventions (from one or more clinics), or a continuing care package in which an 
intervention was followed by one or more further interventions. Episodes commencing 
after 21 days are classified as a new treatment journey (Public Health England, 2015a). 
Recovery support services are offered concurrently or following a treatment episode. 
Patients and treatment provisions are regularly reviewed and at the end of the 
‘treatment journey’ patients who overcome their dependence are successfully 
discharged from the treatment system. 
2.4 PATIENT IDENTIFIERS 
As set out in the confidentiality documentation (Public Health England, 2018d, 2018e), 
NDTMS does not collect a patients full name and address. Instead, it only collects 
patient initials, date of birth, gender, partial postcode and local authority of residence. 
This patient-level information forms part of every record submitted to NDTMS and is 
critical to constructing the patient entity on which all treatment provider, local authority 
and national statistics are generated. 
2.5 MEASURES 
2.5.1 TRIAGE ASSESSMENT 
As part of the core dataset, NDTMS collects information on the patient demographic, 
clinical information and previous treatment exposure. Utilised throughout this thesis are 
the following triage covariates: sex, age, ethnicity, employment, homelessness, 
injecting status, years using heroin, referral route, and whether or not a patient had 
previously accessed treatment. Concurrent substance use disorders are also collected, 
including but not limited to: crack cocaine, cannabis, alcohol, other illicit opioids, 
benzodiazepines, alcohol and other stimulants. As patient residential postcodes are 
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also collected by NDTMS, it is possible to link with the English Indices of Multiple 
Deprivation (IMD). 
2.5.2 TREATMENT OUTCOMES PROFILE 
The Treatment Outcomes Profile (TOP) was implemented across the English treatment 
system in October 2007 and is the national standard for reported in-treatment 
outcomes. The TOP is composed of 20 items that capture the frequency of use of 
opioids, crack cocaine, cocaine powder, amphetamines, cannabis, alcohol and one 
‘other’ substance over the past 28 days. Also recorded are: injecting behaviour; the 
client’s subjective ratings of physical health, psychological health, and quality of life; 
and the client’s reports of criminal behaviours and indicators of social functioning. The 
TOP has shown excellent test-retest reliability for heroin use κ=0·79 and heroin 
abstinence κ=0·88 (Marsden et al., 2008). The TOP is designed to help review clients’ 
progress towards attaining personal treatment goals. These core data are reported to 
NDTMS at the start of treatment, every six months during treatment, and at discharge. 
The date the TOP assessment is completed is also submitted to NDTMS. Responses 
on the TOP are taken to pertain to the 28-day period prior to this date. The date is 
overlaid on the treatment journey. A TOP assessment completed within 14-days of the 
first modality date in the treatment journey is considered the treatment start, or 
admission, assessment. Where multiple TOPs are submitted for an individual, in the 
case for example when a patient accesses two treatment providers, the first 
assessment is utilised. TOPs subsequently submitted throughout the treatment journey 
are allocated into 6-month slots and where multiple TOPs are submitted within a given 
slot the latest assessment is utilised. At the end of treatment, signified by the discharge 
date of the final open modality, the latest TOP completed within +/- 14-days of this date 
is considered the discharge TOP. 
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2.5.3 TREATMENT INTERVENTIONS 
NDTMS records how long patients are in receipt of pharmacological, psychosocial, in-
patient detoxification and residential rehabilitation interventions. Pharmacological 
interventions usually involve a daily dose of an oral opioid agonist (i.e. methadone), a 
partial agonist (i.e. buprenorphine) or sometimes an antagonist (i.e. naltrexone). 
Patients are supported by a keyworker throughout the pharmacological intervention. 
Psychosocial interventions are also recommended, and are usually available from a 
specialist provider, which are often, but not always, available at the same service 
providing the pharmacological intervention. Psychosocial interventions can include 
contingency management, behavioural couples therapy, and cognitive-behavioural 
therapies. In-patient detoxification is sometimes required before a patient can engage 
in community-based treatment. Residential rehabilitation is generally a high-cost and 
low-volume intervention, reserved primarily for the most complex of cases. 
2.5.4 DISCHARGE STATUS 
When a patient is discharged from treatment, one of the following exit reasons are 
recorded: successful completion; drop-out (patient left treatment without discussion or 
before completing their care plan); unsuccessful transfer (patient was referred to 
another treatment service but did not enter treatment within 21 days); incarceration 
(treatment is prematurely terminated due to criminal justice action); or patient died. 
After this point, further treatment is classified as a new treatment journey.  
2.5.5 OUTCOME MEASURE 
The outcome measure used in all three studies was a composite measure of treatment 
effectiveness combining ‘successful completion’ and ‘no re-presentation’ (SCNR). In 
Study 1, the ‘successful completion’ component was measured within five years of 
patients initiating their index treatment journey. In Study 2 and Study 3, where clients 
were by definition already in treatment at the five-year mark, the ‘successful 
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completion’ component was measured in Year 6 and Year 7. Successful completion is 
defined as a clinician-verified report of a patient who had completed OST, was in 
remission from OUD, was abstinent from heroin and crack cocaine, and had achieved 
their care plan goals. The ‘no re-presentation’ component captures the extent to which 
this remission from OUD is enduring. In each study, I conducted a linkage with NDTMS 
six months following the discharge date to identify and remove patients from the 
composite treatment effectiveness criterion if they had re-presented to treatment within 
this timeframe. In Study 2 and 3, I was able to enhance this method by conducting a 
further linkage with prison-based treatment and the drug-related poisoning database to 
also remove patients from the treatment effectiveness criterion if they has been 
incarcerated or succumbed to fatal overdose in the six month period following 
discharge. 
2.6 DATA STRUCTURE 
There is a hierarchical, or multi-level, structure to the data captured by NDTMS. 
Patients access treatment from a local provider in their area. Outcomes for patients 
from a given treatment provider are likely to be correlated as the same clinicians deliver 
similar treatment interventions to each of their patients. As such, patients are said to be 
‘nested’ within the treatment provider. Further, each treatment provider is also ‘nested’ 
within a local administrative area responsible for the commissioning and delivery of 
drug treatment. As each local commissioner will set their own delivery targets for the 
treatment providers, this may influence the strategic decision making of providers in the 
local area, which may also lead to a correlation of outcomes among local providers. 
Failure to account for the hierarchical structure of the data can lead to biased estimates 
when modelling (Kahan and Morris, 2013), the results of which can misinform clinicians 
and policy-makers. 
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In Study 1, a total of 1,421 specialist treatment agencies submitted data on patients (n= 
54,357) initiating treatment in 2008/09 (median of 12 patients per service; interquartile 
range [IQR] 3–45) and there was a median of 302 patients per local treatment area 
(IQR 184–470]. A three-level multivariable logistic regression was used to analyse the 
primary study outcome (i.e. patients nested in agencies, nested in local areas; see 
Section 2.6.4). In Study 2 and 3, however, the cohort was substantially reduced to less 
than 15% of the original cohort and there were too few patients at each treatment 
agency to incorporate this level in the modelling. As such, two-level (i.e. patients 
nested in local area) models were utilised to analyse the primary study outcome. 
2.7 STATISTICAL ANALYSES 
2.7.1 LATENT CLASS ANALYSIS 
Latent Class Analysis (LCA) is a person-centred analytical approach that enables the 
researcher to identify sub-populations within cross-sectional data. LCA assesses the 
relationships between two or more discrete observed variables and clusters individuals 
together based on the similarity of their responses. In Study 1, LCA was utilised to 
identify patterns of poly-drug disorders from the concurrent substance use disorders 
which patients reported at the start of treatment. The substances included crack 
cocaine, cannabis, alcohol; non-medical opioids, stimulants (powder cocaine and d-
amphetamine) and benzodiazepines. The potency of LCA lies in its ability to identify a 
relatively small set of sub-populations, which may differ in their response to treatment. 
With six concurrent substances under investigation, there are 64 possible combinations 
(i.e. 26 = 64). This makes estimating the differential response to treatment difficult as 
there would be 2016 pairwise tests to perform (i.e. (64*63)/2 = 2016). LCA substantially 
reduces this complexity by positing that there is an underlying (i.e. hidden or latent) 
categorical variable that divides people into mutually exclusive groups (i.e. classes). 
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The LCA was iterative with an unconditional 1-class model initially fit to the data and 
sequentially increased to a 6-class model. Each model used 5,000 random sets of 
starting values to guard against convergence on local maxima (McLachlan and Peel, 
2000) and a minimum class size of 5% of the cohort was set for utility (Willey et al., 
2016a; Borders and Booth, 2012). Class identification was informed by posterior fit 
statistics, including the Bayesian and Akaike information criteria and entropy. Patients 
can be fractionally assigned to multiple classes. For example, in a three class solution, 
there may be a 90% probability a patient belongs to Class A, a 7% probability they 
belong to Class B and a 3% chance of belonging to Class C. In Study 1, I assigned 
patients to their most probable class. 
2.7.2 LATENT CLASS GROWTH ANALYSIS 
Previously, I have used the reliable change index (Jacobson and Truax, 1991) to 
identify sub-populations of patients as they progress through treatment across two time 
periods, classifying patients into abstinent, improved, deteriorated or unchanged 
(Marsden et al., 2011). With 11 time periods available in Study 2 and Study 3, however, 
the reliable change index method is not a sustainable approach as there are more than 
a million potential combinations (i.e. 410 = 1,048,576).  
Latent Class Growth Analysis (LCGA) is another person-centred approach and is 
appropriate for identifying a limited set of sub-populations from longitudinal data, 
particularly when there is anticipated heterogeneity in response over time (Grella and 
Lovinger, 2011; Hser et al., 2008a; Teesson et al., 2017b). LCGA has been utilised in 
several substance use studies, including: cocaine (Borders and Booth, 2012); 
methamphetamine (Brecht et al., 2008); cannabis (Caldeira et al., 2012); alcohol 
(Delucchi et al., 2004), and tobacco (Klein et al., 2013). 
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In Study 2, LCGA was used to empirically identify discrete, non-overlapping 
developmental trajectories of opioid use over a five-year period. In Study 3, the same 
LCGA approach was utilised to identify discrete, non-overlapping developmental 
trajectories for alcohol, crack cocaine, cannabis and the ‘other’ substance recorded on 
the TOP. As the prevalence of cocaine power and amphetamines never exceeded 5% 
across the five-year observational period, I did not apply LCGA to these substances. 
A three-step procedure has been recommended (Nagin, 2005) to prevent trajectory 
group membership being influenced by both the covariates set and the distal outcome 
(Huang et al., 2010). In this approach, the identification and assignment of classes 
stems from an unconditional model (i.e. one without covariates and outcome) based on 
reported opioid use over the five-year in-treatment period.  
LCGA is highly flexible. The method allows for latent intercept, latent slope, latent 
quadratic and higher latent terms (i.e. cubic etc) to be incorporated into the model. 
Because a model with a latent intercept only would imply zero change over time, I 
began by applying a latent intercept and a latent slope to the data using a single class 
solution (i.e. all patients belong to the same trajectory group). This model is capable of 
determining whether drug use increases or decreases over time, or if there is no 
reliable change. A further model was then generated including a latent quadratic term, 
allowing me to determine whether change is accelerating or decelerating over time. I 
used the Bayesian and Akaike information criteria to inform whether the inclusion of a 
latent quadric term improved model fit, and judged that incorporation of a latent 
quadratic term improved the models but that adding higher latent terms would add 
unnecessary complexity to the modelling process. 
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An iterative process was then implemented in which the number of classes fit to the 
data were sequentially increased up to a 6-class model. Each model assumed a 
Poisson distribution to model the count of heroin-using days and used 5,000 random 
sets of starting values to guard against convergence on local maxima (McLachlan and 
Peel, 2000). A minimum class size of 5% of the cohort was set for utility (Borders and 
Booth, 2012; Willey et al., 2016). Trajectory identification was informed by posterior fit 
statistics, including the Bayesian and Akaike information criteria and entropy. As 
patients are nested within different local treatment systems, a multi-level LCGA model 
was fitted, and intra-class correlation for each class was computed (Asparouhov and 
Muthén, 2007). As in the LCA approach, patients were assigned to their most probable 
trajectory class. 
2.7.3 MULTINOMIAL LOGISTIC REGRESSION 
A multinomial logistic regression was used to characterise the latent classes from both 
the LCA (Study 1) and LCGA (Study 2 and Study 3) approaches on the patient-level 
characteristics (STATA command: mlogit). Given the hierarchical structure of the study, 
with patients clustered in treatment services and services clustered in local treatment 
systems, confidence intervals (CI) were calculated using robust standard errors. 
Multinomial logistic regressions produce the relative risk ratio (RRR). The RRR is an 
estimate of how the risk of belonging to one class, relative to a referent class, is 
affected by patient-level characteristics.  
2.7.4 MULTILEVEL LOGISTIC REGRESSION 
A multilevel, multivariable logistic regression was utilised to estimate the likelihood of 
SCNR (STATA command: meqrlogit). In Study 1, the intraclass correlation (ICC) was 
used to assess intercept variation at the levels of treatment agency and local treatment 
area. In Study 2 and Study 3, the ICC was calculated for the local treatment area only 
(see section 2.6). 
63  
In all studies, a combination of variable-centred and person-centred covariates were 
used. In Study 1, together with the variable-centred covariates outlined in section 2.4.1, 
the person-centred drug use sub-populations derived from the LCA analysis were also 
included. In Study 2, I added to the set of covariates by including the heroin use 
developmental trajectories derived from the LCGA analysis. I also included a set of 
adjunctive treatment exposure measures; i.e. whether or not, alongside OST, patients 
had been exposed to psychosocial, in-patient detoxification or residential rehabilitation 
interventions. In Study 3, I ran separate analyses for each of the heroin developmental 
trajectory groups and added the alcohol, crack cocaine, cannabis and ‘other drug’ 
developmental trajectory groups to the above covariate set. 
2.7.5 MISSING DATA 
Both LCA and LCGA implement a full information maximisation likelihood approach. As 
a result, a patient with at least one assessment of substance use can be assigned to a 
latent class describing their longitudinal patterns of substance use. Analyses following 
LCGA are, however, likely to be impacted by the extent of missing data in the baseline 
predictors in a given model. Because a complete case analysis is likely to induce bias 
and risks reducing the precision of estimates (with no evidence that either the 
predictors or outcome variables were not missing-at-random (Little and Little, 2002)), a 
multiply imputed dataset was created for subsequent analyses (STATA procedure MI 
impute chained). Logistic regression, multinomial regression and predictive mean 
matching were utilised, respectively, for binary, multinomial or continuous covariates 
with missing data. Twenty probabilistic datasets were imputed and combined in 
analyses using Rubin’s rules, resulting in a relative efficiency of over 98% (Rubin, 
1987) and a reduction in power of than 1% (Graham et al., 2007). 
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2.8 SOFTWARE USED IN THIS THESIS 
SPSS version 21 was used for data management of the NDTMS extract. STATA 
version 13.1 and 15.1 were utilised for multinomial logistic regressions and logistic 




Chapter 3  STUDY 1: EFFECTIVENESS OF TREATMENT 
FOR OPIOID USE DISORDER: A NATIONAL, FIVE-YEAR, 
PROSPECTIVE, OBSERVATIONAL STUDY IN ENGLAND 
3.1 DESCRIPTION OF STUDY IN THE CONTEXT OF THE THESIS 
This chapter presents a five-year investigation into the effectiveness of treatment in a 
national cohort of patients accessing treatment for OUD in England. NTORS (Section 
1.3.2.4) was the last five-year, national cohort, study of patients accessing drug 
treatment services in England. The present study investigates the population of OUD 
patients initiating treatment in 2008/09, utilises Latent Class Analysis (Section 2.6.1) to 
identify sub-populations of OUD patients at treatment admission, and estimates the 
association between sub-population membership on an objective summative measure 
of treatment effectiveness: successful completion and non-representation.  
This study was published as follows:  
Eastwood, B., Strang, J., Marsden, J., 2017. Effectiveness of treatment for opioid use 
disorder: A national, five-year, prospective, observational study in England. 





BACKGROUND: This the first 5-year effectiveness study of publicly funded treatment 
for opioid use disorder (OUD) in England.  
METHODS: All adults initiating treatment in 2008/09 in all 149 local treatment systems 
reporting to the National Drug Treatment Monitoring System (n=54,347). Admission 
polydrug use sub-populations were identified by Latent Class Analysis. The treatment 
outcome measure was ‘successful completion and no re-presentation within six 
months’ (SCNR) analysed by multilevel, multivariable logistic regression and funnel 
plots to contrast outcome by treatment system.  
RESULTS: SCNR was achieved by 21.9%. Heroin and crack cocaine users were 
significantly less likely to achieve this outcome than patients who used heroin only 
(adjusted odds ratio [AOR] 0.90; 95% confidence interval [CI] 0.85-0.95). Older patients 
(AOR 1.09; CI 1.07-1.11), those employed (AOR 1.27; CI 1.18-1.37) and those enrolled 
for longer treatment were more likely to achieve the outcome measure. After risk 
adjustment, the local treatment systems that achieved substantially better outcome 
performance (14/149) had a lower rate of opiate prevalence in the local population at 
time of study initiation (incidence rate difference [IRD] 4.1; CI 4.0-4.2), fewer criminal 
offences per thousand (IRD 28.5; CI 28.1-28.8) and lower drug-related deaths per 
million (IRD 5.9; CI 5.9-5.9). 
CONCLUSIONS: In an English national study, one fifth of patients successful 
completed treatment for OUD and did not present for further treatment within six 
months. Longer time in treatment increases the probability of achieving and 
maintaining clinical benefit from treatment. After risk-adjustment, an important minority 




Heroin and non-medical opioids are associated with a substantial global burden of 
disease (Degenhardt et al., 2013). In the United States (US), it is estimated that 2.6 
people per 1,000 aged 12 and above used heroin in the past year (Jones et al., 2015). 
In Europe, the estimated annual heroin use prevalence is 4 per 1,000 aged 15-64 
(EMCDDA, 2015) and 7.3 per 1,000 among people aged 16-64 in England (Hay et al., 
2014).  
Opioid use disorder (OUD), and the conceptually identical ‘opioid dependence’, is a 
debilitating and often chronic bio-behavioural disorder (DSM-5; American Psychiatric 
Association, 2013; ICD-10; WHO, 2016). People with OUD typically use illicit heroin 
and/or non-medical opioid pharmaceutical products, developing physiologically 
dependence and strong motivational urges. Around one quarter of opioid users develop 
OUD (Gable, 1993;  Anthony et al., 1994). Left untreated, OUD typically follows a 
chronic course causing substantial health, social and economic problems (Hser et al., 
2001; Grella and Lovinger, 2011; Hser et al., 2015). In the classic Grella and Lovinger 
study, half of the sample died and a quarter did not experience any sustained 
improvement in their drug use (Grella and Lovinger, 2011).  
The OUD population is far from homogenous. Several behaviours are associated with 
increasing severity of the disorder (Marsden et al., 2014) and treatment effectiveness 
may vary between sub-populations. For example, drop-out is more likely among 
patients with comorbid psychiatric conditions and more criminal justice involvement in 
the year before treatment, and less likely among those living with dependent children 
(Evans et al., 2009). Ethnic minority populations have been reported to have a lower 
rate of treatment episode completion (Mennis and Stahler, 2016). An important sub-
population are polydrug users, typically involving concurrent use of one or more of the 
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following: alcohol, cocaine powder, smokeable (crack) cocaine and benzodiazepines 
(Darke and Hall, 1995; Monga et al., 2007; Harrell et al., 2012; Kuramoto et al., 2011). 
Heroin smokers who use crack cocaine are substantially less likely to be infected with 
Hepatitis C virus than those who inject heroin (Harrell et al., 2012). Opioid-polydrug 
users have been observed to have greater health and social problems (Leri et al., 
2003b) and a relatively poorer response to OUD treatment (Williamson et al., 2006; 
Marsden et al., 2011, 2009).  
The majority of countries with a high prevalence of OUD have an array of well-
developed treatment services. The opioid medications methadone and buprenorphine 
are front-line, randomised-controlled trial supported pharmacotherapies (Mattick et al., 
2014, 2009). In England, some OUD patients may receive psychosocial interventions 
without opioid psychotherapy. Interventions are typically provided by specialist 
community, primary care and hospital providers. Inpatient withdrawal management and 
drug-free residential rehabilitation services are also available (Clinical Guidelines on 
Drug Misuse and Dependence Update 2017 Independent Expert Working Group, 
2017). In addition to case management, national clinical guidelines recommend 
psychosocial interventions to address cognitive and behavioural symptoms of OUD 
(e.g. National Institute for Clinical Excellence, 2007).  
Internationally, there have been several longitudinal cohort studies of the effectiveness 
of these interventions as delivered under routine conditions by US, Australian and 
English public treatment systems (e.g. Simpson and Sells, 1990; Stewart et al., 2002; 
Darke et al., 2007; Marsden et al., 2009; White et al., 2015). Taken together, these 
studies conclude that treatment is associated with reduced opioid use, drug injecting, 
and offending behaviour, and improvements in health (including a substantially reduced 
risk of fatal overdose), social functioning and employment.  
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Longitudinal cohort studies are time consuming and expensive. Public accountability 
means that the commissioners of publicly funded services need information on the 
effectiveness of treatment as it is delivered. Various proxy measures of outcome have 
been used in treatment systems research, including unsanctioned discharge (drop-out) 
from treatment and retention (Brorson et al., 2013; Stark, 1992; Faggiano et al., 2003). 
A commonly used measure is the proportion of patients treated who complete 
treatment successfully (Alterman et al., 2001). This indicator is associated with reduced 
drug use (Evans et al., 2009; Kornør and Waal, 2005), increased employment (Lang 
and Belenko, 2000; Zarkin et al., 2002; Evans et al., 2009; Sung and Chu, 2011), lower 
arrests and incarceration (Campbell et al., 2007; Evans et al., 2009; Gifford et al., 
2014), and a reduced likelihood of readmission to treatment services (Luchansky et al., 
2000). In the US, substantial inter-state (Arndt et al., 2013) and regional variation in 
completion rates have been reported (Hawkins et al., 2014), and this is now monitored 
at the federal/government level (Stahler et al., 2016). 
The ‘successful completion’ indicator has a key limitation – it does not capture the 
extent to which treatment benefit is enduring. This is important because relapse is 
common, affecting 50-60% of people within six months after leaving treatment 
(McLellan et al., 2005). The process of achieving stable recovery from OUD may 
involve several cycles of treatment over a decade or more (Dennis et al., 2005; Hser et 
al., 1997).  
To fully assess the effectiveness of treatment systems, national administrative 
databases need to be able to capture this process, yet the requirements of such 
systems are difficult to implement. In the US, the absence of a patient consent prevents 
linkage across consecutive treatment episodes. At the national level, the impact of this 
is twofold: it is not possible to objectively assess whether an individual has previously 
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engaged in treatment (an indicator of patient-level complexity (Marsden et al., 2012b; 
Siguel and Spillane, 1978). It is also not possible to determine whether a patient’s 
successful completion status is enduring. 
England has a well-developed public treatment system for drug use disorders with 
service delivery involving specialist clinics in the National Health Service (NHS) and 
non-governmental sector. Services are commissioned by 149 local treatment systems 
across the country aligned to local government geographical boundaries. All public 
providers report clinical and effectiveness data to the National Drug Treatment 
Monitoring System (NDTMS). NDTMS is operated by Public Health England and 
provides outcome monitoring and performance benchmarking for each local system 
(see Marsden et al., 2009 for an operational description). The latest national report 
shows that 28% of people treated for OUD complete treatment successfully (Public 
Health England, 2016a).  
With temporal linkage of episodes, NDTMS can record re-presentation to treatment as 
a proxy remission indicator. To our knowledge, a ‘successful completion and no re-
representation’ outcome measure has not been used in previous OUD treatment 
systems research. Accordingly, the aim of this study was to estimate the effectiveness 
of OUD treatment in England for OUD using this indicator and contrast the 
effectiveness of local treatment systems.  
3.4 METHODS 
3.4.1 DESIGN 
This was an English national, five-year, prospective, observational cohort study of 
publicly-funded, specialist treatment services for OUD reporting to the NDTMS, and 
reported following the STROBE guideline for observational research (Elm et al., 2007). 
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The population for the study was all adults (≥18 years) diagnosed with OUD who 
presented for treatment in England between 1 April 2008 and 31 March 2009.  
The study included all local treatment systems and all operational specialist community 
agencies in the NHS and third-sector providing pharmacotherapies, psychosocial 
interventions and adjunctive support services for OUD in community, inpatient (short-
term medically supervised withdrawal), and residential (drug-free rehabilitation) 
settings. 
3.4.2 OUD TREATMENTS  
The opioid pharmacotherapies included methadone, buprenorphine and also 
naltrexone. Psychosocial interventions such as contingency management and 
motivational interviewing complement pharmacotherapy and target underlying 
psychological aspects of dependence. In addition to opioid pharmacotherapy and/or 
psychosocial interventions, a patent’s treatment programme could include adjunctive 
‘recovery support’ services, including: facilitated access to mutual aid; complementary 
therapies; and family, housing, employment, education and training supports. 
3.4.3 TREATMENT EPISODES AND JOURNEYS 
Following the NDTMS reporting protocol, each patient-level ‘treatment journey’ 
comprised: a single episode of pharmacotherapy or psychosocial intervention provided 
by a clinic; enrolment in concurrently delivered medication and psychosocial 
interventions (from one or more clinics); or a continuing care package in which an 
intervention was followed by one or more further interventions. Episodes commencing 
after 21 days are classified  as a new treatment journey (Public Health England, 
2015a). Recovery support services are offered concurrently or following a treatment 
episode. Patients are regularly reviewed, treatment provision changes, and at the end 
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of the ‘treatment journey’, patients who overcome their dependence are successfully 
discharged from the treatment system. 
When a patient was discharged from treatment, one of the following exit reasons was 
recorded: successful completion; drop-out (patient left treatment without discussion or 
before completing their care plan); unsuccessful transfer (patient was referred to 
another treatment service but does not enter treatment within 21 days); incarceration 
(treatment is prematurely terminated due to criminal justice action); or patient died. 
After this point, further treatment was classified as a new treatment journey. 
3.4.4 OUTCOME MEASURE 
The outcome measure for the study combined two components: successful completion 
and no re-presentation. Successful completion was assigned to each patient that was 
reported by the clinic as meeting the following criteria within five years (ending 31 
March 2014):  
• in remission from OUD;  
• abstinent from all opioids and crack cocaine;  
• completed all opioid pharmacotherapy and psychosocial interventions;  
• met all care plan goals, with mutual agreement to exit treatment.  
For the ‘no re-presentation’ element of the outcome measure, we judged that a six-
month period was reasonable (ending 30 September 2014). Therefore, the 
effectiveness measure was assigned to those patients who met the above criteria at 
exit from treatment and did not re-present for any treatment within six months 
(‘successful completion, no re-representation’, SCNR for economy herein). 
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3.4.5 COVARIATES 
We followed an integrated variable-centred and person-centred approach to evaluate 
treatment effectiveness for OUD using the following patient demographic, clinical 
information and previous treatment exposure (all recorded at initial assessment): 
Demographic. Sex; age (centred at 18 years and grouped in five-year increments); 
Black and Minority Ethnicities (BME: a legal monitoring requirement (Race Relations 
(Amendment) Act, 2000)); employed; housing problems (defined primarily as having no 
fixed abode, but can also include squatting, short-term hostel/B&B, staying with 
friends/relatives; [(homeless, herein]). 
Social deprivation. Local area deprivation was measured by the Indices of Multiple 
Deprivation (IMD; Department for Communities and Local Government, 2007). IMD 
data were linked to NDTMS based on the patient’s residential postcode district or the 
location of their first treatment provider in instances of missing postcode information. 
As opposed to poverty, which indicates a lack of financial resources to meet a person’s 
needs, deprivation is a term that indicates a lack of resources across multiple domains, 
not just income (Ministry of Housing, Communities and Local Government, 2019). It is 
important to adjust for deprivation as it has been shown to be strongly associated with 
numerous outcomes in the OUD population including, for example, an increased risk of  
non-fatal overdose and longer prison sentences (Carrà et al., 2017) and a decreased 
likelihood of achieving abstinence from illicit heroin during specialist treatment 
(Marsden et al., 2012b). In the wider community, it is interesting to note that there is 
also an association between the level of deprivation and the rate at which General 
Practitioners prescribe anti-depressants, benzodiazepines, gabapentinoids, z-drugs 
and opioids (Marsden et al., 2019b). 
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The IMD used in this study is a summary measure of 37 distinct resource indicators 
covering income, employment, health and disability, education, housing, local 
environment and crime. The IMD is a relative measure of deprivation, meaning that 
while it can be used to indicate that a patient is from a more deprived area than another 
patient, it cannot be used, for example, to say that the former is twice as deprived as 
the latter. Deprivation has been estimated at a local level in England since the 1970s, 
and the 2007 estimates are generated for each of the 32,482 Lower Super Output 
Areas (LSOA) in England at the time (Department for Communities and Local 
Government, 2007). LSOAs are geographical areas in which 1,000 to 3,000 persons 
are resident. All postcodes within a given LSOA have been assigned the same 
deprivation value. It is important to note that the IMD measure provides only an insight 
into deprivation within a given LSOA, which is to say that many deprived people are 
resident in non-deprived areas and vice versa. Accurately capturing person-level 
deprivation is, however, beyond the scope of a national administrative database and 
the IMD is considered to provide a reasonable proxy of individual-level deprivation. 
Injecting status. Three levels of injecting status are recorded at the start of treatment: 
never injected; lifetime history of injecting, and current injector. 
Career length. The number of years between first initiating opioid use and enrolment in 
the index treatment journey (length of the substance-using career). This measure was 
mean centred and coded in five-year increments.   
Treatment history. Referral route into treatment was categorised into whether the 
patient was self-referred, referred via the criminal-justice system or other (e.g., referral 
from health service or substance abuse service). Whether an individual had previously 
accessed treatment was also included. 
75  
3.4.6 DRUG USE SUB-POPULATIONS 
Given anticipated heterogeneity in drug use profile of the OUD population at 
presentation to treatment (Monga et al., 2007; Public Health England, 2016a), we used 
latent class analysis (LCA [Section 3.1]) in Mplus to identify discrete sub-populations of 
OUD patients who presented for treatment with concurrent disorder with one or more of 
the following 6 substances: crack cocaine; cannabis; alcohol; non-medical opioids; 
stimulants (powder cocaine and d-amphetamine) and benzodiazepines.  
The LCA was iterative with an unconditional 1-class model initially fit to the data and 
sequentially increased to a 6-class model. Each model used 5,000 random sets of 
starting values to guard against convergence on local maxima (McLachlan and Peel, 
2000) and a minimum class size of 5% of the cohort was set for utility (Willey et al., 
2016a; Borders and Booth, 2012). Class identification was informed by posterior fit 
statistics, including the Bayesian and Akaike information criteria and entropy. A 
multinomial logistic regression was then used to characterise the latent classes on the 
patient-level characteristics. Given the hierarchical structure of the study, with patients 
clustered in treatment services and services clustered in local treatment systems, 
confidence intervals (CI) were calculated using robust standard errors.  
3.4.7 OUTCOME ANALYSIS 
A three-level, multivariable logistic regression was used for the analysis of the outcome 
measure (Stata command: meqrlogit). The complete-case model contained the 
following random intercepts: patients (level one); treatment services (level two); and 
local treatment system (level three). Model discrimination and variation (at level two 
and three) was estimated by c-index (Hanley and McNeil, 1982), and intra-cluster 
correlation (ICC), respectively.  
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Reflecting the hierarchical design of the study (Hofmann, 1997; Heo and Leon, 2008) 
and with alpha, statistical power and a medium effect size on the outcome measure 
pre-set (0.05, 0.90 and 2 = 0.15, respectively [Cohen, 1988]), we ensured that that 
there were at least 15 cases per covariate in the regression analysis to minimise 
overfitting (Green, 1991; Babyak, 2004).  
With no contrary evidence that data loss was missing-at-random (Little and Little, 
2002), a multiply imputed dataset was computed by chained equations (Stata 
command: mi: impute chained). An all-case multivariate logistic model was run to 
check on potential bias and loss of precision (Sterne et al., 2009). To achieve a relative 
efficiency above 98% (Rubin, 1987), and to ensure that reduction in power was less 
than 1% (Graham et al., 2007), 20 datasets of probabilistic values were created, each 
analysed separately, and then combined using Rubin’s rules. 
3.4.8 ANALYSIS OF LOCAL TREATMENT SYSTEMS  
A fixed-effects approach was used to determine the relative effectiveness of each local 
treatment system because random intercepts could mask real variation in achieving the 
outcome (Marsden et al., 2012b). For each treatment system, predicted outcome 
probabilities were summed across patients and divided by the number of patients 
treated in the area. A risk-adjusted outcome rate was then calculated by dividing the 
expected rate by the observed rate and multiplying this by the national average.  
A funnel plot with 95% control limits (Spiegelhalter, 2005) then identified areas where 
outcome performance was better or worse than expected (where the area was located 
above or the control limit, respectively). Local treatment systems rates of opiate 
prevalence, offending and drug-related deaths were contrasted by incidence-rate ratio.  
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Outcome performance was contrasted using pooled estimates of the rate of opiate 
users per thousand inhabitants (Hay et al., 2010), incidence of drug related deaths per 
million inhabitants (Public Health England, 2016b) and the criminal offence rate per 
thousand inhabitants (Office for National Statistics, 2016) The offending rate was 
based on the local area population estimates used in the development of the opiate 
prevalence estimates (Hay et al., 2010). 
3.5 RESULTS 
3.5.1 STUDY COHORT AND FOLLOW-UP 
The population for the study was all adults (≥18 years) diagnosed with OUD who 
presented for treatment in England between 1 April 2008 and 31 March 2009 
(N=56,156). As 1,799 (3.2%) people did not commence treatment by 31 March 2014, 
they were removed from further analyses.  
Patients in the cohort (n = 54,357) commenced treatment for OUD in 1,421 specialist 
clinics and primary care teams in the National Health Service (NHS) and the non-
governmental sector (median of 12 patients per service; IQR 3-45), and in all 149 local 
treatment systems in England (median 302 patients per area; interquartile range [IQR] 
184-470]).  
At the end of the five-year period, 7,890 people (14.5%) were continuously enrolled in 
treatment for OUD. Given the aims of the present study, this group was removed. 
Among the final all-case cohort (n = 46,467), 9,007 patients (19.4%) had missing 
observations on one or more covariates, yielding a complete-case cohort of 37,460. 
The covariate with the highest level of missing data was length of heroin use career 
(11.4%), followed by employment status (9.1%), housing status (3.4%) and injecting 
(3.4%). 
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3.5.2 DRUG USE SUB-POPULATIONS 
At clinical assessment, 67% of patients had a concurrent substance use disorder, as 
follows: crack cocaine (44.1%), cannabis (14.1%), alcohol (13.3%), other illicit opioids 
(11.4%), benzodiazepines (9.4%) and other stimulants (8.8%).  
Table 4.1 displays the results of the LCA models. The value of each information 
criterion (Akaike, Bayesian and adjusted Bayesian) reduced as the number of classes 
increased, indicating successively better fitting models. The bootstrapped likelihood 
ratio test confirmed that each model was a statistically better fit than the preceding one. 
Entropy was high (>0.8) for all except the 3-class solution, which reflected relative 
uncertainty in the assignment of individuals to the third class. The 5-class and 6-class 
solutions resulted, however, in at least one class with less 5% of the cohort. 
Accordingly, we judged that a 4-class solution best identified the heroin and other drug 
use sub-populations at treatment admission, and labelled these as follows: 
• Class 1 (n=30,339, 56%: heroin low level concurrent drug use disorders); 
• Class 2 (n=2,794, 5%: heroin, crack, alcohol); 
• Class 3 (n=17,907, 33%: heroin, crack); 





Table 3.1 Unconditional latent class analysis of drug use at presentation to treatment (n=54,347) 
 
     Model a       
Parameter Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
No. of parameters   6    13    20    27   34   41 
AIC 266,371.29 264,740.91 262,525.26 261,201.63 260,527.17 260,033.40 
BIC 266,424.71 264,856.65 262,703.32 261,442.02 260,829.88 260,398.43 
aBIC 266,405.65 264,815.33 262,639.76 261,356.22 260,721.83 260,268.13 
aBIC change (%) - -0.60 -0.82 -0.49 -0.24 -0.17 
Entropy - 0.999 0.718 0.830 0.861 0.857 
BLRT - -133,179.65 -132,357.45 -131,242.63 -130,573.82 -130,229.58 
BLRT reduction (%) - - 0.62 0.84 0.51 0.26 
Class (probability) 
      
1 1.00 (1.00) 0.44 (1.00) 0.06 (0.99) 0.56 (0.83) 0.29 (0.99) 0.01 (0.71) 
2 - 0.56 (1.00) 0.38 (1.00) 0.05 (0.99) 0.04 (0.97) 0.55 (0.79) 
3 - - 0.56 (0.69) 0.33 (0.99) 0.05 (0.99) 0.04 (0.99) 
4 - - - 0.06 (0.99) 0.06 (0.99) 0.06 (0.99) 
5 - - - - 0.56 (0.84) 0.29 (0.99) 
6 - - - - - 0.05 (0.98) 
AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion;  
aBIC, sample-size adjusted BIC; BLRT, bootstrapped likelihood ratio test (all P < 0.00005). 
a For the following drugs: crack cocaine, cannabis, alcohol, other opioids, benzodiazepines and other stimulants.  
Classification based on most likely latent class membership. 
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3.5.3 CHARACTERISTICS OF THE COHORT  
Table 3.2 shows the demographic and clinical characteristics of the cohort and the 
results of the multinomial logistic regression analysis of the profile of the drug problem 
classes on socio-demographic, injecting, heroin career and treatment referral 
characteristics (with the heroin and low concurrent drug use disorders [class 1] as the 
referent).  
There were relatively less employment and more homelessness among the members 
of classes 2, 3 and 4. Class 4 was also relatively more likely to be referred to treatment 
from the criminal justice system (35.3%) and have previous OUD treatment (50.4%).  
3.5.4 TREATMENT EXPOSURE AND STATUS AT EXIT  
Patients in the cohort received a median of 31.0 weeks of treatment (IQR 12.6-80.3) 
and 13,360 (28.8%) successfully completed their treatment journey (Table 3.3). One-
third (32.1%) of discharged patients were readmitted for further treatment for substance 
use disorders within six months.  
Readmission was more likely for those who were incarcerated (re-admission rate 
45.2%; odds ratio [OR] 2.67; 95% CI 2.50-2.82), dropped out (re-admission rate 34.8%; 
OR 1.72; 95% CI 1.63-1.81), or transferred unsuccessfully to another SUD treatment 
service (re-admission rate 28.3%; OR 1.27; 95% CI 1.20-1.35) compared with those 
who completed treatment successfully (re-admission rate 23.7%). 
Relative to Class 1, patients assigned to Class 2 and Class 4 were less likely to have 
received opioid pharmacotherapy, Class 4 was more likely to have received 
psychosocial interventions, and Class 2 received more in-patient services. Class 1 
received the least amount of residential services and was retained in treatment longer 
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than any other class. Class 3 reported more incarceration, unsuccessful transfers and 
dropouts, but less deaths, while Class 2 had fewer incarcerations but more drop outs. 
There were relatively fewer deaths in Class 4.  
3.5.5 SUCCESSFUL COMPLETION OF TREATMENT AND NO RE-PRESENTATION WITHIN SIX 
MONTHS 
Overall, 21.9% of the cohort (10,194) attained the SCNR outcome (Table 3.3). Class 3 
were less likely to achieve the outcome. After negative multi-collinearity screening for 
all covariates, the results of the unadjusted, covariate adjusted complete-case 
(n=37,460) and multiply-imputed, all-case (n=46,467) analyses are shown in Table 3.4.  
The complete- and all-case models yielded very similar covariate estimates. In the all-
case model, with statistically significant adjustment for clustering effects associated 
with treatment agency and local treatment system (ICC 0.13 and 0.17, respectively) 
there was satisfactory discrimination between patients who achieved the SCNR 
outcome (c-index 0.74; 95% CI 0.74-0.75).  
There was an increased likelihood of positive outcome among older patients, those 
with pre-treatment employment, and those who with longer time enrolled in treatment 
(particularly for more than 2 years; adjusted odds ratio [AOR] 2.60; 95% CI 2.43-2.78).  
A negative outcome was associated with men, patients who were homeless before 
admission and in areas of greater social deprivation (gradient with likelihood lowest at 
highest quintile; AOR 0.77; 95% CI 0.70-0.85); drug injectors; those referred from the 
criminal justice system; those with previous treatment for OUD; those with shorter 
heroin using career; and members of class 3. 
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Table 3.2 Characteristics of the cohort and drug use sub-populations 
Covariate 
Total 










Socio-demographic       
Male 41,099  (75.6) (76.5) (74.9) (73.0) (82.0) 
Age a 32.9  (7.8) 32.9 (7.9) 34.2 (7.9) 33.0 (7.5) 31.9 (7.9) 
Black/Minority Ethnic 7,342 (13.5) (10.9) (15.8) (15.9) (22.4) 
Employed 6,222  (12.5) (14.7) (8.1) (9.7) (11.4) 
Homeless 17,343  (32.9) (29.5) (43.1) (36.8) (35.1) 
Social deprivation:       
  Quintile 1 (lowest) 10,857  (20.0) (21.6) (19.9) (17.1) (20.4) 
   2 10,922  (20.1) (19.9) (21.9) (20.1) (20.3) 
   3 10,823  (19.9) (19.9) (23.3) (19.3) (20.2) 
   4  10,859  (20.0) (19.8) (18.9) (20.3) (20.6) 
  Quintile 5 (highest) 10,896  (20.0) (18.7) (16.0) (23.2) (18.5) 
Clinical        
Heroin career a 11.4  (7.5) (7.6) (8.3) (7.2) (7.4) 
Drug injecting:       
  Never 17,715  (33.6) (32.8) (32.5) (33.1) (44.5) 
  Lifetime 18,004  (34.2) (34.9) (35.4) (33.5) (30.4) 
  Current 16,996  (32.2) (32.3) (32.1) (33.4) (25.0) 
Referral source:       
  Other 17,453  (32.1) (35.0) (35.1) (27.6) (27.2) 
  Self 20,570  (37.8) (39.4) (37.6) (35.2) (37.5) 
  Criminal justice 16,334  (30.0) (25.6) (27.3) (37.1) (35.3) 
Previous OUD treatment: 30,212  (55.6) (55.6) (52.4) (57.0) (50.4) 
  < 6 months 20,835  (38.3) (35.3) (45.1) (41.4) (44.1) 
  6 months to < 1 year 8,917  (16.4) (16.1) (16.4) (16.9) (17.0) 
  1 year to < 2 years 8,014  (14.7) (15.4) (14.3) (13.6) (14.9) 
  2 years to 5 years 16,591  (30.5) (33.2) (24.3) (28.1) (24.0) 
Class 1: Heroin and low likelihood of problem substance use; Class 2: Heroin, problem crack cocaine and alcohol use; 
Class 3: Heroin and crack cocaine use; Class 4: Heroin and crack and cannabis use. 
Figures in parentheses in table are percentages unless otherwise stated. 
a Year (SD) 
Emboldened percentages and means are statistically significant (P < 0.05) from multivariable, multinomial logistic 
regression (Class 1: referent). 
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Exposure – interventions received      
  Opioid pharmacotherapy, n (%) 36,122 (77.7) 20,377 (80.0) 1,602 (64.2) 12,082 (77.6) 2,061 (70.2) 
  Psychosocial interventions, n (%) 25,742 (55.4) 13,682 (53.7) 1,537 (61.6) 8,694 (55.9) 1,829 (62.3) 
  In-patient withdrawal management, n (%) 3,010 (6.5) 1,546 (6.1) 275 (11.0) 1,021 (6.6) 168 (5.7) 
  Residential rehabilitation, n (%) 1,620 (3.5) 711 (2.8) 167 (6.7) 617 (4.0) 125 (4.3) 
Total time in treatment journey      
  Median weeks (IQR)* 31.0 (12.6-80.3) 34.3 (13.3-87.0) 25.6 (11.8-67.9) 28.0 (11.6-73.4) 27.0 (11.9-69.9) 
Treatment exit status      
  Successful completion, n (%) 13,360 (28.8) 7,675 (30.1) 718 (28.8) 4,066 (26.1) 901 (30.7) 
  Died, n (%) 684 (1.5) 435 (1.7) 52 (2.1) 182 (1.2) 15 (0.5) 
  Incarcerated, n (%) 7,425 (16.0) 3,820 (15.0) 299 (12.0) 2,845 (18.3) 461 (15.7) 
  Unsuccessful transfer, n (%) 8,385 (18.1) 4,498 (17.7) 449 (18.0) 2,922 (18.8) 516 (17.6) 
  Dropped out, n (%) 16,613 (35.8) 9,041 (35.5) 978 (39.2) 5,551 (35.7) 1,043 (35.5) 
Treatment outcome       
  Successful completion and no re- 
    presentation within six months, n (%) 
10,194 (21.9) 5,882 (23.1) 566 (22.7) 3,063 (19.7) 683 (23.3) 
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 Table 3.4 Unadjusted and multi-level, complete-case and all-case multivariable logistic 
regression of SCNR outcome 
Covariates 
Unadjusted 
OR (95% CI) 
(n=37,460) 
Complete-case  
AOR (95% CI) 
(n=37,460) 
All-cases  
AOR (95% CI) 
(n=46,467) 
Socio-demographic    
Male 0.87 (0.82, 0.92) 0.88 (0.83, 0.94) 0.88 (0.83, 0.93) 
Age 1.07 (1.06, 1.09) 1.09 (1.07, 1.11) 1.09 (1.07, 1.11) 
BME 1.11 (1.03, 1.20) 1.05 (0.97, 1.14) 1.02 (0.94, 1.09) 
Employed 1.46 (1.36, 1.58) 1.24 (1.15, 1.34) 1.27 (1.18, 1.37) 
No fixed abode 0.74 (0.70, 0.79) 0.85 (0.80, 0.91) 0.86 (0.81, 0.91) 
Deprivation:    
Quintile 2 0.88 (0.80, 0.96) 0.93 (0.84, 1.02) 0.94 (0.86, 1.02) 
Quintile 3 0.82 (0.74, 0.90) 0.91 (0.82, 1.00) 0.91 (0.83, 1.00) 
Quintile 4 0.79 (0.71, 0.87) 0.84 (0.76, 0.93) 0.86 (0.78, 0.94) 
Quintile 5 (highest) 0.63 (0.57, 0.70) 0.74 (0.67, 0.83) 0.77 (0.70, 0.85) 
Clinical    
Injecting:    
Previously injected 0.81 (0.76, 0.86) 0.87 (0.81, 0.93) 0.86 (0.81, 0.91) 
Currently injector 0.59 (0.55, 0.63) 0.64 (0.60, 0.69) 0.64 (0.60, 0.69) 
Referral route:    
Self 0.95 (0.88, 1.01) 0.96 (0.90, 1.03) 0.97 (0.92, 1.04) 
Criminal justice 0.58 (0.54, 0.63) 0.68 (0.63, 0.74) 0.68 (0.63, 0.73) 
Drug use class:    
Class 2: Heroin, crack & alcohol 0.92 (0.81, 1.03) 1.02 (0.90, 1.15) 0.97 (0.87, 1.08) 
Class 3: Heroin & crack 0.82 (0.77, 0.87) 0.92 (0.86, 0.98) 0.90 (0.85, 0.95) 
Class 4: Heroin, crack & cannabis 0.99 (0.89, 1.11) 1.08 (0.97, 1.20) 1.02 (0.92, 1.12) 
Previously treated 0.64 (0.61, 0.67) 0.66 (0.62, 0.69) 0.66 (0.63, 0.70) 
Heroin career  0.99 (0.97, 1.00) 0.97 (0.95, 0.99) 0.97 (0.95, 0.99) 
Time in index treatment journey:    
6 months to < 1 year 1.28 (1.19, 1.39) 1.28 (1.19, 1.38) 1.32 (1.23, 1.41) 
1 year to < 2 years 1.43 (1.33, 1.55) 1.40 (1.29, 1.51) 1.39 (1.30, 1.49) 
2 years to 5 years 2.70 (2.51, 2.90) 2.59 (2.41, 2.79) 2.60 (2.43, 2.78) 
Model statistics    
Constant - 0.38 (0.33, 0.43) 0.39 (0.34, 0.44) 
Wald X2 (d.f. = 21) - 1,538 1,834-1,854 
LR test X2 (d.f. = 2) - 938 1,342-1.349 
Random effects parameters (ICC):    
 Treatment system (Level 3)  - 0.01 (0.00, 0.02) 0.17 (0.11, 0.27) 
 Treatment agency (Level 2)  - 0.13 (0.11, 0.15) 0.13 (0.11, 0.15) 
SCNR, ‘successful completion of treatment journey and no representation to treatment within six months’; OR, odds 
ratio; AOR, adjusted odds ratio; CI, confidence interval; d.f., degrees of freedom; ICC, intra-class correlation coefficient. 
Emboldened percentages and means are statistically significant (P < 0.05) 
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3.5.6 COMPARISON OF LOCAL TREATMENT SYSTEMS 
Following risk-adjustment, 14 of 149 local treatment systems were classified as 
achieving performance that was better than expected on the SCNR outcome, and 38 
local treatment systems achieved performance that was worse than expected (Figure 
3.1). In comparison to the better performing areas, these 38 areas were characterised 
with a higher estimated level of opiate use in the local population (an extra 4.1 (95% CI 
4.0-4.2) opiate users per thousand population), a higher level of drug-related offences 
(an extra 28.5 (95% CI 28.1-28.8) offences per thousand population), and more drug-
related deaths (an extra 5.9 (95% CI 5.9-5.9) deaths per thousand population) (Table 
5). 
 
Figure 3.1 Funnel plot of outcome performance (SCNR rate) by local treatment system 
NB: The horizontal line is the national average for the SCNR outcome. The curved lines are the upper and lower 95% 
confidence interval. Each black dot represents a local treatment system. Local systems lying above the upper CI have 
an SCNR outcome performance that is better than average after risk-adjustment. Local systems lying below the lower 
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Over the five-year observation period, we observed that nearly one in three patients 
successfully completed treatment for OUD. Reinforcing previous research (Luchansky 
et al., 2000), patients who successfully completed treatment were least likely to be re-
admitted to treatment within a subsequent six month period. In our national population 
of patients accessing publicly-funded treatment, one in five achieved a sustained 
benefit from treatment.  
Other studies have noted two (Shand et al., 2011), three (Harrell et al., 2012; Monga et 
al., 2007), five (Kuramoto et al., 2011), or eight (Patra et al., 2009) latent class 
structures. Our analysis of polydrug dependence in patients seeking treatment for OUD 
in England revealed a four class structure. Crack cocaine was a defining characteristic 
in three of these classes, with one class being further classified with alcohol 
dependence and another classified with cannabis dependence. It is interesting to note 
that the only crack cocaine class without alcohol or cannabis dependence had worse 
outcomes than the heroin with low polydrug class.  
3.6.1 INTEGRATION WITH THE LITERATURE 
Unlike other large-scale studies on treatment completion (Arndt et al., 2013; Mennis 
and Stahler, 2016), in our unadjusted models patients from Black and Minority 
Ethnicities (BME) were more likely to recover. After controlling for other socio-economic 
factors, however, this disparity no longer held, highlighting the importance controlling 
for employment and stable housing (Saloner and Lê Cook, 2013; Hawkins et al., 2014). 
Our findings provide general support for the construct of ‘physical capital’ (Cloud and 
Granfield, 2008) playing a major role in recovery from heroin use disorder, as 
employment and stable housing were found to significantly affect the likelihood of 
88 
 
recovery. The finding that increased time spent engaged in treatment increases the 
likelihood of successful completion aligns with previous research (Hubbard et al., 2003; 
Simpson and Sells, 1990) and provides evidence that OUD treatment should not be 
time-limited (Advisory Council on the Misuse of Drugs, 2014). 
After controlling for patient-level and area-level deprivation predictors of outcome, local 
treatment systems that were performing significantly below the expected rate also 
appeared to have a much larger opiate using population and, presumably as a result of 
this, a higher rate of both offending and drug-related deaths. We are not able to 
determine a mechanism for this association. There may be social network influences in 
operation. For example, social networks can influence both a transition to injecting 
heroin (Neaigus et al., 2006) and the decision to share injecting equipment (De et al., 
2007). Heroin users who have achieved abstinence often cite moving away from drug-
using social networks and receiving support from non-using friends as a contributory 
factor to their success (Best et al., 2008). 
3.6.2 STRENGTHS AND LIMITATIONS 
The main study strength is the national, large scale, long-term follow-up of all 
individuals accessing treatment for heroin use disorder in England and the utilisation of 
the national administrative database to monitor relapse. Unlike other comprehensive 
administrative datasets (Sahker et al., 2015; Alterman et al., 2001; Stahler et al., 2016), 
NDTMS has patient-level identifiers that enable cross-referencing with subsequent 
treatment admissions. This utility provides not only an objective summative measure of 
the sustainability of recovery in this population, it also enables national administrative 
systems to objectively capture whether patients had previously accessed treatment 
services, which is an important negative predictor of treatment outcome (Siguel and 
Spillane, 1978; Marsden et al., 2012b). 
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Several study limitations are also acknowledged: firstly, our analysis of OUD sub-
populations is based on clients entering the treatment system in 2008/09. It is possible 
that since this period, with the rise of novel psychoactive substances for example, a 
different class structure would emerge for clients currently accessing treatment. 
Second, we were not able to access data from the national deaths registry or the 
national prisons system, and there remains a concern that at least some of our patients 
who did not re-present to treatment were simply unable to. Third, while all available 
covariates in NDTMS were screened in the present analysis, other covariates could 
further elucidate the likelihood of sustaining recovery, including treatment motivation 
(Simpson and Joe, 1993), engagement (Simpson et al., 1995) and other recovery 
strengths (Gossop et al., 2002d). Fourth, it is possible that other interventions were 
experienced by the patients in this cohort, such as privately-funded residential 
treatment or attending Alcoholics Anonymous, but these interventions are not captured 
by NDTMS and it is not possible to assess the potential impact these may have had. 
3.6.3 CONCLUSIONS 
Relapse requiring treatment is relatively common in the six months following treatment 
completion. This study highlights the importance of including re-presentation to 
treatment as a summative measure of the effectiveness of local treatment systems. We 
note a sizeable proportion of individuals, nearly one in seven, who have been 
continuously engaged in treatment throughout the five-year observation period. The 
next questions for our research group are whether, and to what degree, heroin and 
other drug use changes throughout this time period; how change in heroin use relates 
to change in other drugs; whether five-year in-treatment change predicts subsequent 
successful completion of treatment, and to examine the longitudinal inter-relationship 
between substance use, employment and housing.  
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Chapter 4  STUDY 2: CONTINUOUS OPIOID 
SUBSTITUTION TREATMENT OVER FIVE YEARS: 
HEROIN USE TRAJECTORIES AND OUTCOMES 
4.1 DESCRIPTION OF STUDY IN THE CONTEXT OF THE THESIS 
In the previous chapter, we demonstrated that latent polydrug subpopulations could be 
derived from admissions data, and that heroin and crack cocaine patients exhibit a 
decreased likelihood of achieving and maintaining clinical benefit from treatment 
(Eastwood et al., 2017). One in seven patients (14.5%) were identified as being 
continuously enrolled in treatment for five years and form the basis of the current study. 
Taking a longitudinal perspective, the aim of the study is to explore whether or not 
differential response trajectories can be identified from repeated measures of heroin 
use frequency across five years of continuous enrolment in treatment in England and, 
should differing trajectories be identified, whether or not trajectory membership can be 
predicted from admission covariates and whether or not trajectories are predictive of 
subsequent recovery from OUD. To achieve these aims, a combination of multilevel 
Latent Class Growth Analysis (Section 2.6.2), multinomial logistic regression (Section 
2.6.3) and multilevel logistic regressions (Section 2.6.4) are utilised. 
This chapter was published as follows: 
Eastwood, B., Strang, J., Marsden, J., 2018. Continuous opioid substitution treatment 
over five years: Heroin use trajectories and outcomes. Drug and Alcohol 






Background: This is the first national study in England of continuous long-term opioid 
substitution treatment (OST). 
Methods: All adults admitted to community OST for opioid use disorder (OUD) in 
2008/09, with continuous enrolment to 2013/14 (n=7,719). Heroin use trajectories were 
identified by multilevel Latent Class Growth Analysis. In Year 6 and 7 of follow-up, the 
outcome measure (analysed by multilevel, multivariable logistic regression) was 
‘successful completion and no re-presentation’ (SCNR) to community treatment within 
six months.  
Results: Five heroin use trajectory classes were identified: ‘gradual decreasing’ 
(20.9%); ‘decreasing then increasing’ (21.7%); ‘continued low-level’ (17.0%); ‘rapid 
decreasing’ (25.6%), and ‘continued high-level’ (14.8%). At the end of Year 7, 4,616 
people (60.3%) remained in OST. Of those discharged, 28.8% achieved the SCNR 
follow-up outcome. SCNR was more likely in the ‘gradual decreasing’ (adjusted odds 
ratio [AOR] 2.40; 95% confidence interval [CI] 1.77-3.26), ‘continued low-level’ (AOR 
2.46; CI 1.78-3.40) and ‘rapid decreasing’ (AOR 3.40; CI 2.43-4.37) classes, relative to 
the ‘continued high-level’ class. SCNR was more likely among patients employed at 
admission (AOR 1.45; 95% CI 1.15 to 1.83) and those receiving adjunctive 
psychosocial interventions (AOR 1.44; 95% CI 1.03 to 2.02).  
Conclusions: Among English patients in OST for 5-years, heroin use trajectories were 
clearly delineated, with a gradient of response on the study outcome. Successful 
completion and no re-presentation was achieved by 28.8% of discharged patients. The 
rapid decreasing trajectory had the greatest likelihood of positive outcome. Adjunctive 





Oral methadone or buprenorphine are the first-line medical therapies for opioid use 
disorder (OUD). These opioid substitution treatments (OST) are consistently 
associated with abstinence from illicit opioid use (e.g. Hubbard et al., 2003; Gossop et 
al., 2003; Teesson et al., 2006), a lower risk of opioid overdose (White et al., 2015), 
and reductions in criminal behaviour (Gossop et al., 2005b). Aggregate statistical 
results may, however, mask differential clinical response among sub-populations. For 
example, in an English national study of ongoing OUD treatment, 37% of patients were 
abstaining from heroin during the 28-days before six-month follow-up; a further 31% 
were using heroin less often; but 29% continued to use heroin at the same frequency 
as at admission, and 3% had deteriorated (Marsden et al., 2009).  
Longer follow-up studies have identified distinct sub-populations of people who share a 
similar heroin use trajectory. In a US cohort study of 471 heroin users followed-up over 
16 years, Hser and colleagues identified three classes: nine per cent were ‘early-
quitters’; 32% achieved improvements at a later stage in follow-up (‘late-decelerated 
users’), and 59% were labelled ‘stably high-level’ heroin users with no identifiable 
improvement (Hser et al., 2007). In a recent 4.5 year follow-up of study of 795 
participants in a treatment trial, Hser’s group identified the following classes: ‘low use’ 
(42.0%); ‘high use’ (22.3%); ‘decreasing use’ (18.6%); and ‘increasing use’ (17.1%), 
with people in the ‘decreasing use’ class spending more time in treatment than those in 
the ‘high use’ class (Hser et al., 2017). Comparable findings have been reported in 
Australia (Teesson et al., 2017a).  
Recently, we estimated the likelihood of successfully completing OUD within five years 
among a national cohort of patients (all adults admitted to public treatment services in 
2008/09; N=54,357; Eastwood et al., 2017). Approximately 1:7 patients were enrolled 
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in OST continuously up to the five-year follow-up. In the present study, we report on 
the status of this cohort and determine follow-up outcomes over the next two years. 
This is the first national outcome study of long-term, continuous OST in England. To 
our knowledge, there has been no national study of OST over this time-frame reported 
elsewhere.  
In this report, we aim to:  
(1) identify heroin use response trajectories during five years of OST and estimate 
associations with patient-level characteristics and treatment exposure;  
(2) estimate whether heroin use response trajectories predict positive outcome during 
the sixth and seventh year of follow-up. 
We hypothesised that: (a) patients with trajectories demonstrating positive response to 
ongoing OST would be more likely to exit treatment successfully; and (b) adjunctive 
psychosocial, in-patient and residential interventions would increase the likelihood of 
completing OST successfully. 
4.4 METHODS 
4.4.1 DESIGN 
This was a seven-year, prospective observational cohort study of all publicly-funded 
specialist community-setting treatment services providing OST in England reporting to 
the National Drug Treatment Monitoring System (NDTMS). The study is reported 
following the RECORD guidelines for observational research using routinely collected 
health data (Benchimol et al., 2015).  
The study cohort is all adults (≥18 years; n=7,877) diagnosed with OUD (almost all 
relating to use of heroin) who initiated treatment between 1 April 2008 and 31 March 
2009, were continuously enrolled in OST for the next five years (ending 31 March 
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2014) and then followed-up to 30 September 2016. Following the NDTMS reporting 
protocol, ‘continuous enrolment’ was defined as either a single unbroken episode of 
OST, or two or more linked (continuing care) episodes in which there was no more 
than 21 days between the end of one methadone or buprenorphine prescribing 
intervention and the start of another (Public Health England, 2015a).  
4.4.2 MEASURES 
4.4.2.1 DEVELOPMENTAL TRAJECTORY INDICATOR 
The Treatment Outcomes Profile (TOP; Marsden et al., 2008) is the English national 
standard measure for substance use disorder treatment outcomes monitoring. The 
TOP is a structured clinical interview which is completed at admission, every six 
months thereafter, and at the completion of treatment. In this study, we used the 
number of days of heroin use in the 28 days prior to each TOP interview conducted 
between Year 1 (2008/09) and Year 5 (2013/14).  
4.4.2.2 OUTCOME MEASURE 
‘Successful completion’ of treatment has been widely used as an outcome measure in 
effectiveness studies. Definitions vary, but this typically denotes satisfactory resolution 
of primary clinical problems and agreement between the clinician and patient to exit 
treatment (e.g. Luchansky et al., 2000; Alterman et al., 2001; Stahler et al., 2016).  
The outcome measure in the present study combined two components: successful 
completion and no re-presentation (SCNR). SCNR is the English national proxy 
remission measure for OUD treatment outcome monitoring (Public Health England, 
2015a). The ‘successful completion’ component was measured in Year 6 and Year 7 
(ending 31 March 2016). It was defined as a clinician-verified report of a patient who 
had completed OST, was in remission from OUD, was abstinent from heroin (and any 
other non-medical opioids) and cocaine, and had attained their care plan goals. The 
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‘no re-presentation’ element captures the extent to which the successful completion is 
sustained by linking patients with a successful completion to the community-based and 
prison-based treatment databases, as well as the Office for National Statistics’ fatal 
drug-poisoning database over the subsequent six-month period (ending 30 September 
2016), and removing all cases of re-presentation to treatment or fatal overdose from 
the summative effectiveness measure. 
4.4.2.3 BASELINE COVARIATE MEASURES 
The following patient demographic, clinical and previous treatment exposure variables 
(all recorded at initial assessment) were included as potential confounders in the 
analysis:  
Demographic. Sex; age (centred at 18 years and utilised in five-year increments); 
Black and Minority Ethnicities (BME: a legal monitoring requirement; (Race Relations 
(Amendment) Act, 2000)); employed; housing problems (defined primarily as having no 
fixed abode, but can also include squatting, short-term hostel/B&B, staying with 
friends/relatives [homeless, herein]); 
Social deprivation. Local area deprivation was measured by the English Indices of 
Multiple Deprivation (IMD; Department for Communities and Local Government, 2007). 
IMD data were linked to NDTMS based on the patient’s residential postcode district or 
the location of their first treatment provider in instances of missing postcode 
information (see section 3.4.5). 
Treatment admission drug use latent class. Four heroin-based latent classes from 
admission data: (1) heroin low level with concurrent drug disorder; (2) heroin, crack 
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and alcohol; (3) heroin and crack, and (4) heroin, crack and cannabis. These classes 
were identified in Eastwood et al. (2017). 
Injecting status. Recorded at the start of treatment, as: (1) never injected; (2) lifetime 
history of injecting; and (3) current injector. 
Duration of heroin use ‘career’. This was defined as the number of years between first 
initiation to heroin use and initiating OUD treatment. In the models, this variable was 
mean centred and utilised in five-year increments.   
Treatment history. The patient’s referral route into treatment was categorised as: (1) 
self-referred; (2) criminal-justice system; or (3) other. Whether a patient had previously 
accessed OUD treatment was also included. 
Adjunctive treatment exposure. Together with OST, NDTMS records the following 
interventions: psychosocial interventions; in-patient detoxification, and residential 
rehabilitation.  
4.4.3 STATISTICAL ANALYSIS 
Data management was done with SPSS (version 21). We used multilevel Latent Class 
Growth Analysis (LCGA) to identify discrete, non-overlapping heroin use change 
trajectories across five-years of OST (MPlus; version 7). Management of missing data 
by multiple imputation and all regression analyses was done with Stata (version 13).  
4.4.3.1 HEROIN USE TRAJECTORIES 
In a longitudinal latent analysis of behaviour change, trajectory membership can be 
influenced by inclusion of covariates and distal outcomes (Huang et al., 2010). 
Following recommendation by Nagin (2005), 1-class through 6-class models were fit to 
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the data. Each model assumed a Poisson distribution and 5,000 random sets of 
starting values were used to guard against convergence on local maxima (McLachlan 
and Peel, 2000). A minimum class size of 5% was set for utility (Borders and Booth, 
2012; Willey et al., 2016b).  
Trajectory identification was informed by posterior fit statistics. As patients were nested 
within different local treatment systems, we used multilevel LCGA models and an intra-
class correlation coefficient (ICC) was computed for each class (Asparouhov and 
Muthén, 2007). Multinomial logistic regression then regressed trajectory classes on 
patient-level characteristics. Robust standard errors were utilised to calculate 95% 
confidence intervals (CI), to account for clustering of patients in each treatment system 
(Petersen, 2009). 
4.4.3.2 OUTCOME ANALYSIS 
A multilevel, multivariable logistic regression model was used to estimate the likelihood 
of SCNR (Stata command: meqrlogit), and the ICC was estimated to assess intercept 
variation. As a sensitivity analysis, we calculated the E-value from the adjusted odds 
ratios of the LCGA trajectories and the estimate of its uncertainty from the CIs closest 
to the null. In this application, the E-value is the minimum strength needed by an 
unmeasured confounder to account for any significant association between trajectory 
membership and outcome, conditional on the included covariates (VanderWeele and 
Ding, 2017).  
4.4.3.3 MISSING DATA 
LCGA is implemented by full-information maximisation likelihood and can assign 
patients with at least one measurement to a latent class. However, a complete case 
analysis may yield biased estimates due to missing covariate data. With no evidence 
that either the predictors or outcome variables were not missing-at-random (Little and 
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Rubin, 1987), we created a multiply imputed dataset (Stata command: MI impute 
chained). Logistic regression, multinomial regression, and predictive mean matching 
were utilised, respectively, for binary, multinomial or continuous covariates with missing 
data. Twenty probabilistic datasets were imputed, resulting in a relative efficiency of 
over 98% (Rubin, 1987) and a reduction in power of less than 1% (Graham et al., 
2007).  
4.5 RESULTS 
4.5.1 STUDY COHORT 
Patients were recruited from all 149 local treatment systems in England (median 41; 
interquartile range [IQR] 23-71). The flow of the 7,877 participants continuously 
enrolled in OST for five years is shown in Figure 4.1. Two percent of the cohort 
(n=158) had no TOP data and were removed. Therefore, LCGA was undertaken on 
7,719 cases. A median of 10 TOP interviews were completed (IQR 8-11) and 2,211 
patients (28.6%) completed all 11 TOP assessments. A further 58 people (0.7%) were 
removed as their follow-up status could not be determined.  
At the end of Year 7, 4,616 (60.3%) were still enrolled in OST. During Year 6 and 7, 
1,987 (25.9%) exited treatment unsuccessfully, and 1,058 (13.8%) successfully 
completed treatment. Among those successfully completing treatment, 16.5% (n=175) 
were re-admitted to community treatment in the next six months, five were incarcerated 
and one person died from opioid-related poisoning. The ‘successful completion and no 
re-presentation’ (SCNR) outcome was achieved by 877 (28.8%) of those discharged 




Figure 4.1 Study profile 
 
4.5.2 HEROIN USE DURING FIVE YEARS OF OST 
Heroin use was reported by 85.8% of the cohort during the 28-days before the start of 
treatment (Table 4.1). Proportionately, the greatest reduction in heroin was in the first 
six months of OST, at which point 62.7% were still using. Overall, 39.6% of the cohort 
were using heroin at Year 3, and there was a slight increase at each six-monthly 
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assessment to Year 5 (43.2%). The mean number of days used reduced from 19.5 
days at intake to 7.4 days at six months and did not exceed four days after 2.5 years in 
treatment. Correlations over follow-up are shown in Table 4.2 
4.5.3 HEROIN USE TRAJECTORIES 
Table 4.3 displays the results of the multilevel LCGA models. Model indicators pointed 
to a 6-class solution. However, two classes had consistently low heroin use over the 
five-years. Accordingly, we judged a parsimonious 5-class model to be optimal. The 
ICC for classes 1, 2, 4 and 5 ranged between 0.46 and 0.49 and was 0.04 for class 3. 
We labelled the heroin use trajectory classes as follows (Figure 4.2): 
• Class 1 (n=1,617, 20.9%: ‘gradual decreasing’) 
• Class 2 (n=1,673, 21.7%: ‘decreasing then increasing’) 
• Class 3 (n=1,310, 17.0%: ‘continued low-level’) 
• Class 4 (n=1,973, 25.6%: ‘rapid decreasing’) 





Table 4.1 Heroin use during five years of continuous OST (n=7,719) 
TOP assessment Responses (n) No. (%) using heroin Mean days used (SD) 
* 
Admission 5,567 4,775 (85.8) 19.5 (11.6) 
Year 0.5 5,774 3,622 (62.7) 7.4 (9.7) 
Year 1 6,409 3,796 (59.2) 6.0 (8.7) 
Year 1.5 6,449 3,673 (57.0) 5.9 (8.6) 
Year 2 6,567 3,498 (53.3) 5.4 (8.3) 
Year 2.5 6,649 2,899 (43.6) 4.0 (7.5) 
Year 3 6,670 2,639 (39.6) 3.5 (6.9) 
Year 3.5 6,713 2,729 (40.7) 3.7 (7.1) 
Year 4 6,733 2,821 (41.9) 3.6 (730) 
Year 4.5 6,743 2,873 (42.6) 3.9 (7.2) 
Year 5 6,748 2,913 (43.2) 4.0 (7.4) 
TOP = Treatment Outcomes Profile; SD = standard deviation 









Table 4.2 Correlation matrix of illicit opioid responses across the five-year observation period 
 
Admission Year 0.5 Year 1 Year 1.5 Year 2 Year 2.5 Year 3 Year 3.5 Year 4 Year 4.5 Year 5 
Admission 1.000 
          
Year 0.5 0.191 1.000 
         
Year 1 0.166 0.443 1.000 
        
Year 1.5 0.123 0.370 0.510 1.000 
       
Year 2 0.125 0.305 0.382 0.491 1.000 
      
Year 2.5 0.099 0.261 0.300 0.375 0.478 1.000 
     
Year 3 0.103 0.235 0.291 0.346 0.372 0.429 1.000 
    
Year 3.5 0.100 0.214 0.280 0.326 0.369 0.390 0.483 1.000 
   
Year 4 0.098 0.214 0.262 0.297 0.331 0.333 0.409 0.515 1.000 
  
Year 4.5 0.104 0.197 0.234 0.263 0.319 0.327 0.347 0.433 0.514 1.000 
 
Year 5 0.069 0.173 0.215 0.262 0.293 0.283 0.305 0.352 0.422 0.502 1.000 









Table 4.3 Unconditional multilevel latent class growth analysis of heroin use over five years (n=7,719) 
 
1-Class 2-Class 3-Class 4-Class 5-Class 6-Class 
AIC 886002.87 671087.82 610578.39 580090.68 553248.75 537428.48 
BIC 886023.73 671136.50 610654.88 580194.97 553380.86 537588.40 
aBIC 886014.20 671114.25 610619.92 580147.31 553320.48 537515.31 
Entropy - 0.975 0.971 0.964 0.950 0.956 
Class (probability) 
      
Class 1 1.00 (1.00) 0.58 (0.99) 0.42 (0.99) 0.24 (0.97) 0.21 (0.97) 0.12 (0.96) 
Class 2 - 0.42 (0.99) 0.21 (0.99) 0.37 (0.99) 0.22 (0.97) 0.25 (0.97) 
Class 3 - - 0.37 (0.99) 0.23 (0.97) 0.17 (0.97) 0.18 (0.97) 
Class 4 - - - 0.16 (0.99) 0.26 (0.94) 0.14 (0.98) 
Class 5 - - - - 0.15 (0.98) 0.17 (0.96) 
Class 6 - - - - - 0.15 (0.95) 
VLMR - <0.01 0.12 <0.01 <0.01 <0.01 
BLRT - <0.01 <0.01 <0.01 <0.01 <0.01 
AIC: Akaike Information Criterion; 
BIC: Bayesian Information Criterion; 
aBIC: sample-size adjusted BIC; 
VLMR: Vuong-Lo-Mendel-Ruben test; 








Figure 4.2 Heroin use trajectories over 5 years of continuous OST 
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Table 4.4 Patient-level characteristics by heroin use trajectories (n=7,719) 














Male 5,562 (72.1) (72.2) (75.2) (72.7) (70.5) (70.1) 
Age a 34.4 (7.9) 34.2 (7.4) 33.9 (7.5) 35.2 (8.3) 33.7 (7.8) 34.9 (8.2) 
Black/Minority Ethnic 718 (9.3) (8.4) (9.7) (8.5) (8.7) (10.5) 
Employed b 1,164 (15.7) (13.7) (16.9) (13.3) (14.1) (18.5) 
Homeless c 1,775 (23.4) (25.4) (23.7) (20.6) (26.1) (21.5) 
Social deprivation: 
 
   
  
Quintile 1 (lowest) 1,935 (25.1) (23.6) (25.5) (25.9) (25.2) (24.9) 
Quintile 2 1,562 (20.2) (19.0) (20.1) (18.9) (18.6) (23.3) 
Quintile 3 1,434 (18.6) (18.1) (19.4) (18.2) (19.2) (17.9) 
Quintile 4 1,595 (20.7) (20.9) (21.2) (20.0) (21.3) (20.1) 
Quintile 5 (highest) 1,193 (15.5) (18.5) (13.8) (17.0) (15.7) (13.8) 
Heroin career a,d 12.3 (7.7) 12.3 (7.2) 11.9 (7.2) 13.3 (8.0) 11.9 (7.4) 12.5 (8.2) 
Drug injecting: e 
 
   
  
Never  2,290 (29.9) (25.4) (31.5) (27.7) (27.9) (34.3) 
Lifetime 2,976 (38.9) (33.3) (36.6) (54.5) (35.7) (36.5) 
Current 2,387 (31.2) (41.3) (31.9) (17.8) (36.4) (29.2) 
Referral source: 
 
   
  
Other 2,964 (38.4) (32.6) (37.2) (49.5) (36.2) (37.2) 
Self 3,244 (42.0) (46.3) (44.3) (26.8) (43.5) (46.6) 
Criminal justice 1,511 (19.6) (21.2) (18.5) (23.7) (20.3) (16.2) 
Previous OUD treatment 4,871 (63.1) (72.8) (64.4) (59.4) (65.9) (56.6) 
Drug use sub-population: 
 
   
  
Heroin low-level concurrent  
   drug use disorder 
4,295 (55.6) (55.2) (56.6) (53.4) (54.9) (57.1) 
Heroin, crack and alcohol 388 (5.0) (4.9) (5.1) (4.6) (6.3) (4.3) 
Heroin and crack 2,589 (33.5) (34.8) (32.6) (36.0) (32.8) (32.5) 
Heroin, crack and cannabis 447 (5.8) (5.1) (5.7) (6.0) (5.9) (6.1) 
Adjunctive treatment exposure: 
 
   
  
Psychosocial 7,121 (92.3) (95.0) (93.0) (90.5) (93.9) (89.8) 
In-patient 566 (7.3) (11.4) (7.2) (5.3) (8.8) (5.2) 
Residential 109 (1.4) (3.0) (1.9) (0.9) (1.2) (0.6) 
Figures in parentheses in table are number of participants (percentages) unless otherwise stated. Emboldened percentages and means are statistically significant (P<0.05) from all-case, multiply imputed, 
multivariable multinomial logistic regression (continued high-level use group as referent). a Year (SD); b Percentage after excluding 286 participants with missing data on this covariate; c Percentage after 
excluding 123 participants missing data on this covariate; d Percentage after excluding 261 participants missing data on this covariate; e Percentage after excluding 66 participants missing data 
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4.5.4 PATIENT-LEVEL CHARACTERISTICS  
Patient-level characteristics are shown in Table 4.4, together with the results of the all-
case multinomial logistic regression of the heroin use trajectory classes on patient-level 
characteristics. Compared to the poor response (‘continued high-level’) class, 
participants in the other classes had less previous OUD treatment exposure, and the 
‘decreasing then increasing’, ‘continued low-level’ and ‘rapid decreasing’ classes were 
less likely to be currently injecting at admission. 
The ‘decreasing then increasing’ heroin use class had more men and were less likely 
to be resident in an area of high social deprivation. The ‘continued high-level’ heroin 
use class were more likely to be exposed to psychosocial, in-patient and residential 
treatments during their enrolment in OST. 
4.5.5 TREATMENT STATUS AT THE END OF YEAR 7 
Continued enrolment in OST at the end of Year 7 was not associated with heroin use 
trajectory (Table 4.5). Among the treatment leavers, the ‘continued high-level’ heroin 
users were most likely to have an unsuccessful discharge. There was an outcome 
response gradient by class among those who left treatment successfully: successful 
completion of treatment was recorded for 8.6% of the ‘continued high-level’ class 
compared to 18.7% of the ‘rapid-decreasing’ class. Patients who continuously enrolled 
at Year 7 were removed from further analysis at this point.  
Table 4.5 OST status at Year 7, by heroin use trajectory (n = 7,661) 




Continued high-level (n=1,142) 678 (59.4) 366 (32.1) 98 (8.6) 
Decreasing then increasing (n=1,660) 1,016 (61.2) 482 (29.0) 162 (9.8) 
Continued low-level (n=1,298) 803 (61.9) 304 (23.4) 191 (14.7) 
Gradual decreasing (n=1,604) 975 (60.8) 388 (24.2) 241 (15.0) 
Rapid decreasing (n=1,957) 1,144 (58.5) 447 (22.8) 366 (18.7) 
Total  4,616 (60.3) 1,987 (25.9) 1,058 (13.8) 
 Numbers in parentheses are percentages unless otherwise shown 
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Compared to the ‘rapid decreasing’ heroin use class (re-admission rate 11.2%), re-
presentation within six months for community treatment was more likely among the 
‘continued high-level’ heroin use class (22.4%; odds ratio [OR] 2.29; 95% CI 1.29-
4.08); followed by the ‘decreasing then increasing’ class (22.2%; OR 2.26; 95% CI 
1.38-3.71), the ‘gradual decreasing’ class (17.3%; OR 1.72; 95% CI 1.08-2.73) and the 
‘continued low-level’ class (17.8%; OR 1.66; 95% CI 1.01-2.72).  
4.5.6 IMPACT OF TRAJECTORY MEMBERSHIP ON OUTCOME 
The poor responding ‘continued high-level’ heroin using class had the lowest proportion 
achieving SCNR (16.2%), followed by the ‘decreasing then increasing’ group (19.6%). 
The ‘continued low-level use’ and ‘gradual decreasing use’ groups has similar levels of 
SCNR (31.2% and 31.7%, respectively), while SCNR was most likely to be attained by 
the ‘rapid decreasing’ class (39.7%).  
The multiply imputed, multilevel logistic regression analysis (Table 4.6) indicated that 
three trajectory groups (i.e. ‘gradual decreasing’, ‘continued low-level’ and ‘rapid 
decreasing’) were more likely to achieve SCNR compared to the ‘continued high-level’ 
class (adjusted odds ratio [AOR] 2.40 [95% CI 1.77 to 3.26]); AOR 2.46 [95% CI 1.78 
to 3.40]; AOR 3.26 [95% CI 2.43 to 4.37]), respectively.  
The E-value estimate for the ‘gradual decreasing use’ class was 4.23 (with an 
uncertainty estimate of 2.94 for the minimum risk ratio needed to shift the CI to the 
null), E=4.36 (uncertainty estimate = 2.96) for the ‘continued low-level use’ class and 
E=5.97 (uncertainty estimate = 4.29) for the ‘rapid decreasing use’ class. There was 
also an increased likelihood of achieving SCNR among those with pre-admission 
employment (AOR 1.45; 95% CI 1.15 to 1.83), those who received adjunctive 
psychosocial treatment during OST (AOR 1.44; 95% CI 1.03 to 2.02) and a positive 
association for increasing age (AOR 1.07; 95% CI 1.00 to 2.14). Longer heroin using 
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career, lifetime history of injecting, and referral from the criminal justice system was 
associated with a decreased likelihood of achieving SCNR. 
4.5.7 POST-HOC ANALYSIS 
Finally, we created a binary ‘non-response’ measure by combining the ‘continued high-
level use’ and ‘decreasing then increasing use’ trajectory groups against the remaining 
three trajectory groups. This measure was then collapsed at the local treatment system 
level, resulting in a range of non-response from 0-70%. Also available at local area 
level were the prevalence of opiate users per 1,000 population in 2008/09 (Hay et al., 
2010), the rate of offending per 1,000 population (Office for National Statistics, 2016), 
and the rate of drug-related deaths per million population (Public Health England, 
2016b). Non-response was regressed on these three measures in a linear regression. 
The offending rate and the drug-related death rate was not associated with non-
response. However, for every extra opiate user per 1,000 population, there was an 
increase in non-response by almost two percentage points (1.97; 95% CI 0.76 to 3.17).  
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Table 4.6 Unadjusted and multi-level, all-case multivariable logistic regression 
  
Covariate 
Unadjusted OR  
(95% CI) 
All-case AOR  
(95% CI) 
Male 0.90 (0.75, 1.07) 0.95 (0.79, 1.15) 
Age 1.03 (0.98, 1.08) 1.07 (1.00, 1.14) 
Black/Minority Ethnic 1.03 (0.78, 1.36) 0.94 (0.70, 1.26) 
Employed 1.61 (1.29, 1.99) 1.45 (1.15, 1.83) 
Homeless 0.79 (0.66, 0.96) 0.88 (0.72, 1.08) 
Social deprivation 
  
Quintile 1 (lowest) 1.06 (0.84, 1.35) 1.07 (0.83, 1.37) 
Quintile 2 0.78 (0.60, 1.00) 0.84 (0.64, 1.09) 
Quintile 3 0.86 (0.67, 1.10) 0.94 (0.73, 1.22) 
Quintile 4 0.82 (0.62, 1.09) 0.89 (0.67, 1.20) 
Quintile 5 (highest) - - 
Heroin career 0.95 (0.90, 1.01) 0.93 (0.87, 1.00) 
Drug injecting: 
  
Never  - - 
Lifetime 0.71 (0.58, 0.86) 0.79 (0.64, 0.97) 
Current 0.65 (0.53, 0.80) 0.80 (0.64, 1.00) 
Referral source: 
  
Other - - 
Self 0.92 (0.77, 1.10) 0.94 (0.78, 1.14) 
Criminal justice 0.62 (0.50, 0.79) 0.68 (0.54, 0.87) 
Previous OUD treatment 0.73 (0.62, 0.86) 0.87 (0.73, 1.03) 
Drug use classification: 
  
Heroin low level concurrent drug disorder - - 
Heroin, crack and alcohol 1.05 (0.72, 1.54) 1.02 (0.69, 1.51) 
Heroin and crack 1.01 (0.85, 1.20) 0.99 (0.83, 1.19) 
Heroin, crack and cannabis 0.93 (0.65, 1.33) 0.87 (0.60, 1.25) 
Treatment exposure: 
  
Psychosocial 1.26 (0.91, 1.75) 1.44 (1.03, 2.02) 
In-patient 0.70 (0.52, 0.95) 0.79 (0.57, 1.11) 
Residential 0.84 (0.43, 1.64) 1.34 (0.65, 2.76) 
Heroin use trajectory class: 
  
Gradual decreasing  2.37 (1.75, 3.21) 2.40 (1.77, 3.26) 
Decreasing then increasing  1.28 (0.93, 1.76) 1.23 (0.89, 1.70) 
Continued low-level  2.48 (1.81, 3.40) 2.46 (1.78, 3.40) 
Rapid decreasing  3.47 (2.60, 4.64) 3.26 (2.43, 4.37) 
Continued high-level  - - 
Model statistics 
  
Constant - 0.16 (0.09, 0.29) 
Wald χ2 (d.f. = 25) - 159.6 - 163.8 
LR test χ2 (d.f. = 1) - 12.0 - 12.7 





In a time of increased focus on recovery (HM Government, 2017; Laudet and 
Humphreys, 2013), a greater understanding of the heterogeneous response to 
treatment is required by policy makers, treatment purchasers and clinicians to inform 
their decision making processes. This report extends our previous study (Eastwood et 
al., 2017) by estimating heroin use change trajectories over long-term enrolment in 
OST. We identified five heroin use trajectory groups and found that the trajectory 
groups tending towards abstinence at Year 5 were significantly more likely to achieve a 
sustained benefit from treatment (SCNR follow-up outcome).  
4.6.1 INTEGRATION WITH THE LITERATURE 
In the treatment literature, several demographic and patient-level characteristics have 
been linked to developmental trajectories associated with relatively poor treatment 
response, including: males; people from some ethnic minorities; lower educational 
achievement; earlier onset of drug use, and involvement with the criminal justice 
system (Grella and Lovinger, 2011; Hser et al., 2008b, 2007). 
Our ‘continued low-level’, ‘continued high-level’ and ‘decreasing then increasing’ 
classes are similar to the ‘low use’, ‘high use’ and ‘increasing use’ response groups 
identified by Hser’s group (Hser et al., 2008b). Other studies have also highlighted a 
sub-population that does not exhibit substantial reduction in drug use, as well as a 
group demonstrating rapid reductions (Grella and Lovinger, 2011; Teesson et al., 
2017a). This points to a degree of phenotypic similarity across different countries, 
settings and cohort characteristics. Similar to the Australian study (Teesson et al., 
2017a), we note that few baseline covariates predict trajectory membership, although 
higher deprivation, currently injecting, and previous treatment were associated with 
relative non-response to treatment. 
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The validity of person-centred latent trajectory modelling has been criticised (Sher et 
al., 2011). Our finding that more favourable trajectory memberships are associated with 
sustained benefit provides support for the predictive validity of the approach. It also 
extends previous work documenting associations with decreased mortality and better 
employment, substance use and mental health outcomes (Hser et al., 2007; Teesson 
et al., 2017a; Hser et al., 2017), and highlights the importance of incorporating 
independent outcomes in person-centred research design. 
Our findings also highlight the positive role of employment in recovery, although it is 
interesting that stable housing did not affect the likelihood of recovery as in other 
studies (e.g. Cloud and Granfield, 2008). Injecting and criminal justice referrals were, 
as expected (Marsden et al., 2012a), negatively associated with positive outcome. 
4.6.2 CLINICAL IMPLICATIONS 
In our study, we estimate that one in seven patients demonstrate sustained non-
response over significant periods of time and a further fifth of patients exhibit a 
tendency to deteriorate after three years of treatment. Continued illicit opioid use on top 
of an opioid prescription is a recognised problem (Clinical Guidelines on Drug Misuse 
and Dependence Update 2017 Independent Expert Working Group, 2017). It is 
important for clinicians to identify non-response at an early stage and to review and 
optimise the treatment care package. Several clinical responses are available, 
including: increasing the dose; dividing the dose into smaller daily doses in the case of 
faster metabolism; offering to change the OST medication, and reintroducing daily 
supervised consumption (ibid). Service user views on medication should be taken into 
account, as a quarter consider the OST dose to be ‘poor or bad’ (Advisory Council on 
the Misuse of Drugs, 2015). In the US, around a quarter of patients also receive 
methadone doses too low to be effective (D’Aunno et al., 2014). 
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4.6.3 POLICY IMPLICATIONS 
Our finding that more than 40% of patients continue to use illicit opioids after five years 
of continuous treatment supports the conclusion that a blanket time limit on prescribing 
would not be clinically appropriate (Advisory Council on the Misuse of Drugs, 2014). 
National drug treatment administrators should make available performance monitoring 
reports for clinics and treatment purchasers focused on long-term use of illicit opioids, 
which could aid local planning, resource allocation and improve outcomes. Further, 
incorporation of prescription dose into the NDTMS would help estimate whether, and to 
what degree, sub-optimal dosing is associated with continued use on top. 
Our finding that psychosocial interventions, received by most but not all patients, is 
advantageous for sustaining recovery underscores the importance of comprehensive 
interventions being made available in the treatment of OUD. More frequent or 
personalised psychosocial interventions may also be of benefit (Marsden et al., 2017). 
Treatment clinics may benefit from an audit of clinical practices as it has been 
suggested that interventions are ‘front-loaded’ and less intensive support is available to 
those in treatment over longer periods (Finch, 2003).  
In the current study, it appears that areas with a greater degree of non-response are 
also affected by a larger opiate-using population. Although we are unable to determine 
a precise mechanism, there may be social network influences in operation to explain 
this association. For example, heroin users who have achieved abstinence often cite 
moving away from drug-using social networks as a factor in their success (Best et al., 
2008). Greater integration of treatment services with local recovery groups may help 
mitigate this influence. 
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4.6.4 STRENGTHS AND LIMITATIONS 
A major study strength is the national, large-scale, long-term follow-up of all individuals 
accessing treatment for opioid use disorder in England. In addition, the consent model 
supporting NDTMS enables cross-referencing with subsequent treatment admissions 
and drug-poisoning databases, providing the utility to examine an objective summative 
measure of sustained recovery from OUD.  
Several limitations are also acknowledged: first, while all available covariates in 
NDTMS were screened in the present analysis, other covariates could further elucidate 
the likelihood of sustaining recovery, including treatment motivation (Simpson and Joe, 
1993), engagement (Simpson et al., 1995) and other recovery strengths (Gossop et al., 
2002). Second, it is possible that other interventions, such as attending Narcotics 
Anonymous, were experienced by the patients in this cohort. These interventions are 
not, however, captured by NDTMS and it is not possible to assess the potential impact 
these may have had. We note that the E-value parameter suggests such a variable 
would need to have an adjusted odds ratio of at least 2.9 to mitigate the association 
between trajectory membership and outcome.  
4.6.5 CONCLUSIONS 
This study highlights the importance of research analytical methods that capture 
longitudinal trajectories. Within a cohort of patients continuously enrolled in treatment 
for five years, diverse treatment-response trajectories emerge. The differential 
association between trajectory membership and subsequent outcomes has real 
application and could be important to clinicians and treatment purchasers as it 
indicates a substantial proportion of patients exhibit chronic or relapsing opioid use in 




Chapter 5  STUDY 3: CHANGE IN ALCOHOL AND 
OTHER DRUG USE DURING FIVE YEARS OF 
CONTINUOUS OPIOID SUBSTITUTION TREATMENT 
5.1 DESCRIPTION OF STUDY IN THE CONTEXT OF THE THESIS 
The previous chapter focused on the response trajectories of heroin use frequency 
over the course of five years of continuous enrolment in treatment. Heroin users are, 
however, a heterogeneous group in terms of adjunctive substance use. Indeed, as 
noted in Chapter 3, some 67% of heroin users had a concurrent substance use 
disorder at the point of treatment admission. As it may prove informative to clinical and 
policy decision making, the current study examines whether or not Latent Class Growth 
Analysis can also identify differing trajectory groups based on their use of the other 
substances recorded via the Treatment Outcomes Profile i.e. crack cocaine, cocaine 
powder, amphetamines, cannabis, alcohol, as well as a further unspecified substance. 
This chapter was published as follows: 
Eastwood, B., Strang, J., Marsden, J., 2019. Change in alcohol and other drug use 
during five years of continuous opioid substitution treatment. Drug and Alcohol 






Background: English national prospective, observational cohort study of patients 
continuously enrolled for five years in opioid substitution treatment (OST) with oral 
methadone and sublingual buprenorphine. This is a secondary outcome analysis of 
change in use of alcohol and other drug use (AOD) following identification of heroin use 
trajectories during OST. 
Methods: All adults admitted to community OST in 2008/09 and enrolled to 2013/14 
(n=7,717). Data from 11 sequential, six-monthly clinical reviews were used to identify 
heroin and AOD use trajectories by multi-level Latent Class Growth Analysis. OST 
outcome in the sixth and seventh year was ‘successful completion and no re-
presentation’ (SCNR) to structured treatment and was assessed using multi-level 
logistic regression. 
Results: With 'rapid decreasing' heroin use trajectory as referent, ‘continued high-level’ 
heroin use predicted ‘continued high-level’ crack cocaine use (relative risk ratio [RRR] 
58.7; 95% confidence interval [CI] 34.2-100.5),‘continued high-level’ alcohol use (RRR 
1.2; 95% CI 1.0-1.5), ‘increasing’ unspecified drug use (RRR 1.7; 95% CI 1.4-2.1) and 
less ‘high and increasing’ cannabis use (RRR 0.5; 95% CI 0.4-0.6). 'Increasing’ crack 
use was negatively associated with SCNR outcome for the ‘decreasing then increasing’ 
and 'gradual decreasing' heroin use groups (adjusted odds ratio [AOR] 0.5; 95% CI 
0.3-0.9 and AOR 0.2; 95% CI 0.1-0.7, respectively). 
Conclusions: Continued high-level heroin use non-response during long-term OST is 
associated with high-level crack cocaine and alcohol use, increasing unspecified drug 
use, but less high and increasing cannabis use. Increasing use of crack cocaine is 





Opioid substitution treatment (OST), with oral methadone or sublingual buprenorphine, 
is the first-line maintenance intervention for opioid use disorder (OUD). Observational 
studies have consistently reported OST to be associated with suppression of illicit 
opioid use (e.g. Hubbard et al., 2003; Mattick et al., 2014, 2009; Simpson et al., 1982; 
Teesson et al., 2006), a lower risk of opioid overdose (White et al., 2015), and 
reductions in crime (Russolillo et al., 2018).  
Many people with OUD present for treatment with problems associated with several 
substance classes. Darke and Hall (1995) reported that 99% of heroin users had used 
another drug class in the six-months before treatment and reported using an average 
of 5.2 other substances. In England, national statistics demonstrate that crack cocaine 
is the most prevalent of concurrent substance use disorders and has increased in 
those starting treatment from 42% to 54% in the four years to 2017/18 (Public Health 
England [PHE], 2018a, 2017, 2016, 2015). Crack cocaine use during treatment for 
OUD is associated with poorer suppression of illicit opioid use, worse acquisitive crime 
and psychological health outcomes and a lowered likelihood of completing treatment 
successfully (Eastwood et al., 2017; Gossop et al., 2002a; Heidebrecht et al., 2018; 
Marsden et al., 2012b, 2009). Concurrent alcohol use disorder has been reported to 
affect around a third of OUD patients in treatment, although in England the prevalence 
is somewhat lower at 17% (Nolan et al., 2016; Public Health England, 2018a).  
There have been mixed findings from observational follow-up studies of change in 
concurrent alcohol and other drug use (AOD) during OUD treatment. Brecht et al. 
(2008) observed an aggregate reduction in use, while Gossop et al. (2003) reported a 
return to baseline levels following a temporary reduction, and others have reported a 
worsening state in a subset of non-users at treatment admission (Gossop et al., 2002b; 
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Weiss et al., 2015). A two-year study of heroin users enrolled in the Australian 
Treatment Outcomes Study reported that reductions in heroin use were not associated 
with increases in the use of cocaine, amphetamine, cannabis, benzodiazepines and 
other opioids (Darke et al., 2006). A longer 11-year follow-up study reported the use of 
alcohol was to be consistent across waves, ranging between 49% and 56% (Darke et 
al., 2015). Similar reductions in alcohol and other drug use has been reported in Ireland 
over a 3-year follow-up period (Comiskey et al., 2009).  
Aggregated findings may, however, mask differential clinical response among sub-
populations. In their classic 30-year study of heroin and other drug use, Grella and 
Lovinger (2011) reported that a quarter of those followed up tracked a ‘rapid decrease’ 
heroin use trajectory and over half of these reported an early increase in AOD 
(although specific non-opioid substance classes were not reported). Recently, Teesson 
et al. (2017) identified six heroin use trajectory groups over 11-years. They reported 
that those following the ‘no decrease’ track were more likely to have been incarcerated 
and to be currently affected by unstable housing and to be using benzodiazepines, but 
did not examine longitudinal patterns of concurrent substance use. 
In a recent report in this journal, we identified five heroin use trajectories in a national 
cohort of patients who were continuously enrolled in OST for five years (n=7,719; 
Eastwood et al., 2018). We showed that patients following a positive treatment 
response trajectory towards abstinence were more likely to successfully complete 
treatment in the subsequent two-year period.  
To inform clinical practice and treatment policy, studies are needed to determine 
specific substance use change trajectories during long-term OUD treatment. 
Accordingly, in this related article, we determined the strength of evidence:  
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(1) for a trajectory of patients characterised by increasing use of alcohol, cannabis, 
crack cocaine, cocaine powder, amphetamines and any unspecified drug use; 
(2) that positive and negative change in heroin use is associated with an increase in 
alcohol and other drug use; and  
(3) increased use of alcohol and other drug use predicts poor OST outcome. 
5.4 METHODS 
5.4.1 DESIGN 
Using data from the English National Drug Treatment Monitoring System (NDTMS), 
this was a national, seven-year, prospective cohort study reported following the 
RECORD guidelines for observational research using routinely collected health data 
(Benchimol et al., 2015). The study cohort has been described in two previous reports 
in the journal where a detailed description of measures is presented (Eastwood et al., 
2018, 2017). 
The present analysis concerns all patients who initiated OST between 1 April 2008 and 
31 March 2009 and were enrolled for five years, ending 31 March 2014 and followed-
up to 30 September 2016 (7,719 [14.2%] of 54,357). Following the NDTMS reporting 
protocol, all members of the cohort were either continuously enrolled in OST (i.e. they 
had a single unbroken episode of OST), or there was no more than 21 days between 
the end of one prescribing episode and the initiation of another (i.e. in the context of a 
transfer of a patient from one OST prescribing service to another).  
5.4.2 MEASURES 
5.4.2.1 DEVELOPMENTAL TRAJECTORY INDICATORS 
The Treatment Outcomes Profile (TOP; Marsden et al., 2008) is a structured, clinical 
interview for substance use disorder treatment monitoring. Using a recall period of the 
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past 28 days, the TOP is completed by the clinician at the patient’s admission; then as 
part of a clinical review conducted every six months, and at treatment completion. 
There were 11 TOP interviews conducted between Year 1 (2008/09) and Year 5 
(2013/14) recording the number of days the patient reported using alcohol, cannabis, 
crack cocaine, cocaine powder, amphetamines, and any unspecified drug. The latter 
drug category is known only at the level of the treatment clinic. However, annual 
aggregate data suggest it is likely to involve benzodiazepines rather than anti-
depressants, hallucinogens, volatile solvents, or major tranquillisers (10% prevalence 
versus <1%, respectively; Public Health England, 2018). 
For the present analysis, we used the following five heroin use trajectory classes 
identified by Eastwood et al. (2018; Figure 5.1)1: 
• Class 1 (n=1,617, 20.9%: ‘gradual decreasing’) 
• Class 2 (n=1,672, 21.7%: ‘decreasing then increasing’) 
• Class 3 (n=1,310, 17.0%: ‘continued low-level’) 
• Class 4 (n=1,973, 25.6%: ‘rapid decreasing’) 
• Class 5 (n=1,145, 14.9%: ‘continued high-level’) 
 
                                               
1 Due to two individuals with no AOD data, the ‘decreasing then increasing’ and ‘continued 




Figure 5.1 Heroin use trajectories over 5 years of continuous OST 
5.4.2.2 OUTCOME MEASURE 
The OST outcome was the national summative measure of treatment effectiveness 
defined as successful completion and no re-presentation (SCNR) for further treatment 
within six months (Public Health England, 2018f). ‘Successful completion’ was 
recorded in Year 6 and Year 7 (ending 31 March 2016) by a clinician-verified report 
indicating: (1) abstinence from heroin (and any other non-medical opioids) and cocaine; 
(2) remission from OUD; (3) attainment of personal care plan goals and (4) completion 
of OST. For this summative measure of OST effectiveness, we removed all individuals 
to 30 September 2016 who were re-admitted to community-based or prison-based 




5.4.2.3 BASELINE COVARIATE MEASURES 
Patient-level variables in the analysis included demographics (sex, age, ethnicity, 
employment, homelessness); social deprivation (linked to NDTMS based on the 
patient’s residential postcode district or the location of their first treatment provider in 
instances of missing postcode information; see section 3.4.5); treatment admission 
latent drug use class from Eastwood et al. (2017); drug injecting status; duration of 
heroin use ‘career’; referral route; other interventions (psychosocial; in-patient 
detoxification; or residential rehabilitation); and previous treatment for OUD. 
5.4.2.4 STATISTICAL ANALYSIS 
Data management was done with SPSS (version 21). Given the clustering of patients 
within local treatment systems, we used multi-level Latent Class Growth Analysis 
(LCGA) to identify discrete, non-overlapping AOD use change trajectories across the 
five-years of OST (MPlus; version 7). Management of missing data (by multiple 
imputation) and all regression analyses was done with Stata (version 15.1).  
5.4.2.5 AOD USE TRAJECTORIES 
Sequentially, 1-class through 6-class models were fit to the data to identify 
unconditional trajectory membership. A Poisson distribution was assumed for all 
models and 5,000 random sets of starting values were used to guard against 
convergence on local maxima (McLachlan and Peel, 2000). The LCGA approach aims 
to converge on what is termed the ‘global maximum’, which is the set of parameter 
estimates associated with the largest loglikelihood for the entire curve being estimated 
(Jung and Wickrama, 2008). In effect, the LCGA algorithm can get stuck on an 
incorrect solution if it erroneously considers the maximum loglikelihood of only part of a 
curve to be the maximum of the entire curve. The LCGA algorithm cannot distinguish 
between local and global maxima, which is why a high number of random starts can 
only protect against, rather than fully eliminate, the risk of an incorrect solution. 
122 
 
Trajectory identification was informed by the Aikaike and Bayesian information criteria 
(AIC and BIC), entropy and the Vuong-Lo-Mendel-Ruben (VLMR) and bootstrapped 
likelihood ratio tests (BLRT).  
AIC and BIC are relative fit indices and, as such, require more than a single model for 
their utility to become apparent (Sen and Bradshaw, 2017). Both criteria are useful, 
particularly when exploring a new dataset as the BIC is expected to perform better 
when the true model has a simple structure or is present among the set of candidate 
models which the AIC is expected to perform better when the true model has a 
complex structure or is absent from the set of candidate models (Sen and Bradshaw, 
2017; Vrieze, 2012). 
Entropy is a measure of how well the LCGA model assigns individuals to a given 
trajectory group. It is possible, for example, to assign a given individual an equal 
probability of being in each of the identified classes. This would have low entropy as 
the model cannot ‘decide’ in which class to best place the individual. In contract, should 
an individual be assigned a 100% probability of being in one class and 0% for all 
remaining classes, the entropy score would be high as the model was quite certain. 
The VLMR and BLRT specifically test whether a model with k classes provides a 
significantly better fitting solution that a model with k-1 classes. A minimum class size 
of 5% of the cohort was pre-specified for utility (Borders and Booth, 2012; Willey et al., 
2016b) as it was decided that any class with less than this proportion, while potentially 
interesting, does not readily lend itself to policy decision making.  
5.4.2.6 MISSING DATA 
As LCGA is implemented by full-information maximisation likelihood, all patients with at 
least one measurement could be assigned to a latent class, but a complete case 
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sample may yield biased estimates due to missing covariate data. As such, and with no 
evidence that missing data was not missing-at-random, a set of  twenty multiply 
imputed datasets was created using logistic regression, multinomial regression, and 
predictive mean matching for missing binary, multinomial or continuous data, 
respectively (Stata command: MI impute chained).  
5.4.2.7 ANALYSIS OF HEROIN AND AOD USE TRAJECTORIES 
A series of multiply imputed, multivariable, multinomial logistic regressions regressed 
AOD use trajectory classes on heroin use trajectory groups, controlling for patient-level 
characteristics (Stata command: mlogit). Robust standard errors were utilised to 
calculate 95% confidence intervals (CI) to adjust for clustering of patients in each 
treatment system. Multiply imputed, multilevel, multivariable logistic regression models 
were used to estimate the likelihood of SCNR (Stata command: meqrlogit). As the 
likelihood of SCNR varied by heroin use trajectory, we estimated the association 
between AOD use trajectory groups and SCNR for each group. 
5.5 RESULTS 
5.5.1 STUDY COHORT 
The study cohort includes 7,719 patients for which heroin use trajectories were 
identified (sample details in Eastwood et al. 2018). These patients were recruited from 
all 149 local treatment systems in England (median 41; interquartile range [IQR] 23-
71). Two patients did not complete a TOP assessment across all 11 assessment 
periods and were removed. Multilevel LCGA models were undertaken on 7,717 
patients. A further 58 patients (0.8%) were subsequently removed as their original 
treatment records from 2008/09 were no longer available on NDTMS when assessing 
their follow-up status.   
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5.5.2 HEROIN AND AOD USE DURING FIVE YEARS OF CONTINUOUS OST 
Heroin use was reported by 85.8% of the cohort during the 28-days preceding 
treatment admission (Table 5.1). The most prevalent substances reported in the pre-
admission month were alcohol (41.7%), crack cocaine (40.3%), cannabis (27.2%) and 
unspecified drugs (19.7%). Less than 5% reported using cocaine powder or an 
amphetamine.  
At the end of Year 5, the prevalence of heroin use fell by almost half to 43.2%. The 
largest reduction in AOD use was observed for crack cocaine (20.6%), unspecified 
drugs (12.0%) and cannabis (6.7%). The prevalence of alcohol use was reduced by 
2.7%. Although cocaine powder and amphetamines were reduced by 2.1% and 1.5%, 
respectively, this represented a reduction of over a third (36.6%) for amphetamines and 
nearly a half (44.7%) for cocaine powder. Due to the marginal prevalence of 
amphetamines and cocaine powder use in the cohort, these substances were not 
included in the models.  
5.5.3 AOD USE TRAJECTORIES 
Table 5.2 displays the results of the multilevel LCGA models for alcohol, crack cocaine, 
cannabis and unspecified drug. For each substance, AIC, BIC, aBIC, entropy and 
BLRT indicators all pointed to six-class solutions. However, based on the model 
indicators, as well as the longitudinal separation between trajectory groups, we judged 
that alcohol, crack cocaine, cannabis and unspecified drug were best described by a 
more parsimonious four, five, three and three class model, respectively.  
Figure 2 (charts A-D) show the following trajectory classes: 
Alcohol (Figure 2A: Class 1 [n=1,323, 17.1%: ‘continued high-level]; Class 2 
[n=3,810, 49.4%: ‘continued low-level]; Class 3 [n=1,230,15.9%: ‘increasing’]; Class 4 
[n=1,354, 17.6%: ‘decreasing’]). 
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Crack cocaine (Figure 2B: Class 1 [n=735, 9.5%: ‘gradual decreasing’]; Class 2 
[n=924, 12.0%: ‘increasing’]; Class 3 [n=4,576, 59.3%: ‘continued low-level’]; Class 4 
[n=407, 5.3%: ‘continued high-level’]; Class 5 [n=1,075, 13.9%: ‘rapid decreasing’]). 
Cannabis (Figure 2C: Class 1 [n=4,565, 59.2%: ‘continued low-level’], Class 2 
[n=1,834, 23.8%: ‘low and decreasing], Class 3 [n=1,318, 17.1%: ‘high and 
increasing’].  
Unspecified drug use (Figure 2D: Class 1 [n=1,047, 13.6%: ‘increasing’], Class 2 
[n=5,490, 71.1%: ‘continued low-level’], Class 3 [n=1,180, 15.3%: ‘decreasing’]. 
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Table 5.1 Heroin, alcohol and other drug use during five years of continuous OST (n=7,717) 
  Treatment Outcomes Profile assessment 
 Substance  Admission Year 0.5 Year 1 Year 1.5 Year 2 Year 2.5 Year 3 Year 3.5 Year 4 Year 4.5 Year 5 
Heroin responses (n)  5567 5774 6409 6449 6567 6649 6670 6712 6733 6742 6746 
% using  85.8 62.7 59.2 57.0 53.3 43.6 39.6 40.6 41.9 42.6 43.2 
Mean days using  
(SD) *  19.5 (11.6) 7.4 (9.7) 6.0 (8.7) 5.9 (8.6) 5.4 (8.3) 4.0 (7.5) 3.5 (6.9) 3.7 (7.1) 3.6 (7.0) 3.9 (7.2) 4.0 (7.4) 
Alcohol responses (n)  5496 5758 6407 6450 6569 6652 6675 6716 6737 6748 6739 
% using  41.7 43.3 43.3 42.5 41.9 42.5 42.3 41.2 40.9 40.2 39.0 
Mean days using  
(SD) *  5.4 (9.3) 5.2 (8.9) 5.3 (9.0) 5.2 (9.0) 5.3 (9) 5.3 (9.1) 5.5 (9.3) 5.3 (9.2) 5.4 (9.2) 5.3 (9.3) 5.3 (9.3) 
Crack responses (n)  5511 5761 6401 6444 6565 6642 6667 6708 6728 6738 6740 
% using  40.3 25.1 20.4 20.3 20.3 19.6 19.2 19.2 19.1 19.2 19.7 
Mean days using  
(SD) *  4.5 (8.5) 2.0 (5.4) 1.5 (4.4) 1.5 (4.5) 1.5 (4.7) 1.4 (4.5) 1.5 (4.6) 1.4 (4.3) 1.4 (4.3) 1.4 (4.4) 1.4 (4.5) 
Cannabis responses (n)  5463 5741 6391 6434 6555 6643 6670 6709 6721 6735 6731 
% using  27.2 24.3 23.5 22.3 21.2 22.3 22.4 22.1 21.3 21.8 20.5 
Mean days using  
(SD) *  3.8 (8.4) 3.5 (8.3) 3.5 (8.4) 3.4 (8.1) 3.2 (8.0) 3.4 (8.2) 3.5 (8.3) 3.5 (8.4) 3.4 (8.3) 3.5 (8.3) 3.2 (8.0) 
Unspecified drug responses (n)  5395 5684 6356 6407 6554 6627 6654 6695 6713 6710 6703 
% using  19.7 9.5 8.3 7.3 7.4 6.9 7.1 7.3 7.2 7.9 7.7 
Mean days using  
(SD) *  3.3 (8.1) 1.7 (6.3) 1.3 (5.6) 1.2 (5.4) 1.2 (5.2) 1.1 (5.0) 1.1 (4.9) 1.0 (4.9) 1.1 (5.0) 1.1 (5.0) 1.1 (5.1) 
Cocaine powder responses (n)  5438 5736 6391 6435 6559 6635 6655 6686 6700 6705 6701 
% using  4.7 3.2 2.5 2.3 2.3 2.7 2.4 2.6 2.4 2.6 2.6 
Mean days using  
(SD) *  0.2 (1.8) 0.1 (0.9) 0.1 (0.8) 0.1 (0.9) 0.1 (0.9) 0.1 (0.9) 0.1 (1.1) 0.1 (0.9) 0.1 (0.8) 0.1 (1.0) 0.1 (0.9) 
Amphetamines responses (n)  5434 5734 6390 6434 6559 6637 6660 6692 6700 6708 6705 
% using  4.1 2.7 2.5 2.8 2.6 2.5 2.8 2.3 2.3 2.5 2.6 
Mean days using  
(SD) *  0.4 (2.6) 0.1 (1.4) 0.2 (1.5) 0.2 (1.6) 0.2 (1.6) 0.2 (1.7) 0.2 (1.8) 0.2 (1.5) 0.2 (1.7) 0.2 (1.8) 0.2 (1.9) 
SD = standard deviation 
* Mean days of use in past 28 days
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Table 5.2 Unconditional multilevel latent class growth analysis of alcohol and other drug use over five years (n=7,717) 
 
Post-hoc criteria Class proportion (probability of assignment) 
Substance AIC BIC aBIC Entropy VLMR BLRT 1 2 3 4 5 6 
Alcohol 
            
Class 1 1035730.70 1035751.55 1035742.02 - - - 1.00 (1.00) 
     
Class 2 596761.37 596810.03 596787.78 0.994 <0.0001 <0.0001 0.67 (1.00) 0.33 (1.00) 
    
Class 3 518637.67 518714.13 518679.18 0.985 0.293 <0.0001 0.29 (0.99) 0.51 (1.00) 0.20 (0.99) 
   
Class 4 488513.21 488617.47 488569.81 0.980 0.135 <0.0001 0.17 (0.99) 0.49 (1.00) 0.16 (0.98) 0.18 (0.98) 
  
Class 5 466197.73 466329.81 466269.43 0.971 0.650 <0.0001 0.11 (0.97) 0.14 (0.99) 0.12 (0.98) 0.24 (0.97) 0.40 (0.99) 
 
Class 6 450851.39 451011.27 450938.18 0.967 0.200 <0.0001 0.12 (0.99) 0.11 (0.97) 0.15 (0.95) 0.09 (0.97) 0.14 (0.96) 0.40 (0.99) 
Crack cocaine 
            
Class 1 521547.29 521568.15 521558.61 - - - 1.00 (1.00) 
     
Class 2 317093.91 317142.57 317120.33 0.988 <0.0001 <0.0001 0.27 (1.00) 0.73 (1.00) 
    
Class 3 272328.31 272404.78 272369.82 0.979 0.057 <0.0001 0.10 (0.99) 0.26 (0.98) 0.64 (1.00) 
   
Class 4 252515.88 252620.15 252572.48 0.974 <0.05 <0.0001 0.15 (0.96) 0.08 (0.99) 0.63 (1.00) 0.14 (0.97) 
  
Class 5 241212.70 241344.77 241284.40 0.965 0.210 <0.0001 0.10 (0.96) 0.12 (0.96) 0.59 (0.99) 0.05 (0.98) 0.14 (0.94) 
 
Class 6 233444.82 233604.70 233531.61 0.958 0.536 <0.0001 0.05 (0.98) 0.07 (0.96) 0.14 (0.93) 0.09 (0.90) 0.56 (0.99) 0.09 (0.97) 
Cannabis 
            
Class 1 938291.53 938312.38 938302.85 - - - 1.00 (1.00) 
     
Class 2 535324.30 535372.95 535350.71 0.994 <0.0001 <0.0001 0.28 (1.00) 0.72 (1.00) 
    
Class 3 464870.58 464947.04 464912.09 0.988 0.319 <0.0001 0.59 (1.00) 0.24 (0.99) 0.17 (0.99) 
   
Class 4 432664.99 432769.26 432721.59 0.986 <0.05 <0.0001 0.13 (0.98) 0.14 (0.98) 0.60 (1.00) 0.13 (0.99) 
  
Class 5 412930.72 413062.79 413002.41 0.982 0.305 <0.0001 0.57 (1.00) 0.11 (0.98) 0.09 (0.99) 0.13 (0.97) 0.10 (0.98) 
 
Class 6 397768.05 397927.93 397854.84 0.983 0.103 <0.0001 0.56 (1.00) 0.07 (0.99) 0.08 (0.98) 0.11 (0.97) 0.11 (0.97) 0.08 (0.98) 
Unspecified 
drug 
            
Class 1 539800.54 539821.40 539811.86 - - - 1.00 (1.00) 
     
Class 2 348344.25 348392.91 348370.66 0.991 <0.0001 <0.0001 0.27 (0.99) 0.73 (1.00) 
    
Class 3 297333.74 297410.20 297375.25 0.986 0.217 <0.0001 0.14 (0.99) 0.71 (1.00) 0.15 (0.98) 
   
Class 4 269356.09 269460.36 269412.70 0.985 0.623 <0.0001 0.69 (1.00) 0.07 (0.99) 0.10 (0.99) 0.14 (0.97) 
  
Class 5 246710.61 246842.68 246782.31 0.981 0.409 <0.0001 0.68 (1.00) 0.09 (0.98) 0.98 (0.96) 0.99 (0.99) 0.98 (0.98) 
 
Class 6 230945.90 231105.78 231032.69 0.980 0.0187 <0.0001 0.05 (0.99) 0.68 (1.00) 0.05 (0.99) 0.10 (0.95) 0.05 (0.97) 0.06 (0.97) 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; aBIC: sample-size adjusted BIC; VLMR: Vuong-Lo-Mendel-Ruben test; BLRT: bootstrapped 





A. Alcohol use trajectories  B. Crack cocaine trajectories 
  
C. Cannabis use trajectories D. Unspecified drug use trajectories 
Figure 5.2 AOD trajectories over 5 years of continuous OST 
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5.5.4 AOD TRAJECTORIES REGRESSED ON HEROIN USE  
The distribution of AOD trajectory groups within each of the heroin use trajectory classes is 
shown in Table 5.3. Relative risk ratios (RRR) and 95% confidence intervals (CI) from the 
multiply imputed multivariable multinomial regression analyses of the relationship between 
heroin and AOD use are displayed in Tables 5.4-5.7.  
For brevity, we focused on the ‘rapid decreasing’ heroin class as the referent (Model 4, 
Tables 5.4-5.7). Members of the ‘continued high-level’ heroin use class were:  
• more likely to be members of the ‘continued high-level’ alcohol class (21.7% vs 
15.5%: RRR 1.24; 95% CI 1.01-1.53), and less likely to be members of the 
‘decreasing’ alcohol use class (12.1% vs 20.4%: RRR 0.57; 95% CI 0.45-0.71);  
• more likely to members of crack cocaine ‘continued high-level’ (23.7% vs 0.8%; RRR 
58.66; 95% CI 34.23-100.54), ‘increasing’ (17.3% vs 4.5%; RRR 6.45; 95% CI 4.89-
8.51), ‘gradual decreasing’ (10.9% vs 3.4%; RRR 5.65; 95% CI 4.09-7.79) classes, 
were less likely to be members of the ‘rapid decreasing’ class (8.9% vs 22.3%; RRR 
0.66; 95% CI 0.52-0.84);  
• less likely to be members of the ‘high and increasing’ cannabis group (11.0% vs 
19.2%: RRR 0.49; 95% CI 0.39-0.62); and  
• more likely to be members of the ‘increasing’ unspecified drug class (17.6% vs 9.7%: 










AOD use trajectory groups 



















      
Continued high-level 283 (17.6) 284 (17.1) 197 (15.2) e 304 (15.5) e 247 (21.7) c,d 1315 (17.2) 
Continued low-level+ 769 (47.9) 800 (48.2) 677 (52.2) 965 (49.3) 566 (49.6) 3777 (49.3) 
Increasing 247 (15.4) c 312 (18.8) c,d 184 (14.2) a,b,e 288 (14.7) b 190 (16.7) c 1221 (15.9) 
Decreasing 305 (19.0) e 263 (15.9) d,e 240 (18.5) e 400 (20.4) b,e 138 (12.1) a,b,c,d 1346 (17.6) 
Crack cocaine 
      
Gradual decreasing 317 (19.8) b,c,d,e 197 (11.9) a,c,d 25 (1.9) a,b,d,e 67 (3.4) a,b,c,e 124 (10.9) a,c,d 730 (9.5) 
Increasing 169 (10.5) b,c,d,e 368 (22.2) a,c,d 94 (7.2) a,b,e 87 (4.5) a,b,e 197 (17.3) a,c,d 915 (11.9) 
Continued low-level+ 793 (49.4) 837 (50.5) 1107 (85.3) 1352 (69.1) 448 (39.3) 4537 (59.2) 
Continued high-level 51 (3.2) c,d,e 64 (3.9) c,d,e 5 (0.4) a,b,e 15 (0.8) a,b,e 270 (23.7) a,b,c,d 405 (5.3) 
Rapid decreasing 274 (17.1) b,c,e 193 (11.6) a,c,d 67 (5.2) a,b,d,e 436 (22.3) b,c,e 102 (8.9) a,c,d 1072 (14.0) 
Cannabis 
      
Continued low-level+ 930 (58.0) 969 (58.4) 760 (58.6) 1133 (57.9) 737 (64.6) 4529 (59.1) 
Low and decreasing 391 (24.4) 433 (26.1) c,e 271 (20.9) b 448 (22.9) 279 (24.5) b 1822 (23.8) 
High and increasing 283 (17.6) e 257 (15.5) c,e 267 (20.6) b,e 376 (19.2) b ,e 125 (11.0) a,b,c,d 1308 (17.1) 
Unspecified drug 
      
Increasing 245 (15.3) c,d 248 (15.0) d 159 (12.3) a,e 189 (9.7) a,b,e 201 (17.6) c,d 1042 (13.6) 
Continued low+ 1075 (67.0) 1189 (71.7) 934 (72.0) 1464 (74.8) 781 (68.5) 5443 (71.1) 
Decreasing 284 (17.7) b,e 222 (13.4) a 205 (15.8) 304 (15.5) 159 (13.9) a 1174 (15.3) 
Figures presented in table are number of participants (percentages) 
+ Represents the base outcome in the from all-case, multiply imputed, multivariable multinomial logistic regression models  




Table 5.4 Multiply imputed, multivariable, multinomial logistic regression models of alcohol trajectory group membership (n=7,717) 
    Multinomial logistic regression model 
Alcohol trajectory 
group  Heroin trajectory group  




















Continued high level  Gradual decreasing  - 1.02 (0.84,1.25) 1.24 (1.00,1.54) 1.08 (0.89,1.31) 0.87 (0.70,1.07) 
  Decreasing then increasing  0.98 (0.80,1.19) - 1.21 (0.98,1.50) 1.05 (0.87,1.28) 0.85 (0.69,1.04) 
  Continued low-level  0.81 (0.65,1.00) 0.82 (0.66,1.02) - 0.87 (0.70,1.07) 0.70 (0.56,0.88) 
  Rapid decreasing  0.93 (0.76,1.12) 0.95 (0.78,1.15) 1.15 (0.93,1.42) - 0.80 (0.65,0.99) 
  Continued high-level  1.15 (0.94,1.42) 1.18 (0.96,1.45) 1.43 (1.14,1.80) 1.24 (1.01,1.53) - 
         
Increasing  Gradual decreasing  - 0.84 (0.69,1.02) 1.25 (1.00,1.56) 1.05 (0.86,1.28) 0.97 (0.78,1.21) 
  Decreasing then increasing  1.19 (0.98,1.44) - 1.48 (1.20,1.84) 1.25 (1.04,1.51) 1.15 (0.93,1.42) 
  Continued low-level  0.80 (0.64,1.00) 0.67 (0.54,0.83) - 0.84 (0.68,1.04) 0.78 (0.61,0.99) 
  Rapid decreasing  0.95 (0.78,1.16) 0.80 (0.66,0.97) 1.19 (0.96,1.47) - 0.92 (0.74,1.14) 
  Continued high-level  1.03 (0.83,1.28) 0.87 (0.70,1.07) 1.29 (1.01,1.63) 1.08 (0.87,1.34) - 
         
Decreasing  Gradual decreasing  - 1.21 (1.00,1.47) 1.09 (0.89,1.34) 0.92 (0.77,1.10) 1.63 (1.29,2.05) 
  Decreasing then increasing  0.83 (0.68,1.00) - 0.90 (0.73,1.11) 0.76 (0.63,0.91) 1.35 (1.07,1.70) 
  Continued low-level  0.92 (0.75,1.12) 1.11 (0.90,1.36) - 0.84 (0.70,1.02) 1.49 (1.17,1.90) 
  Rapid decreasing  1.09 (0.91,1.30) 1.31 (1.09,1.58) 1.19 (0.98,1.44) - 1.77 (1.41,2.21) 
    Continued high-level   0.61 (0.49,0.77) 0.74 (0.59,0.94) 0.67 (0.53,0.85) 0.57 (0.45,0.71) - 





Table 5.5 Multiply imputed, multivariable, multinomial logistic regression models of crack cocaine trajectory group membership (n=7,717) 
    Multinomial logistic regression model 
Crack cocaine 
trajectory group  Heroin trajectory group  








Model 3 (Referent: 
Continued low-level 
heroin trajectory group) 









decreasing  Gradual decreasing  - 1.65 (1.35,2.03) 18.59 (12.19,28.35) 8.10 (6.11,10.72) 1.43 (1.13,1.83) 
  Decreasing then increasing  0.61 (0.49,0.74) - 11.25 (7.32,17.29) 4.90 (3.65,6.57) 0.87 (0.67,1.12) 
  Continued low-level  0.05 (0.04,0.08) 0.09 (0.06,0.14) - 0.44 (0.27,0.70) 0.08 (0.05,0.12) 
  Rapid decreasing  0.12 (0.09,0.16) 0.20 (0.15,0.27) 2.30 (1.44,3.67) - 0.18 (0.13,0.24) 
  Continued high-level  0.70 (0.55,0.89) 1.15 (0.89,1.49) 12.96 (8.27,20.33) 5.65 (4.09,7.79) - 
         
Increasing  Gradual decreasing  - 0.47 (0.38,0.58) 2.47 (1.88,3.24) 3.17 (2.41,4.16) 0.49 (0.39,0.62) 
  Decreasing then increasing  2.11 (1.72,2.60) - 5.21 (4.07,6.68) 6.69 (5.21,8.59) 1.04 (0.84,1.28) 
  Continued low-level  0.41 (0.31,0.53) 0.19 (0.15,0.25) - 1.28 (0.95,1.74) 0.20 (0.15,0.26) 
  Rapid decreasing  0.32 (0.24,0.42) 0.15 (0.12,0.19) 0.78 (0.57,1.06) - 0.16 (0.12,0.20) 
  Continued high-level  2.04 (1.61,2.58) 0.96 (0.78,1.19) 5.02 (3.81,6.62) 6.45 (4.89,8.51) - 
         
Continued high 
level  Gradual decreasing  - 0.80 (0.54,1.17) 14.86 (5.88,37.58) 5.93 (3.30,10.66) 0.10 (0.07,0.14) 
  Decreasing then increasing  1.25 (0.85,1.84) - 18.63 (7.43,46.71) 7.43 (4.19,13.18) 0.13 (0.09,0.17) 
  Continued low-level  0.07 (0.03,0.17) 0.05 (0.02,0.13) - 0.40 (0.14,1.10) 0.01 (0.00,0.02) 
  Rapid decreasing  0.17 (0.09,0.30) 0.13 (0.08,0.24) 2.51 (0.91,6.95) - 0.02 (0.01,0.03) 
  Continued high-level  9.9 (7.14,13.73) 7.89 (5.82,10.7) 147.10 (59.89,361.27) 58.66 (34.23,100.54) - 
         
Rapid decreasing  Gradual decreasing  - 1.47 (1.19,1.82) 5.60 (4.20,7.45) 1.02 (0.85,1.22) 1.55 (1.20,2.00) 
  Decreasing then increasing  0.68 (0.55,0.84) - 3.80 (2.83,5.11) 0.69 (0.57,0.84) 1.05 (0.80,1.37) 
  Continued low-level  0.18 (0.13,0.24) 0.26 (0.20,0.35) - 0.18 (0.14,0.24) 0.28 (0.20,0.39) 
  Rapid decreasing  0.98 (0.82,1.17) 1.44 (1.19,1.75) 5.49 (4.18,7.21) - 1.52 (1.19,1.94) 
    Continued high-level   0.65 (0.50,0.84) 0.95 (0.73,1.24) 3.62 (2.60,5.05) 0.66 (0.52,0.84) - 
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Table 5.6 Multiply imputed, multivariable, multinomial logistic regression models of cannabis trajectory group membership (n=7,717) 
    Multinomial logistic regression model 
Cannabis trajectory 
























Low and decreasing  Gradual decreasing  - 0.94 (0.79,1.10) 1.13 (0.94,1.36) 1.00 (0.85,1.17) 1.15 (0.96,1.38) 
  Decreasing then increasing  1.07 (0.91,1.26) - 1.21 (1.01,1.45) 1.07 (0.91,1.25) 1.23 (1.03,1.47) 
  Continued low-level  0.88 (0.73,1.06) 0.83 (0.69,0.99) - 0.88 (0.74,1.05) 1.02 (0.83,1.24) 
  Rapid decreasing  1.00 (0.85,1.18) 0.94 (0.80,1.10) 1.14 (0.95,1.36) - 1.15 (0.96,1.38) 
  Continued high-level  0.87 (0.72,1.04) 0.81 (0.68,0.97) 0.98 (0.80,1.20) 0.87 (0.72,1.04) - 
         
High and increasing  Gradual decreasing  - 1.17 (0.96,1.42) 0.90 (0.74,1.10) 0.88 (0.73,1.05) 1.79 (1.42,2.26) 
  Decreasing then increasing  0.86 (0.70,1.04) - 0.77 (0.63,0.94) 0.75 (0.63,0.90) 1.53 (1.21,1.94) 
  Continued low-level  1.11 (0.91,1.36) 1.30 (1.06,1.59) - 0.98 (0.81,1.18) 1.99 (1.56,2.54) 
  Rapid decreasing  1.14 (0.95,1.36) 1.33 (1.11,1.60) 1.02 (0.85,1.23) - 2.04 (1.62,2.56) 











Table 5.7 Multiply imputed, multivariable, multinomial logistic regression models of other drug trajectory group membership (n=7,717) 
    Multinomial logistic regression model 
Unspecified drug 
























Increasing  Gradual decreasing  - 1.06 (0.87,1.29) 1.27 (1.01,1.59) 1.58 (1.28,1.94) 0.93 (0.75,1.15) 
  Decreasing then increasing  0.94 (0.78,1.15) - 1.20 (0.96,1.49) 1.49 (1.21,1.83) 0.88 (0.71,1.08) 
  Continued low-level  0.79 (0.63,0.99) 0.84 (0.67,1.04) - 1.24 (0.99,1.57) 0.73 (0.58,0.93) 
  Rapid decreasing  0.63 (0.51,0.78) 0.67 (0.55,0.82) 0.80 (0.64,1.01) - 0.59 (0.47,0.73) 
  Continued high-level  1.08 (0.87,1.33) 1.14 (0.93,1.41) 1.37 (1.08,1.73) 1.70 (1.36,2.12) - 
         
Decreasing  Gradual decreasing  - 1.39 (1.15,1.69) 1.18 (0.96,1.45) 1.19 (0.99,1.43) 1.33 (1.07,1.65) 
  Decreasing then increasing  0.72 (0.59,0.87) - 0.85 (0.68,1.05) 0.86 (0.71,1.04) 0.95 (0.76,1.19) 
  Continued low-level  0.85 (0.69,1.04) 1.18 (0.95,1.46) - 1.01 (0.83,1.24) 1.13 (0.89,1.42) 
  Rapid decreasing  0.84 (0.70,1.01) 1.17 (0.96,1.41) 0.99 (0.81,1.21) - 1.11 (0.90,1.38) 








5.5.5 PROBABILITY OF MEMBERSHIP IN THE HEROIN USE TRAJECTORY GROUP 
Table 5.8 shows the probability of membership in the heroin use trajectory group 
conditional on AOD classes. Among patients classified as members of ‘decreasing’ 
alcohol use trajectory, 10% were members of ‘continued high-level’ heroin non-
response class, and 30% were members of the ‘rapid decreasing’ heroin good 
response class.  
In the ‘gradual decreasing’ crack cocaine use class, 43% were members of the ‘gradual 
decreasing’ heroin use class, and among ‘rapid decreasing’ crack cocaine group, 41% 
were members of ‘rapid decreasing’ heroin use class. Only 1% of the ‘continued high-
level’ crack cocaine use group were members of the ‘continued low-level’ heroin use 
class while 67% of this non-responding crack cocaine class were in the ‘continued 
high-level’ heroin use class. For cannabis, only 10% of the patients in the ‘high and 
increasing’ class up were members of the ‘continued high-level’ heroin use class. For 
the unspecified drug, only 14% of the continued low-level class were members of the 
‘continued high-level’ heroin class and 27% were in the ‘rapid decreasing’ heroin group. 
5.5.6 TREATMENT STATUS AT THE END OF YEAR 7 
At the end of Year 7, 4,615 (60.3%) were still enrolled in OST. During Year 6 and 7, 
1,986 (25.9%) exited treatment unsuccessfully, and 1,058 (13.8%) successfully 
completed treatment. Among this group, 16.5% (n=175) were re-admitted to treatment 
in the next six months, five were incarcerated and one person died from opioid-related 
poisoning. The SCNR outcome was therefore achieved by 877 of 3,044 patients 
discharged from OST (28.8%) .  
SCNR was most likely to be attained by the ‘rapid decreasing’ heroin class (39.7%). 
The ‘continued high-level’ heroin use trajectory group was least likely to achieve the 
SCNR (16.2%), followed by the ‘decreasing then increasing’ group (19.6%). The 
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‘continued low-level use’ and ‘gradual decreasing use’ groups had similar levels of 
SCNR (31.2% and 31.7%, respectively).   
5.5.7 IMPACT OF AOD TRAJECTORY MEMBERSHIP ON OUTCOME 
Table 5.9 shows the results of the multiply imputed, multivariable, multilevel logistic 
regression analyses. Within the ‘continued high-level’ heroin use class, patients with a 
‘rapid decreasing’ crack cocaine trajectory had an increased likelihood of achieving 
SCNR (adjusted odds ratio [AOR] 1.70; 95% confidence interval [CI] 1.04-2.77). 
Membership of the ‘increasing’ unspecified drug class was associated with a 
decreased likelihood of achieving SCNR (AOR 0.47; 95% CI 0.27-0.81).  
Among the ‘decreasing then increasing’ heroin trajectory group, a decreased likelihood 
of achieving SCNR was associated with ‘continued high-level’ alcohol use (AOR 0.43; 
95% CI 0.21-0.88), ‘gradual decreasing’ crack use (AOR 0.42; 95% CI 0.18-0.96), 
‘increasing’ crack use (AOR 0.50; 95% CI 0.27-0.93) and ‘low and decreasing’ 
cannabis use (AOR 0.50; 95% CI 0.28-0.92). 
There was a decreased likelihood of achieving SCNR for patients in the ‘increasing’ 
crack cocaine class within the ‘gradual decreasing’ heroin use class (AOR 0.22; 95% 
CI 0.07-0.66) and an increased likelihood of achieving SCNR for patients in the ‘rapid 
decreasing’ heroin class who were members of the ‘low and decreasing’ cannabis 
class (AOR 2.39; 95% CI 1.29-4.40). 
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Table 5.8 Probability of heroin use trajectory group conditional on AOD use trajectory group 
                  
AOD use trajectory 
groups 




















Alcohol         
Continued high-level  283 (0.22) 284 (0.22) 197 (0.15) 304 (0.23) 247 (0.19)  1315 (1.00) 
Continued low-level  769 (0.20) 800 (0.21) 677 (0.18) 965 (0.26) 566 (0.15)  3777 (1.00) 
Increasing  247 (0.20) 312 (0.26) 184 (0.15) 288 (0.24) 190 (0.16)  1221 (1.00) 
Decreasing  305 (0.23) 263 (0.20) 240 (0.18) 400 (0.30) 138 (0.10)  1346 (1.00) 
Crack cocaine         
Gradual decreasing  317 (0.43) 197 (0.27) 25 (0.03) 67 (0.09) 124 (0.17)  730 (1.00) 
Increasing  169 (0.18) 368 (0.40) 94 (0.10) 87 (0.10) 197 (0.22)  915 (1.00) 
Continued low-level  793 (0.17) 837 (0.18) 1107 (0.24) 1352 (0.30) 448 (0.10)  4537 (1.00) 
Continued high-level  51 (0.13) 64 (0.16) 5 (0.01) 15 (0.04) 270 (0.67)  405 (1.00) 
Rapid decreasing  274 (0.26) 193 (0.18) 67 (0.06) 436 (0.41) 102 (0.10)  1072 (1.00) 
Cannabis         
Continued low-level  930 (0.21) 969 (0.21) 760 (0.17) 1133 (0.25) 737 (0.16)  4529 (1.00) 
Low and decreasing  391 (0.21) 433 (0.24) 271 (0.15) 448 (0.25) 279 (0.15)  1822 (1.00) 
High and increasing  283 (0.22) 257 (0.20) 267 (0.20) 376 (0.29) 125 (0.10)  1308 (1.00) 
Unspecified drug         
Increasing  245 (0.24) 248 (0.24) 159 (0.15) 189 (0.18) 201 (0.19)  1042 (1.00) 
Continued low-level  1075 (0.20) 1189 (0.22) 934 (0.17) 1464 (0.27) 781 (0.14)  5443 (1.00) 









AOD use trajectory 
groups 






















     
Continued low-level - - - - - 
Continued high-level 0.47 (0.27,0.82) 0.43 (0.21,0.88) 0.66 (0.33,1.30) 0.75 (0.47,1.20) 1.29 (0.65,2.55) 
Increasing 0.59 (0.34,1.01) 0.97 (0.53,1.76) 0.65 (0.34,1.23) 1.31 (0.82,2.08) 0.94 (0.43,2.08) 
Decreasing 0.75 (0.46,1.22) 1.06 (0.57,1.97) 0.90 (0.51,1.59) 1.13 (0.76,1.69) 1.00 (0.42,2.39) 
Crack cocaine 
     
Continued low-level - - - - - 
Gradual decreasing 0.98 (0.60,1.61) 0.42 (0.18,0.96) 0.22 (0.02,2.04) 0.49 (0.18,1.33) 1.15 (0.43,3.04) 
Increasing 0.58 (0.29,1.16) 0.50 (0.27,0.93) 0.58 (0.23,1.44) 0.22 (0.07,0.66) 1.13 (0.53,2.41) 
Continued high-level 1.18 (0.47,2.97) 0.86 (0.29,2.55) - a - b 1.23 (0.61,2.50) 
Rapid decreasing 1.70 (1.04,2.77) 1.03 (0.54,1.97) 0.59 (0.20,1.77) 1.18 (0.81,1.71) 1.16 (0.41,3.30) 
Cannabis 
     
Continued low-level - - - - - 
Low and decreasing 0.90 (0.57,1.43) 0.50 (0.28,0.92) 1.15 (0.68,1.95) 1.31 (0.90,1.90) 2.39 (1.29,4.40) 
High and increasing 1.30 (0.80,2.12) 1.53 (0.84,2.76) 1.04 (0.59,1.83) 1.44 (0.96,2.17) 1.43 (0.59,3.42) 
Unspecified drug 
     
Continued low-level - - - - - 
Increasing 0.47 (0.27,0.81) 1.04 (0.55,1.96) 0.70 (0.34,1.43) 0.88 (0.49,1.57) 0.97 (0.47,2.00) 
Decreasing 0.84 (0.52,1.34) 1.28 (0.69,2.37) 1.02 (0.54,1.91) 0.70 (0.45,1.11) 0.92 (0.41,2.07) 
Adjusted odds ratios for baseline covariates are not shown 
a There were only 3 patients from the ‘continued low-level’ heroin trajectory group who were also in the ‘continued high-level’ crack cocaine trajectory, and these were removed from analysis. 





Over long-term continuous OST, we identified five trajectory classes for use of 
crack cocaine, four for alcohol, three for cannabis and three for unspecified drug 
use. In relation to our aims, each of these four substances contained an 
‘increasing’ trajectory class. We found that the ‘rapid decreasing’ heroin trajectory 
group was less likely to be represented in both the ‘increasing’ crack cocaine and 
‘other drug’ classes (although there was an increased likelihood of being 
represented in the ‘high and increasing’ cannabis use group). Membership of the 
‘increasing’ crack cocaine class was associated with a decreased likelihood of 
achieving the study outcome measure for two of the five heroin classes, while 
membership of the ‘increasing’ unspecified drug class was also associated with a 
decreased likelihood of achieving the outcome, at least for the ‘continued high-
level’ heroin trajectory group. 
5.6.1 INTEGRATION WITH THE LITERATURE 
Similar to other group based trajectory modelling studies (Grella and Lovinger, 
2011; Teesson et al., 2017b), we identified a sub-population of OUD patients who 
do not report a substantial improvement in drug use. In our study, we 
demonstrate that these patients are also more likely to use crack cocaine and 
alcohol at a higher frequency than other subpopulations, and the pattern of 
alcohol and other drug use has a detectable and negative influence on eventual 
successful completion of treatment. Grella and Lovinger (2011) reported that their 
‘no decrease’ group was more likely to be represented in the ‘late-onset increase’ 
of alcohol and other drug use while Teesson et al (2017) noted that their ‘no 
decrease’ trajectory group were more likely to live in unstable accommodation, to 
be imprisoned and to have injection-related health problems. Taken together, this 
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seems to indicate a subpopulation for whom multiple problems emerge across 
several domains. 
The increased likelihood of ‘rapid decreasing’ and ‘continued low-level’ heroin 
trajectory groups being represented in the ‘high and increasing’ cannabis 
trajectory group may reflect the potential for use of cannabis to be associated 
with a pathway away from use of heroin during OST (Sifaneck and Kaplan, 
1995). Daily cannabis use has also been associated with less severe heroin 
dependence, a lowered likelihood of daily heroin use and an increasing likelihood 
of never injecting heroin (Valdez et al., 2008). It is notable, however, that the 
increased use of cannabis in these two heroin groups did not confer any 
advantage in terms of completing OST successfully. If cannabis use does 
increase the likelihood of OUD recovery, it would be expected to be associated 
with treatment completion, though improved treatment outcomes have not been 
reported elsewhere (Budney et al., 2002; Epstein and Preston, 2003). While 
outside the scope of this paper, it is interesting to note the emerging evidence 
base of cannabinoid-opioid interactions within noradrenergic neural circuitry and 
the potential for cannabinoids to influence opioid withdrawal symptoms (Scavone 
et al., 2013). 
5.6.2 STRENGTHS AND LIMITATIONS 
A key study strength is the national, large-scale follow-up of all individuals 
accessing treatment for opioid use disorder in England and the utilisation of the 
national outcomes monitoring system to measure change in heroin and 
concurrent substance use throughout patients’ long-term enrolment in treatment. 
This ‘concurrent recovery monitoring’ system (McLellan et al., 2005) is a powerful 
platform for policy makers and researchers to efficiently evaluate the 
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effectiveness of community-based treatment under routine conditions. In addition, 
unlike other comprehensive administrative databases (Sahker et al., 2015; 
Stahler et al., 2016), the consent model supporting NDTMS enables linkage with 
subsequent treatment admissions to provide a measure of sustained recovery 
from OUD in patients exiting the treatment system.  
Several limitations are also acknowledged: first, while the frequency of use is 
captured by the Treatment Outcomes Profile, NDTMS does not capture the 
quantity of heroin and other drugs being consumed. It is possible that analysis of 
composite frequency by quantity metrics would yield different substance use 
trajectories, or that the ‘continued high-level’ groups do in fact demonstrate 
improvements in terms of quantity consumed. Second, NDTMS is a ‘core dataset’ 
and does not capture several covariates that may affect trajectory membership, 
including treatment motivation (Simpson and Joe, 1993), engagement (Simpson 
et al., 1995) and other recovery strengths (Gossop et al., 2002d). Third, the 
observational design of this study does not allow inference of causality. It is not 
possible to determine whether low-level or reducing heroin use was caused by 
increased use of cannabis (or vice versa), or whether a complex set of causal 
factors are involved. Finally, it is unfortunate that illicit benzodiazepine use is not 
captured by the TOP. This remains an important clinical issue in the treatment of 
OUD and is reported by a sizeable minority in the English treatment system.  
5.6.3 CLINICAL IMPLICATIONS 
Findings from this study and earlier reports underscore the challenge for OST 
services to support engagement and recovery for patients with illicit OUD. If OST 
does not supress a patient's heroin use to any clinically meaningful extent, then 
there is a likelihood that approximately 40% will use alcohol or crack cocaine at a 
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consistently high or increasing level and 1 in 7 will report increasing use of other 
unspecified drugs. Helping a patient with heroin and poly-substance use may be 
very challenging, but this should be a high priority because of immediate health 
needs and because the success of OST is diminished. Screening for AOD use is 
recommended at treatment admission and at regular clinical reviews, which can 
be a rapid assessment (Ali et al., 2013), and the assessment of other important 
aspects of personal and social functioning should not be overlooked (Marsden et 
al., 2014).  
If there is an unsatisfactory response to flexible dosing, it may be appropriate to 
suggest a change in medication (e.g. switching from methadone to 
buprenorphine), reinstate supervised administration (Clinical Guidelines on Drug 
Misuse and Dependence Update 2017 Independent Expert Working Group, 
2017), or offer a targeted psychosocial intervention for opioids (Marsden et al., 
2017), alcohol (Nolan et al., 2016) or cocaine (Marsden et al., 2018a) from the 
service if there are resources or by referral. Although it may be discouraging that 
some patients continue to alcohol and other drugs, treatment may still offer 
provide important harm reduction benefits by reducing the risk of opioid poisoning 
(Cornish et al., 2010; White et al., 2015) and, taking a wider societal perspective, 
there is an overall economic benefit-cost ratio from investing in OST (Zarkin et 
al., 2005).  
5.6.4 CONCLUSIONS 
This study highlights the importance of concurrent monitoring of adjunctive 
substance use in the treatment of opioid use disorder as a sizeable minority of 
patients either increase or maintain a high level of concurrent drug use and 
increasing drug use trajectories have a negative impact on positive outcome. 
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These findings reinforce the conception of OUD as a complex and chronic 
condition. The next task for our research group is to examine the longitudinal 




Chapter 6  DISCUSSION OF THESIS 
6.1 SUMMARY OF MAIN FINDINGS 
This thesis has been structured around findings from three interconnected 
studies on an English national prospective cohort of adults who have been 
treated for OUD. All of them use administrative data and multivariable, 
longitudinal statistical procedures to investigate the effectiveness of treatment. 
During the course of my doctoral studies, each of these three studies was 
reported and published as a research article in one of the leading peer reviewed 
addictions scientific journals (Drug and Alcohol Dependence).  
Study 1 demonstrated that patients presenting with OUD are far from 
homogeneous, that sub-populations can be identified at the start of treatment and 
that these sub-populations do not all share the same likelihood of completing 
treatment successfully. I showed that Latent Class Analysis can be used to 
identify different groups of heroin users. In addition, those heroin users who also 
report a concurrent crack cocaine disorder are less likely to complete treatment 
successfully within five years. Spending at least two years in treatment increased 
the likelihood of completing treatment successfully. In contrast, I demonstrate that 
being a current injector, being referred to treatment from the criminal justice 
system or having a history of previous treatment decreased the likelihood of 
completing treatment successfully.  
Study 2 extended the evidence base of longitudinal sub-populations in OUD 
patients by demonstrating that different trajectory groups can be identified in 
national administrative databases and that they are predictive of subsequent 
successful completion of treatment. I used Latent Class Growth Analysis to 
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identify five distinct groups of heroin users based on their response to treatment 
and concluded that those least responsive in terms of reducing heroin using days 
were also those least likely to subsequently recover. 
Study 3 demonstrated the importance for clinicians, researchers and policy 
makers to ensure due diligence is paid not only to the changes in the primary 
problematic substance during treatment – heroin in this case – but also to that of 
other highly prevalent substances in the OUD population. I showed that these 
adjunctive substance use trajectories mitigated positive treatment outcomes. This 
study also utilised Latent Class Growth Analysis and showed that those heroin 
users least likely to reduce their frequency of heroin use were generally the same 
individuals that were consistently reporting high levels of crack cocaine use. Of 
particular note is the finding that of individuals who had been considered 
members of a positive response heroin use trajectory in Study 2 (i.e. their heroin 
use was described as ‘gradual decreasing’ and this group was more than twice 
as likely to achieve the distal outcome), around one in ten were also on an 
‘increasing’ crack cocaine trajectory and this severely hampered their likelihood 
of success. 
All of these findings have implications for all levels of stakeholders who seek to 
increase the effectiveness of treatment and promote recovery from substance 
use disorders, be they keyworkers, service managers, treatment purchasers or 
government officials responsible for the effective delivery of treatment services. 
On this basis, it is reasonable to conclude that the National Drug Treatment 
Monitoring System, while imperfect, is a valuable resource to researchers 




6.2 INTEGRATION AND IMPLICATIONS OF FINDINGS 
6.2.1 UNSUCCESSFUL TREATMENT COMPLETION 
Before turning to those patients whose frequency of heroin use did not 
substantially reduce over the time spent enrolled in treatment, it is important to 
recognise the considerable proportion of patients who prematurely disengaged 
from OUD treatment. Within the NDTMS lexicon, ‘unsuccessful completions’ (a 
collective term for those patients who died, were imprisoned, had an 
unsuccessful transfer or dropped out from treatment) accounted for 72.2% of 
patients discharged within the first five years of treatment as reported in Study 1. 
6.2.1.1 FACTORS ASSOCIATED WITH UNSUCCESSFUL COMPLETIONS 
There have been several reviews of dropout over the past forty years (Baekeland 
and Lundwall, 1975; Craig, 1985; Stark, 1992; Brorson et al., 2013b). These 
reviews consistently report that younger people are more likely to drop out of 
treatment, which aligns with the findings from Study 1 and Study 2 that older 
people were more likely to successfully complete treatment. The literature on 
drop out also points to gender being an inconsistent factor. In Study 1, males 
were less likely to successfully complete treatment while in Study 2 this effect 
was no longer observed. 
Other important patient-level covariates in Study 1 included being homeless, from 
an area with higher deprivation, having a history of injecting, being referred to 
treatment from the criminal justice system, having a history of previous treatment 
and a longer heroin using career. These were all negative factors in recovery. 
Conversely being employed at the start of treatment was a positive factor. In 
Study 2, where patients had already been in treatment for a full five years and 
successful completion of treatment was measured in Year 6 and Year 7, being 
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employed at the start of treatment demonstrated an increased likelihood of 
eventual recovery. Consistent with Study 1, a history of injecting and a longer 
heroin using career were associated with a decreased likelihood of eventual 
recovery.  
It is interesting to note that unlike other large-scale studies on treatment 
completion (Arndt et al., 2013; Mennis and Stahler, 2016), the adjusted models 
reported in Study 1 and Study 2 did not find an association between patients from 
black and minority ethnicities (BME) and the likelihood of recovery. It is possible 
that this reflects a socio-cultural difference in the relationship of BME status and 
heroin use between the UK and North America in that BME status in the UK is 
associated with a lower likelihood of involvement with heroin. The model results 
did, however, find some general support for the construct of ‘physical capital’ 
(Cloud and Granfield, 2008), in that homelessness was a negative predictor of 
recovery in Study 1 while employment was a positive predictor in Study 1 and 
Study 2.  
Given the consistent positive finding surrounding employment, and in the context 
of relatively few patients being employed when first admitted to treatment 
(12.5%), it is encouraging that Public Health England are currently conducting an 
RCT to evaluate the impact of Individual Placement and Support (IPS; Drake et 
al., 2012) in securing gainful employment for patients currently accessing 
treatment. IPS has been shown to increase the employment rate in people with 
severe mental health illness (Marshall et al., 2014). In a recent pilot study of 
individuals receiving methadone treatment, 50% of those assigned to IPS gained 
a job within one year compared with 22% of the control group (Lones et al., 
2017). Public Health England will seek to establish whether or not these gains 
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hold true in a large multi-site study and whether or not other benefits, such as 
reduced criminal offending or hospital resource utilisation, can be detected. 
Also of note in Study 1 is the finding that increased time spent engaged in 
treatment is associated with an increased likelihood of successful completion. 
This aligns with other large-scale studies (Hubbard et al., 2003; Simpson and 
Sells, 1990) and is highly suggestive that OUD treatment should not be time-
limited (Advisory Council on the Misuse of Drugs, 2014).  
After controlling for patient-level and local area-level social deprivation predictors 
associated with outcome, the analysis indicated that local treatment systems with 
a high rate of unsuccessful completions are also those same systems with a 
much larger opiate using population. Likely to be interlinked with this higher 
prevalence rate, these systems also have a higher rate of offending and a higher 
rate of drug-related deaths. This finding suggests that there is some form of 
social network influence in operation.  
A person’s social network is made up of those individuals with whom, to a greater 
to lesser degree, the person is socially acquainted.  Social selection theory 
contends that a drug user would switch social networks in order to be able to 
spend more time with other drug users while social influence theory suggests that 
a person observing drug taking behaviour within their own network be would 
more likely to take drugs and so behave more like their friends (Dohrenwend et 
al., 1992).  
Social networks can influence the transition to injecting as well as the decision to 
share injecting equipment (De et al., 2007; Neaigus et al., 2006). In addition, 
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living with a heroin user is predictive of patients continuing to use illicit opioids 
(Gogineni et al., 2001; Lions et al., 2014). The availability of drugs is often cited 
as a reason for occasional use (Best et al., 1999), and heroin users who have 
achieved abstinence often cite moving away from a drug-using social network 
and towards a non-using network as a contributory factor to overcoming 
dependence (Best et al., 2008; Buchanan and Latkin, 2008).  
By utilising structural equation modelling, it is possible to simultaneously estimate 
the direction of influence over time – i.e. does drug using behaviour lead towards 
drug-using friends (social selection) or do drug-using friends lead towards drug 
using (social influence)? In a study of more than 1,100 adults with a lifetime 
history of heroin and/or cocaine use, Bohnert et al. (2009) found evidence for 
both forms of influence, but noted that most changes in drug use over time were 
due to changes in the make-up of the social network rather than changes in 
friends’ behaviour. Similar evidence for both social selection and social influence 
has been found in terms of alcohol consumption, with the researchers concluding 
that social selection effect appears to exert a stronger effect than social influence 
(Bullers et al., 2001). Changing the composition of social networks to include 
more non-users and fewer users is associated with a reduction in the risk of using 
opioids (Lions et al., 2014) and of engaging in risky injecting behaviour 
(Costenbader et al., 2006). Avoiding other drugs users limits the availability of the 
drug and also serves to reduce exposure to drug conditioned stimuli and social 
pressure to use (Havassy et al., 1995). 
Interventions such as Social Behaviour and Network Therapy (SBNT) are aimed 
at improving the social support for heroin addicts by involving close friends and 
family as part of the treatment process. A recent pilot study in England, however, 
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found that while drug workers could be trained to a satisfactory level in 
administering the intervention, it was difficult to engage patients in this form of 
psychosocial intervention. Only 31% of those assigned to a brief version of SBNT 
arm of the trial completed all four sessions (Day et al., 2018). Overall, no 
statistically significant difference in illicit heroin was found between SBNT and 
treatment as usual. 
6.2.1.2 MORTALITY 
6.2.1.2.1 DRUG-RELATED POISONING MORTALITY 
The smallest of the NDTMS unsuccessful completion categories – patients who 
died (n=684; 1.5% of discharges within five years) – is arguably the most 
important. It should be noted at the outset that large scale treatment provision 
has been estimated to prevent around 900 opioid-related poisonings in England 
each year (White et al., 2015) and it is likely that the number of deaths would 
have been higher in the absence of treatment. 
While the cause of mortality is not recorded on NDTMS, other research in 
England suggests that around 40% suffered a fatal drug poisoning (Pierce et al., 
2015a). Recent national guidelines emphasise the importance of providing take 
home naloxone to mitigate the risk of a fatal opioid overdose (Public Health 
England, 2017b). Naloxone is an opioid antagonist and works by rapidly 
removing other molecules, such as heroin, from the mu-opioid receptors in the 
brain, thereby reversing respiratory depression. Through this action, timely 
administration of naloxone can avert a potentially fatal overdose. Guidelines 
recommend that naloxone is issued not only to the patient themselves, but to any 
individual needing access to it. The latter include the carers, family members or 
friends who may be liable to witness an overdose and, possibly, individuals in a 
151 
 
hostel or other facility where drug users gather and may be at risk (Public Health 
England, 2017b).  
While monitoring the dispensing of naloxone within NDTMS is a welcome step 
forward, PHE does not as yet report the level of naloxone provision as part of 
their annual statistics (Public Health England, 2018a). Nonetheless, a recent PHE 
response to a freedom of information request reported that there were 15,279 
individuals in treatment in 2017/18 who received at least one dose of take-home 
naloxone. There were 141,189 individuals accessing treatment for OUD in 
2017/18, which means that around 11% of individuals at risk – and in contact with 
the treatment system – received this potentially lifesaving medication. In the 
context of continued growth in fatal drug-related poisonings in England, it is 
critically important that local treatment systems ensure that all patients engaging 
with the treatment system for OUD are provided with take-home naloxone and 
that they and any close friends or family are afforded training in its use. 
It must be noted, however, that simply providing naloxone will not eliminate all 
instances of fatal opioid poisoning. Because a person experiencing an overdose 
is not capable of administering the antidote themselves, there must be another 
person present to administer the drug. Between 1997 and 2000 in San Francisco, 
for example, it was reported that almost 70% of those suffering from a fatal 
heroin-related overdose were alone at the time (Davidson et al., 2003). More 
recently, an investigation into 115 coroners’ reports of drug-related deaths in 
England between 2014 and 2015 showed that 46 (40%) were alone at the time of 
death (Office for National Statistics, 2018b). Alongside the provision of naloxone, 
therefore, the harm reduction messaging of ‘never use alone’ needs to be 
promoted (Wojcicki, 2019). 
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6.2.1.2.2 OTHER CAUSE MORTALITY 
If one makes the assumption that 40% of the deaths recorded on NDTMS are 
fatal drug poisonings, 60% die from other causes. In a large scale linkage study 
between NDTMS and the national administrative database on mortality, Pierce et 
al (2015) reported on the standardised mortality rate (SMR) for different causes 
of mortality in opioid users. The SMR is a useful summary of mortality risk in that 
it relates the expected number of deaths to those observed for the given set of 
gender and age. An SMR over one indicates an increased risk. The highest other 
cause SMR in this study was for viral hepatitis at 57.2, indicating that opioid users 
are 57 times more at risk of dying from hepatitis than the general population. 
Testing for, and treating, viral hepatitis should be a priority, and aligns with the 
World Health Organization’s goal of eliminating viral hepatitis by 2030 (World 
Health Organization, 2017). 
Other leading causes of death highlighted by Pierce et al (2015) include diseases 
relating to injections via the skin and subcutaneous tissue (SMR 17.2), chronic 
lower respiratory diseases (SMR 12.8), infectious/parasitic diseases (SMR 12.6) 
and liver cancer (SMR 9.2). A more recent study based in South London also 
reported that around 60% of excess deaths were not due to drug-related causes 
(Lewer et al., 2019). Instead, digestive diseases, respiratory diseases and 
external causes were the most common of the ICD-10 chapters and the largest 
subcategories were for liver disease, chronic obstructive pulmonary disease and 
accidents. Given the scope of diseases putting opioid users at heightened risk of 
death, this is yet another reason for ensuring all heroin users have appropriate 
access to General Practitioners. Regular linkage studies between NDTMS and 
the General Mortality Register held by the Office for National Statistics would 
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enable national administrators and researchers to monitor progress in this 
important area. 
Another key area of concern is the prevalence of tobacco smoking in the OUD 
population. In Australia, almost 85% of patients attending methadone clinics 
reported tobacco smoking (Bowman et al., 2012), while in Mexico around 90% of 
people who inject drugs (PWID) reported tobacco smoking (Shin et al., 2013) and 
almost all (97%) of patients attending methadone or buprenorphine treatment in 
Italy reported tobacco smoking (Pajusco et al., 2012). In England, 68% of those 
starting treatment for OUD in 2017/18 reporting tobacco smoking, more than four 
times the rate of the general adult population (Public Health England, 2018a). 
This national figure masks geographic and setting variation: 97% of drug users in 
an in-patient setting in England reported tobacco smoking (Harris et al., 2000) 
and 88% of patients accessing a community treatment service in London 
reported tobacco smoking (Cookson et al., 2014).  
Tobacco smoking behaviour is important because persons with OUD face a 
higher risk death from at least 19 tobacco-related conditions, with these 
conditions accounting for around 40% of deaths in this group (Callaghan et al., 
2018). Yet the proportion of OUD smokers being referred for tobacco cessation 
services is minuscule. In England it is 3% (Public Health England, 2018a) and 
this is despite evidence that 40% of patients accessing drug treatment who 
smoke tobacco are motivated to quit immediately (Cookson et al., 2014). The 
frequency of tobacco smoking was added to the Treatment Outcomes Profile in 
2016, which was unfortunately outside the timeframe of the studies reported here 




The next largest category of unsuccessful discharges in Study 1 was for patients 
who were imprisoned (n=7,425; 16.0% of discharges). There is little community-
based treatment providers can do in this scenario. An individual arrested and 
subsequently imprisoned will almost certainly undergo at least one healthcare 
assessment at the point of imprisonment and may have already been drug-tested 
by the police. Treatment is available in prisons but often requires the individual to 
declare their problem and consent to treatment. In 206/17, 29,626 individuals 
were treated for OUD while in prison (Public Health England, 2017c). 
6.2.1.4 UNSUCCESSFUL TRANSFERS 
Almost one in five of all patients who exited the treatment system within the first 
five years did so with the discharge status of ‘unsuccessful transfer’ (n=8,385; 
18.1%). Within NDTMS, this discharge status entails an active referral by one 
specialist treatment service to another and yet the patient was not picked up by 
the receiving service within three weeks. There are a number of reasons why a 
patient may have failed to present at the subsequent treatment service. It may be 
that the next service does not submit records to NDTMS and therefore it is simply 
not possible to continue the administrative record of their ongoing treatment. 
Such a situation would emerge if a patient managed to secure funding to attend a 
private residential rehab or if a patient was transferred entirely to the care of a 
General Practitioner. It is also possible that, following the onward referral, a 
patient was imprisoned and this information was not available at the time the 
referring treatment service discharged the patient and submitted their NDTMS 
record. Possibly, the patient did not fully agree with the decision to move on to 
another service or was faced with practical barriers to engage with the next 
service, such as a greater travel distance or additional expense.  
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Whatever the reason, ‘unsuccessful transfers’ represent a substantial number of 
patients who are being failed by the referral pathway. As they are no longer 
receiving treatment, these patients are placed at a heightened risk of a fatal 
overdose. A recent examination of deaths following an ‘unsuccessful transfer’ in 
London revealed that such a discharge code results in excessive fatal overdose 
in the month immediately following the transfer, highlighting the crucial 
importance of ensuring such patients are picked up by the receiving treatment 
provider (Bogdanowicz et al., 2018). 
Treatment services need to work more closely together to ensure the referred 
patient is actually received by the next service and, if not, to actively seek to re-
engage the patient at the original treatment service. It is unfortunate that Public 
Health England do not provide information to the referring service about whether 
or not specific patients have successfully engaged with the service they have 
been referred to. While the referring service may make contact with the next 
service, this lack of data sharing on an ongoing and routine basis may 
unnecessarily be hampering the successful and safe flow of patients through the 
treatment system. 
6.2.1.5 DROPOUTS 
The largest category of ‘unsuccessful discharges’ is that of dropouts, consisting 
of 36% (n=16,613) of those exiting the treatment system in the first five years. 
While it is plausible that ‘drop outs’ are less motivated to continue with treatment 
compared with unsuccessful transfers, it is interesting to note that a higher 
proportion of those dropping out re-engage within six months than those with an 
unsuccessful transfer (35% cf. 28%). It is important that treatment services 
attempt to understand why they face such high levels of discharge and whether 
156 
 
or not the service being provided needs to change to better suit the needs of their 
patients.  
6.2.1.6 RE-ENGAGEMENT 
For patients who drop out of treatment, proactive and early re-engagement is 
recommended and services are encouraged to have effective re-engagement 
pathways in place (Clinical Guidelines on Drug Misuse and Dependence Update 
2017 Independent Expert Working Group, 2017). The results from Study 1 
indicate that re-engagement should also be a priority for at least 54% of the 
English treatment population (i.e. those who drop out or are unsuccessfully 
transferred). One potential framework designed for this purpose is Recovery 
Management Checkups (RMC; Scott and Dennis, 2003). RMC is a multi-
component processing that involves tracking (i.e. maintaining contact with 
patients), assessment (i.e. to determine whether patients have re-engaged in 
substance misuse), linkage (i.e. referrals to treatment), engagement (i.e. to 
ensure entry to treatment is as simple as possible) and retention (i.e. to 
encourage patients to stay in treatment for a defined amount of time). The RMC 
strategy up of ongoing assessment and early re-intervention appears to be 
effective. 
A randomised controlled trial of 446 adults over a four-year period involved 
randomising half the participants to receive quarterly assessments plus RMC and 
the other half to the control condition of quarterly assessments only (Dennis and 
Scott, 2012). Participants in the RMC condition were more likely to return to 
treatment (70% cf. 51%), were faster to return to treatment (13 cf. 45 months), 
experienced fewer quarters in need of treatment (7.6 cf. 8.9) and reported more 
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days abstinent from alcohol and other drugs (70 cf. 63 out of 90 days at the last 
observation). 
It would seem prudent for a similar RCT to be conducted in England in view of 
the large proportion of patients either dropping out of treatment (36%) or being 
unsuccessfully transferred for further treatment (18%). While these two 
premature discharge reasons may be a logical set of inclusion criteria, it would be 
unwise to ignore those patients who had successfully completed treatment (29% 
of those discharged) as almost a quarter of these (23.7%) were re-admitted of 
their own accord within six months of exit. The single most important metric 
adopted by Public Health England specifically defines recovery as a successful 
completion without re-admission within six months (Public Health England, 
2015a) and re-engaging patients who have successfully completed treatment 
shortly after their exit would reduce the proportion achieving this key metric. 
Nonetheless, it would be unethical to ignore a group of patients who may be in 
need of treatment simply because it did not fit neatly within a bureaucratic 
worldview, particularly as those with a planned discontinuation of OST appear to 
be at a heightened risk of fatal overdose following termination of treatment 
(Bogdanowicz et al., 2018). Funding an impartial third party to conduct a multi-
site RCT of RMC for all discharged patients would mitigate against the inherent 
conflict of interest. 
6.2.2 CONTINUED USE OF ILLICIT OPIOIDS 
Study 2 was an in-depth examination of self-reported heroin use frequency in 
those patients who had been continuously engaged in treatment for a five year 
period. A notable finding was that between Years 3 and 5 around 40% of the 
patients continued to report illicit opioid use, underscoring the challenges faced 
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by treatment providers to support patient engagement and recovery. It is 
important to remember that these patients were actively in receipt of OST and it 
is therefore appropriate to ask whether or not the treatment system is adequately 
addressing this level of continued use. One factor for improving this outcome is 
the prescribed medication dose, which can be easily changed. 
When the first network of treatment clinics opened in England in 1968, it quickly 
became clear that there was a tension between patients accessing the service 
and the doctors responsible for their treatment. Patients had a vested interest in 
securing a prescription dose that met their needs while doctors had a duty to 
ensure the prescription was not so generous as to allow diversion to the black 
market. A game of ‘cat and mouse’ emerged, with some doctors assuming that 
whatever level of dose was requested, it should be reduced by half (Stimson and 
Oppenheimer, 1982). Some patients, for their part, were reported to target newly 
appointed doctors with perhaps exaggerated claims of withdrawal symptoms, or 
lost prescriptions, in the hope of gaining an increased dose. The perception of 
treatment clinics as places in which to receive one’s desired drugs was not 
necessarily confined to patients – one doctor referred a patient to the regional 
‘drug abundance clinic’ in Manchester in the early 1980s (Strang, 1984). 
In many ways, this ‘game’ has continued since then. Current clinical guidelines 
place the therapeutic dose of methadone between 60-120mg per day (Clinical 
Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert 
Working Group, 2017) but national surveys have consistently found that more 
than half of patients receiving methadone or buprenorphine are being prescribed 
doses below the lower end of the recommended dose range (Strang et al., 2005, 
1996). The dose received by patients is important in terms of suppressing illicit 
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opioid use. Patients who receive a low dose (20mg per day) are unlikely to 
demonstrate any reductions in illicit use (Strain et al., 1993), and patients 
receiving a dose in the therapeutic range (80-100mg per day) are more likely to 
test negative for illicit opioids than those receiving a lower (40-50mg per day) 
dose (Strain et al., 1999). A Cochrane review of the methadone dose-response 
confirmed that patients prescribed 60-100mg per day are more likely to be 
retained in treatment and to reduce illicit heroin and cocaine while in treatment 
(Faggiano et al., 2003).  
Nonetheless, around a quarter of patients in England consider the dose they 
receive to be ‘poor or bad’ (Advisory Council on the Misuse of Drugs, 2015). 
Similarly, in the US, around a quarter of patients receive methadone doses too 
low to be effective (D’Aunno et al., 2014). The median dose of methadone 
prescribed by general practitioners in England increased between 1995 and 2005 
from 40mg to 50mg (Strang et al., 2007) indicating that, even after a decade of 
recommendations of the greater benefit from daily doses in the 60-120mg dose 
range, at least half of patients in receipt of methadone are receiving a suboptimal 
dose.  
Given the known importance of medication dose, it is unfortunate that NDTMS 
does not capture this information. NDTMS clearly needs to be enhanced to 
incorporate information on dose. The purpose of this is twofold. First, 
incorporation of dose would enable the estimation of whether or not, and to what 
degree, suboptimal dosing is associated with continued use of illicit heroin on top 
of that dose. When oral methadone is optimised (often considered to be ≥80mg), 
it can lead to improved outcomes even in those who may be considered 
persistent treatment non-responders (Strang et al., 2010). Second, it would 
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provide the data required to monitor the degree to which extreme methadone 
prescribing practices may be occurring. Given the relationship between extreme 
methadone dose and the risk of methadone-specific mortality (Gao et al., 2016; 
Pierce et al., 2018), it is important for national administrators, treatment 
commissioners, managers and keyworkers to be aware of the extent of such 
practice and take appropriate action where necessary. It is encouraging that, at 
the time of writing, PHE is in the process of consulting on the next iteration of 
NDTMS. It remains to be seen whether or not dose will be incorporated. 
6.2.3 SUSTAINED NON-RESPONSE 
Study 2 highlighted the importance of research analytical methods to delineate 
longitudinal heroin use trajectories. Of particular concern are the 15% of patients 
who demonstrate sustained non-response over significant periods of time. This 
group of patients showed a rapid reduction in illicit heroin use within the first six 
months of treatment, but continued to report illicit use on about half the available 
days until the end of the observation period. While continued use of illicit opioids 
on top of an opioid prescription is a recognised problem (Clinical Guidelines on 
Drug Misuse and Dependence Update 2017 Independent Expert Working Group, 
2017), it is important for clinicians to identify non-response or deterioration at an 
early stage and to optimise treatment where possible. This could include, for 
example, splitting the dose into smaller daily doses, increasing the dose, 
reintroducing supervised consumption or offering a change in prescribed 
medication.  
Study 2 found that psychosocial interventions, while being received by most but 
not all patients (92%), increased the likelihood of sustaining recovery and 
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underscored the importance of the adjunctive psychosocial component of 
treatment to enhance clinical benefit. 
Attention to alcohol and other drug use is also important. Study 3 revealed that 
almost a quarter of patients in the ‘continued high-level’ heroin use trajectory 
were also on the ‘continued high-level’ crack cocaine use trajectory. Looked at 
another way, of those in this particular crack cocaine trajectory, 67% came from 
the ‘continued high-level’ heroin group. What this demonstrates is that those 
individuals who can be considered non-responders in terms of their heroin use 
are also often the same individuals who can be considered non-responders in 
terms of their crack cocaine use. Treating an OUD patient who has an ongoing 
concurrent crack cocaine problem, or any poly-drug use for that matter, may add 
to the difficulty and challenge, but it should be considered a high priority given the 
disparate health needs they engender and the negative impact they represent for 
OUD outcomes. It may be appropriate to offer targeted psychosocial 
interventions for opioids (Marsden et al., 2017), alcohol (Nolan et al., 2016) or 
cocaine (Marsden et al., 2018b). 
It is important to note that, over the five-year observation period, any given 
patient may have seen up to three different treatment providing organisations – 
even while receiving treatment at the same location. This is because, in England, 
treatment commissioning has moved to being often re-commissioned on a three-
year cycle. A patient may start treatment with one organisation, which is 
decommissioned at the end of Year 1 when a new provider is awarded the 
contract. This provider may subsequently be decommissioned at the end of Year 
4 and so the patient is transferred to the care of yet another provider. A patient 
might be involved with more than three organisations, as was the case when 
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Lifeline (a provider organisation in England) initially secured many new contracts 
by offering low costs, subsequently became financially non-viable and collapsed. 
New arrangements for the patients under their care had to be urgently 
considered. This kind of systemic reorganisation may hinder the progress being 
made by patients as resources need to be redirected from clinical ‘front line’ work 
towards work required for tendering for new contracts (Day et al., 2018). 
It should also be noted that, from the late 2000s onwards, around the time when 
patients selected for inclusion in the three studies of this thesis began treatment, 
there was an apparent shift in the behaviour of third-sector organisations. As 
outlined by Kalk et al (2018), instead of collaborating with existent NHS services, 
the third sector began to successfully bid to take over those same services. This 
change, coupled with budget cuts, has led to a reduction in funding to addiction 
services of around 30-50% and may have led to a situation where services with 
less qualified or experience staff are awarded contracts (Drummond, 2017; Kalk 
et al., 2018). This has been criticised as a move to ‘survival of the cheapest’. It 
has been claimed, for example, that specialist addiction psychiatrists and nurses 
have been replaced, respectively, by sessional GPs and drug workers lacking 
specialist qualifications in order to drive costs down (Mohammadi, 2014). 
Apart from facing changes in organisational philosophies and treatment policies, 
a patient may also be faced with having to develop a therapeutic relationship with 
a new clinician. From a clinician’s perspective, aside from facing increased 
caseloads due to funding cuts – thereby managing the care of more patients with 
less time (The Guardian, 2017) – it is possible the information held on the 
patient’s treatment history is not transferred over, making it difficult if not 
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impossible for the clinician to readily understand the progress a patient has made 
(or not) to date.  
Commissioners should consider building into their contracts a requirement to 
ensure all patient-level data are properly transferred to a new treatment provider 
in those instances where a different organisation assumes the care of patients 
under a new contract. Any software utilised to submit data to NDTMS should 
have the in-built capability to enable for clinicians to track the long-term pattern of 
behaviour for any of the patients they are responsible for. Furthermore, national 
drug treatment administrators should make available performance monitoring 
reports focused on the long-term use of illicit opioids and adjunctive substances 
for managers and commissioners of services. This should be relatively simple to 
implement and could aid local planning and resource allocation and potentially 
improve outcomes in this important domain. 
6.2.4 DETERIORATING HEROIN USE 
Also requiring further consideration is the group of approximately 20% of patients 
who, following initial improvements in their illicit heroin use, exhibited a tendency 
to deteriorate after three years of treatment. Heroin addiction is a complex 
disorder and it is unsurprising that a proportion of patients in treatment take 
retrograde steps on their journey towards recovery. The challenge for 
professionals involved in the treatment of the disorder is to be responsive to such 
changes. Measurement-based care (MBC) is an evidence-based approach in 
which symptoms, such as self-reported illicit heroin use, are used to inform 
clinical practice. Various tools have been suggested for delivering MBC, including 
the Treatment Outcomes Profile (Marsden et al., 2008), the Addiction Dimensions 
for Assessment and Personalised Treatment (Marsden et al., 2014), the Brief 
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Addiction Monitor (Cacciola et al., 2013; Nelson et al., 2014) and the DSM-5 
assessment for OUD (Marsden et al., 2019a). Whatever tool is deemed 
appropriate in a given setting, it is important that clinicians are responsive to 
changes reported by the patient. For example, by engaging with those patients 
whose illicit heroin use is increasing during treatment, it would be possible to offer 
changes to the OST drug or dose. Further, adoption of MBC can benefit the 
professional development of the clinician and lead to quality improvements in the 
treatment provider (Fortney et al., 2017). 
6.2.5 SUSTAINED POSITIVE RESPONSE 
Three other trajectory groups emerged from Study 2 and merit further discussion: 
(1) the ‘continued low-level’ group initiated OST while reporting close to zero 
days of illicit heroin use in the 28-days prior to admission and continued to 
follow this pattern of heroin use throughout the five years they spent in OST; 
 
(2) the ‘rapid decreasing’ group had substantial reductions within the first six-
month period, with their monthly heroin use falling from 25 days to 5 days, 
continued to improve and maintained an abstinent state between Year 2 and 
Year 5; 
 
(3) the ‘gradual decreasing’ group took longer to achieve abstinence, getting 
there at the Year 5 mark.  
These results indicate that abstaining from illicit heroin can be a lengthy process 
but it is achievable while engaged with the treatment system. While it should be 
noted that these results do not prove that treatment caused these changes in 
patient behaviour (or prevented relapse in the case of the ‘continued low-level’ 
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group), they shed light on the heterogenic development of OUD and pose further 
questions of the treatment system. 
To varying extent, these three groups appear to no longer be in treatment. In the 
case of the ‘continued low-level’ group, it is appropriate to ask whether OST is 
suitable given their minimal use of illicit opioids throughout the five years in 
treatment. The ‘rapid decreasing’ group appears to have achieved abstinence by 
Year 2 and is maintained in treatment for another three years. The ‘gradual 
decreasing’ group achieve abstinence by Year 5.  
At what point should clinical discussions move away from maintaining a patient 
on an opioid substitution treatment? This is a difficult question and will fall to the 
specific clinician, alongside their multidisciplinary group, and the specific patient 
to decide when this may be appropriate. Clinical guidelines in England point to 
the importance that the patient fully understands and is committed to the process 
of OST detoxification and is cognisant of the risks of relapse (Clinical Guidelines 
on Drug Misuse and Dependence Update 2017 Independent Expert Working 
Group, 2017). When methadone dose is decreased, for example, it can induce 
craving and increase the risk of relapse (Greenwald, 2002). The risk of relapse is 
not simply about increased illicit heroin use. Alongside such an increase in use 
come the heightened risks of overdose, which can be fatal, and the potential to 
contract blood borne viruses. The detoxification process should therefore be 
slow, lasting up to around 12 weeks in an outpatient setting, and should be 
monitored closely. Signs that the detoxification is not going successfully, such as 
increased illicit heroin use, should result in the patient being offered a seamless 
reintegration into the OST or other treatment (Clinical Guidelines on Drug Misuse 
and Dependence Update 2017 Independent Expert Working Group, 2017). 
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It has been argued addiction treatment should be conceptualised within a chronic 
disease management framework (McLellan et al., 2005). Treatments for asthma, 
diabetes or hypertension, for example, are not time-limited and continued 
engagement to monitor progress and alter treatment if appropriate is a positive 
patient-centred approach. While patients are engaged in treatment for OUD they 
are maintained within a protective environment. For example, for each year a 
patient is receiving OST their risk of mortality falls by 13% and this is despite the 
receipt of OST leading to a longer duration of drug use (Kimber et al., 2010). 
Being maintained in treatment is also associated with substantial reductions in 
offending behaviour (Ministry of Justice and Public Health England, 2017). It is 
also important to recall that Study 1 demonstrated that patients who had been 
engaged in treatment for two or more years had a much greater likelihood of 
successfully completing treatment. What is not presented from the studies in this 
thesis, but would be possible to elucidate with further research, is the extent to 
which other outcomes such as employment, housing and health have also 
changed when patients are maintained in treatment. 
6.3 STRENGTHS OF THE STUDIES 
The main strength across all three studies is the national, large scale and long-
term follow-up of all individuals entering treatment for OUD. The utilisation of 
England’s national administrative database to monitor relapse within six-months 
of discharge allowed for an objective summative measure of recovery to be used 
throughout these studies. Given the rate of short-term re-admission (even for 
those patients who have been discharged as having overcome their opioid 
dependence) incorporating this component into the outcome measure allows for 
a more accurate assessment of recovery. Conversely, it also enables the 
objective capture of whether or not, and how many times, a person has 
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previously engaged in treatment, which is an important negative predictor of 
treatment outcomes (Marsden et al., 2012b; Siguel and Spillane, 1978). Study 2 
and Study 3 further refined the primary outcome measure by linking the records 
of those patients who had successfully completed treatment with the national 
register of fatal drug poisonings and the prison-based treatment system. This 
procedure guarded against the possibility that patients did not re-enter the 
treatment system simply because they were unable to do so. NDTMS, in this 
regard at least, has the advantage over other comprehensive administrative 
datasets (Alterman et al., 2001; Sahker et al., 2015; Stahler et al., 2016). 
Study 2 and Study 3 made extensive use of the Treatment Outcomes Profile 
(Marsden et al., 2008) to measure change in heroin and concurrent substance 
use throughout patients’ long-term enrolment in treatment. This ‘concurrent 
recovery monitoring’ (McLellan et al., 2005) provides a potent platform for policy 
makers and researchers to efficiently evaluate the effectiveness of community-
based treatment under routine conditions. Previous research using the TOP has 
focused only on six-month outcomes (Marsden et al., 2012b, 2011, 2009), but 
these two studies demonstrated that deeper insights into the course of OUD can 
be gained through the appropriate application of modern sophisticated statistical 
methodologies. 
6.4 LIMITATIONS OF THE STUDIES 
Several limitations are need to be acknowledged. Study 1, in which a latent class 
analysis indicated four sub-types of heroin user, was based on the information 
submitted to NDTMS at the start of treatment in 2008/09. It is possible, as 
different drug use patterns come to the fore (such as the concurrent use of novel 
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psychoactive substances or gabapentinoids) that a different class structure could 
emerge if this approach was applied to individuals currently starting treatment.  
NDTMS is a ‘core dataset’ of important variables used at many different levels, 
from treatment service managers to treatment purchasers to government officials. 
While all available covariates in NDTMS were screened for inclusion in the 
various models throughout Studies 1-3, other variables could further influence the 
likelihood of sustaining recovery, such as recovery strengths (Gossop et al., 
2002d), treatment motivation (Simpson and Joe, 1993) and engagement 
(Simpson et al., 1995). It is also noteworthy that while certain adverse childhood 
experiences such as sexual exploitation, domestic abuse or intentional self-harm 
are recorded on NDTMS for those accessing young people’s specialist addiction 
services, these items are not available within the adult core dataset. Capturing 
these experiences is important given their strong correlation with drug and 
alcohol dependence (Fuller-Thomson et al., 2016; Giordano et al., 2014) and, 
together, may represent an important confounding variable. One recent study, for 
example, estimated that almost 60% of heroin/crack prevalence could be 
attributed to adverse childhood experiences (Bellis et al., 2014), and childhood 
trauma is associated with prolonged use of benzodiazepines, which in turn are a 
risk factor for fatal and non-fatal overdose (Darke et al., 1996; Olfson et al., 2018; 
Vogel et al., 2011). 
Capturing multimorbidity on NDTMS has also been a long-standing issue. The 
item ‘dual diagnosis’, which is defined as the presence of a diagnosed mental 
health disorder alongside the patient’s substance use disorder has traditionally 
been poorly completed and could not be utilised in any other national cohort 
study (Eastwood et al., 2018a; Marsden et al., 2012b, 2011, 2009; Peacock et 
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al., 2018; Willey et al., 2016b). It has recently been replaced with a self-reported 
‘mental health treatment need’ item and it has yet to be seen if this will be 
completed with greater rigour. 
It is also important to note that while Study 1 reported that are 13% of patients 
presented to treatment reporting an adjunctive alcohol addiction problems and 
Study 3 revealed that around 40% of patients reported alcohol consumption on 
each of the 11 assessment points, NDTMS does not capture any metric 
pertaining to alcohol-related impairment. This is important as it has been 
estimated that 50-80% of individuals with alcohol use disorder will experience 
mild to severe neurocognitive impairment and such impairment might limit the 
likelihood of positive treatment outcomes (Bates et al., 2002). 
Also applicable to each of the studies is the possibility that patients underwent 
other forms of interventions that could have had an impact on the primary 
outcome measure, such as attending Alcoholics Anonymous or privately-funded 
residential treatment. These are not, however, captured by NDTMS and so it is 
not possible to assess the potential impact. Nonetheless, it is important to 
recognise that the E-value parameter estimated in Study 2 suggested that such 
variables would need to have an adjusted odds ratio of almost three to mitigate 
the association between trajectory membership and outcome. 
Of particular relevance to Study 2 and Study 3 is that NDTMS does not actually 
capture the quantity of heroin and other drugs being used, only the frequency of 
use. It is possible that analysis of composite frequency by quantity metrics would 
yield different substance use trajectories. Further, it may be that the ‘continued 
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high-level’ groups do in fact demonstrate improvements in terms of the quantity 
being consumed. 
6.5 REFLECTIONS ON LATENT CLASS CATEGORISATION 
In the three studies presented in this thesis, I have relied on a combination of 
variable-centred and person-centred approaches to evaluate treatment 
effectiveness for OUD. The person-centred approaches were Latent Class 
Analysis (LCA) and Latent Class Growth Analysis (LCGA), both of which fall 
under the rubric of structural equation modelling. I used LCA to estimate sub-
populations of OUD patients based on the concurrent substance use disorders 
(SUD) with which they presented to treatment. Two-thirds (67%) of patients had 
at least one concurrent SUD at treatment admission and LCA was applied to 
identify four hidden sub-populations that described the associations among crack 
cocaine, cannabis, alcohol, other illicit opioids, benzodiazepines and other 
stimulants. LCGA, on the other hand, was applied to the repeated measures of 
heroin and other drug use over time to reveal distinct groups based on common 
trajectories of change. As statistical tools, LCA and LCGA reduced the complexity 
of the potential combinations of either concurrent SUD (LCA) or change over time 
(LCGA) and demonstrated that some sub-populations have a differential 
likelihood of achieving successful completion of treatment. 
The Guidelines for Reporting on Latent Trajectory Studies (GRoLTS; van de 
Schoot et al., 2017) are relevant here. Within these guidelines are 21 areas 
recommended for inclusion in studies seeking to identify trajectory groups from 
longitudinal data. I have self-assessed my first LCGA study, Study 2, and believe 
it scored at least 13 out of the maximum of 21. Of the 38 studies reviewed by van 
de Schoot et al (2017), only 2 studies scored at this level or above, indicating that 
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Study 2 was relatively well described. A well-described study does not, however, 
mitigate the risk of reification as outlined by Sher et al (2011). In brief, Sher and 
colleagues identified that many studies assessing latent trajectories within the 
alcohol field tended to report four recurring types including a consistently “low” 
group, an “increase” group, a “decrease group” and a consistently “high” group.  
These typologies emerged with sufficient regularity as to raise suspicions on the 
method. These are effectively the heroin trajectory groups identified in Study 2 
except there were two ‘decrease’ groups and the ‘increase’ group had initially 
shown some reduction in heroin use frequency. Sher et al acknowledged that the 
‘statistical abstractions’ that generate trajectory groups may be useful under 
some circumstances but there is a risk that they do not, in themselves, reveal 
fundamental developmental trajectories.  
On reflection, the utility of the approach may lie not in the patterns of change that 
are revealed per se, but in the kind of clinical questions that can be asked of the 
addiction treatment field as a result of identifying these patterns. Some patients 
are less responsive to change and Study 3 demonstrated that heroin 
unresponsiveness overlapped with crack cocaine unresponsiveness. Highlighting 
the long-term need for treatment strategies that include a focus on concurrent 
crack cocaine use is clinically appropriate. It is also clinically appropriate to 
ensure that all patients accessing treatment for OUD are in receipt of a dose 
known to be effective in suppressing illicit heroin use. 
6.6 LIMITATIONS OF NDTMS 
Throughout the process of designing, conducting and publishing the three studies 
presented in this thesis, several problematic areas pertaining to NDTMS came to 
light that could potentially have impacted on successful publication: 
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(1) diagnostic information; 
(2) identifiers; 
(3) gaming the system; 
(4) benzodiazepines; 
(5) national scope. 
6.6.1 DIAGNOSTIC INFORMATION 
When patients are registered on NDTMS, they are asked to name up to three 
‘problematic substances’ that they are seeking treatment for. At no point does 
NDTMS capture whether or not these individuals are presenting with dependence 
on a particular substance or the severity of that dependence (although it should 
be noted that the Severity of Alcohol Dependence Questionnaire (SADQ; 
Stockwell et al (1983, 1979) was incorporated in April 2017). This point was 
picked up in the peer review process during the submission of the paper reporting 
Study 2, namely how are OUD diagnoses obtained and standardised across local 
treatment systems? I argued that such diagnoses are obtained during the initial 
triage assessment and subsequent full clinical assessments, which sit outside the 
core dataset NDTMS, and can include the Structured Clinical Interview for DSM 
or based on ICD-10 criteria. While this was accepted by Drug and Alcohol 
Dependence, it is clearly a weakness in a national administrative dataset 
designed to monitor the effectiveness of specialist drug and alcohol treatment. 
Using DSM nomenclature, is the dependence mild, moderate or severe? In ICD-
10 terminology, is the patient being treatment for harmful use or dependence? 
There are two immediate issues arising from the diagnostic information not being 
centrally collected. These relate to the status of patients at the start of treatment 
and at the end of treatment. At the end of treatment, the use of a severity of 
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dependence tool would enhance the ability of NDTMS to verify, at least internally, 
that the ‘successful completion’ accurately reflects remission from OUD. As it 
stands, it is assumed that this discharge code denotes that a patient is in 
remission from OUD, is abstinent from all opioids and crack cocaine, has 
completed all opioid pharmacotherapy and psychosocial interventions, has met 
all care plan goals and there is a mutual agreement to exit treatment. Such 
assumptions are, at best, questionable. The DSM approach would allow for an 
assessment of ‘early’ or ‘stable’ remission, while the ICD approach would at least 
be able to indicate the absence of harmful use or dependence. That said, 
incorporation of either a DSM or ICD assessment at the point a patient is exiting 
the treatment system would only demonstrate that NDTMS reporting is internally 
consistent and would not necessarily confirm that dependence has been 
overcome (see Section 6.6.3). It would be prudent for national administrators to 
validate the reporting accuracy of this discharge code by, for example, drawing a 
random sample of patients successfully completing treatment for urine screening.  
For patients entering the treatment system, on the other hand, the routine 
availability and reporting of severity of dependence could inform the treatment 
plan and early discussions with patients as to what level of methadone, for 
example, they might be titrated on to. More importantly, however, Study 2 
highlighted that around 15% of patients admitted to treatment for OUD reported 
using no illicit opioids in the 28-day period immediately prior to admission. This 
was also raised by the peer review process and I argued successfully that many 
national studies of OUD patients report varying proportions of patients who do not 
use illicit opioids prior to admission. Reasons for this may vary. It is reasonable to 
presume that one reason was to manage patients entering community-based 
treatment following release from prison. Another might be that a pregnant patient 
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felt she might restart using illicit opioids without a small dose of methadone. 
Neither of these account, however, for the entire 15%. It is important to 
remember that these individuals were all receiving OST and there are 
safeguarding issues that cannot be ignored. The routine use of a severity of 
dependence tool alongside the Treatment Outcomes Profile could potentially 
highlight instances where OST is not appropriate. It could also serve as an 
important covariate in models assessing treatment effectiveness. 
6.6.2 IDENTIFIERS 
There is one important issue which has received little attention. An individual 
patient in NDTMS is effectively a construct. An ‘individual’ is created from the set 
of first name initial, surname initial, gender, date of birth and, crucially, local 
authority of residence. This particular situation is a throwback to the early 
development of treatment databases in the 1980s (Strang et al., 1991). It was 
considered important at the time, in order to increase compliance with reporting 
to the database, that patient anonymity was preserved and the system evolved 
only accepting limited identifiers to ensure individuals were not double counted. 
Should any of these identifiers change, however, a new individual is constructed 
on the system.  
As mentioned in the preceding section, there is a sizeable minority of individuals 
who appear to be initiating OST even though they have reported no heroin use in 
the period immediately prior to admission. It is possible, indeed likely, that many 
of these were not actually new to treatment but instead it was a result of the way 
in which NDTMS constructs individuals. Where individuals start and finish 
treatment at the same treatment provider, there is no problem. It is a problem, 
however, where individuals switch the local authority in which they live frequently, 
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such as in London where the boundaries are much closer together than, say, the 
northern parts of England. As the local authority of residence is changed, a new 
individual is constructed within NDTMS. Other difficulties arise where patients 
change their names after getting married (or divorced), or a date of birth is 
corrected, or a transgender change is recorded on NDTMS or name variations 
(e.g. Tony and Anthony) are used at different treatment services. The records 
received centrally lack the person-specific information required to remedy this. 
What would remedy this would be the inclusion of an administrative identifier that 
is truly unique to the individual, most obviously the person’s National Health 
Service Number. Such inclusion has the potential, when embedded, to make 
tracking people across NDMTS easier and more accurate, and it would also 
enable seamless linkage with other large-scale databases such as the Hospital 
Episode Statistics. Other systems, such as the Scottish Drug Misuse Database 
contain a Community Health Index that allows for trusted linkage between, for 
example, methadone prescriptions and drug-related deaths (Gao et al., 2016). 
The Scottish model does not have an integrated data warehouse per se, but the 
data controllers for each of the datasets – including maternity, GP consultations, 
hospital admissions, clinical imaging, substance misuse, cancer registrations and 
so on – actively assess any given research proposal and provide a de-identified 
dataset to approved researchers when there are clear public benefits of doing so 
(Pavis and Morris, 2015). Incorporation of such an identifier is therefore 
technically possible. It only requires the strategic directive to do so, thereby 
ensuring appropriate information governance and oversight procedures are in 
place to protect the rights of patients reporting to multiple systems. 
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6.6.3 GAMING THE SYSTEM 
Gaming is a term that refers to the misreporting of administrative data to achieve 
a desired aim and is not unheard of in substance misuse treatment. Introducing 
outcome-based contracting arrangements such as performance-based 
contracting (PBC) or payment-by-results (PbR), for example, may provide a 
perverse incentive to engage in such a practice. After the introduction of PBC in 
Maine, for example, it was shown that clinicians had a tendency to increase the 
reported level of alcohol use at the start of treatment and decrease the reported 
level of alcohol use at discharge, thereby boosting the apparent effectiveness of 
the treatment intervention (Lu and Ma, 2006).  
In England, a PbR programme was piloted in eight local authorities between 
2012 and 2014. Recent analysis of that programme demonstrated that in-
treatment outcomes such as abstinence from illicit drug and alcohol improved 
markedly, as too did injecting behaviour (Jones et al., 2018). These are precisely 
the kinds of outcomes that could be easily gamed should there be a desire and 
an incentive to do so. In contrast, however, the evaluation incorporated an 
objective outcome similar to that used in the three studies presented in this thesis 
(i.e. successful completion and non-re-presentation over 12-months) and showed 
that pilot areas actually deteriorated relative to non-pilot areas. These 
contradictory findings are difficult to reconcile, but a cynical reading might 
suggest the subjective in-treatment benefits (i.e. gains in self-reported alcohol 
and drug use and injecting behaviour) may have been inflated. 
Treatment commissioners partly rely on statistics generated from NDTMS during 
their evaluation of contract bids. Falsifying reports to NDTMS is tantamount to 
fraud. That said, it is still possible for misguided services to ‘game’ their reporting 
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to NDTMS. An anonymous clinician, writing in The Guardian newspaper, 
highlighted one such area. As aggregated data on patients dropping out of 
treatment are reported back to managers and commissioners of services (and 
this counts negatively towards the provider), the clinician reported that one way to 
limit the damage is to simply “…not start the most chaotic people in treatment in 
the first place. People aren’t refused treatment but they are asked to jump 
through hoops before structured treatment is commenced” (The Guardian, 2017).  
While not readily testable in NDTMS, perhaps – if these pre-treatment ‘hoops’ 
were systemic – this is one of the reasons why the number of patients accessing 
treatment for OUD is in decline and why waiting times to access treatment in 
England appear to be extremely good. Individuals presented to treatment with 
opiate addiction problems have an average waiting time of 1.7 days to start 
treatment and 98% commence treatment within three weeks (Public Health 
England, 2018a). It would seem reasonable to conclude that rapid access to 
treatment is readily available, but is this an accurate assessment? 
It is important that national administrators of NDTMS invest in auditing local 
services. A greater understanding of local processes and policies may provide 
insight into the reason(s) for falling numbers of OUD patients accessing 
treatment, such as the pre-treatment ‘hoops’ mentioned above. For other in-
treatment outcomes, such as heroin abstinence, a risk-adjustment model would 
highlight which services or local authorities are performing above or below the 
expected level for their given caseloads and would provide fertile ground for 
conducting audits. In terms of waiting times, it should be possible to draw a 
random sample of treatment services with particularly low waiting times and 
interview recent admissions to those services to gain a greater understanding of 
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what a ‘wait’ means to patients accessing the system and whether or not this is 
represented by NDTMS figures. 
6.6.4 BENZODIAZEPINES 
While the misuse of benzodiazepines can be recorded at the start of treatment as 
one of the three substances a patient declares as problematic and in need of 
treatment (see Section 6.6.1), it is unfortunate that the illicit use of this class of 
drug is not routinely collected during a patient’s time in treatment. The reason it is 
not included on the Treatment Outcomes Profile is that the test-retest reliability 
was shown to be poor in the psychometric evaluation of the tool (Marsden et al., 
2008). Specifically, while the test-retest of benzodiazepine prevalence was 
satisfactory (kappa ≥0.61), the inter-rater intraclass coefficient did not reach the 
specified threshold for ‘excellent’ (ICC ≥0.75). Similar findings were reported in 
Chile (Castillo-Carniglia et al., 2015) and Australia (Ryan et al., 2014b). The 
Chilean Government, however, decided the clinical importance of including illicit 
benzodiazepines over-ruled the statistical criteria, while Australia reintroduced 
the item and included both prescribed and illicit benzodiazepines. In the latter 
example, this was due apparently to the difficulty in differentiating between the 
misuse of prescribed benzodiazepines and those illicitly obtained and was in the 
context of high prevalence of benzodiazepine use in the country. 
In response to a query by the peer reviewers of Study 3, concerning the meaning 
of the ‘unspecified drug’ utilised in the study, it was argued successfully that this 
substance was likely to be illicit benzodiazepines because in England illicit 
benzodiazepine use affected 10% of all patients in treatment for OUD in 2017/18 
(Public Health England, 2018a). This is a substantially higher proportion than 
other substances that might be recorded under the ‘unspecified substance’ on 
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the TOP such as anti-depressants, hallucinogens, volatile solvents, or major 
tranquillisers (each <1%).  
The use of benzodiazepines alongside heroin appears to play a central role in 
both fatal and non-fatal overdose (Cousins et al., 2011; Darke et al., 1996; Darke 
and Zador, 1996; Farrell and Marsden, 2008; Olfson et al., 2018; Yamamoto et 
al., 2019). The concurrent use of benzodiazepines can affect the metabolism of 
methadone and is also associated with deteriorated hepatic function in those with 
HCV (Clinical Guidelines on Drug Misuse and Dependence Update 2017 
Independent Expert Working Group, 2017). It is critical, in light of these risks – 
particularly at a time of increasing drug-related deaths in Great Britain (National 
Records of Scotland, 2019; Office for National Statistics, 2019) – that drug 
workers, commissioners and national administrators to have accurate information 
on the use of illicit benzodiazepines. It would seem prudent for this class of drug 
to be incorporated into the standard TOP assessment. 
6.6.5 NATIONAL SCOPE 
NDTMS collates information on all individuals accessing publically funded 
specialist alcohol and drug addiction treatment services. At least, it is intended to. 
The number of individuals accessing treatment for OUD has been falling in recent 
years, at a time when the estimates of the OUD population has remained fairly 
stable (Hay et al., 2019; Public Health England, 2018a). While it is possible that 
the reduction in number is solely the result of an overall reduction in funding for 
treatment services (Drummond, 2017; Kalk et al., 2018) or that patients are 
declining treatment when faced with pre-treatment hurdles, it is also possible that 
individuals are accessing help from outside the current national treatment 
system. Privately-funded residential treatment facilities, for example, are 
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available for those who can afford them. Given the cost of such facilities, it is 
unlikely to account for a large number of patients with OUD. Of more practical 
concern is the potential for GP services, commissioned outside the local authority 
remit for drug and alcohol treatment, to treat patients with OUD. The concern lies 
not so much in whether or not patients are receiving adequate medication to help 
overcome their illicit use of heroin, but whether all other ancillary interventions are 
being made available, such as psychosocial interventions.  
In my position at PHE I have the opportunity to interview commissioners about 
the NDTMS data collected in their area. In one such recent meeting (March 
2019), I was informed of one particular GP practice that may be seeing up to 200 
OUD patients and that these are not reported to NDTMS. It is difficult for national 
administrators to know how widespread such an issue may be, or how they can 
encourage NDTMS reporting in the absence of any financial incentive to do so.  
It is possible, however, to examine GP prescribing data in England as these are 
regularly published by NHS Digital. Using the December 2018 data, for example, 
one can see that 139 GP practices in England (1.5% of the 9,473 reporting in that 
month) issued more than 100 prescriptions for methadone and the mean amount 
issued per prescription was more than 600mg (NHS Digital, 2019). It is of course 
feasible that some of these practices were issuing methadone for chronic pain 
management purposes, but it is likely that many were issued for treating OUD. In 
total, these 139 practices issued 96,596 prescriptions for a total of 58,219,599mg 
methadone in December 2018. If one assumes the intention was to provide 60mg 
or 120mg per person per day, then it is possible that 15650-31,300 individuals 
were being treated for OUD by General Practitioners. After removing practices 
that are clearly operating in conjunction with specialist addiction services (i.e. 
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‘shared care’), there remained 29 practices that may be operating outside of 
NDTMS reporting. These 29 practices issued 2,788 prescriptions for a total of 
1,805,071mg methadone, suggesting that 485-970 patients in December 2018 
were being treated for OUD outside the national reporting system. A more 
detailed examination of these data is required and such practices should be 
encouraged to submit to NDTMS. 
6.7 FUTURE RESEARCH 
The cohort of heroin addicts who have been in opioid substitution treatment 
continuously over a five-year period present a unique and valuable opportunity 
for future research. While some effort was made to examine the relationship 
between longitudinal heroin use and the use of alcohol and other drugs, a 
number of important research questions remain.  
Evidence suggests that unemployment, homelessness, poor physical and 
psychological health and drug use are mutually reinforcing in their damaging 
effect. In a recent review of unemployment and substance use, Henkel (2011) 
noted that unemployment is a risk factor in the development of a substance use 
disorder and that drug use increases the likelihood of unemployment and 
decreases the likelihood of finding or keeping a job. Worklessness has also been 
related to health inequalities (Bambra & Popham, 2010; Bambra, 2011) and early 
unemployment has been shown to contribute to later adult health problems 
(Hammarstrom and Janlert, 2002). Transitioning away from paid employment can 
have a deleterious effect on psychological well-being while gaining a job has 
been shown to reduce psychological distress (Thomas et al., 2005). Being 
employed is associated with a decreased mortality risk in a population of HIV-
positive drug users (Richardson et al., 2014).  
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Taken together, the complex interweaving of personal, social and economic 
problems over the life-course may contribute to the chronic course of OUD 
(Eastwood et al., 2018b; Grella and Lovinger, 2011; Hser et al., 2007). One 
potential way to disentangle these relationships is through the use of cross-
lagged panel models. These models are relevant when estimating the 
relationship between two or more co-occurring phenomena that are repeatedly 
measured over time. They are particularly useful in establishing the direction of 
association (Selig and Little, 2012). More specifically, the cross-lagged panel 
model enables the researcher to simultaneously assess the stability of a given 
phenomenon while also estimating the time-ordered effect of each phenomena 
on the others, controlling for prior levels (Kim et al., 2018). 
In the context of the cohort of heroin addicts continuously enrolled in OST over a 
five-year period, the repeated assessment of patients using the Treatment 
Outcomes Profile is suited to this approach. Within a structural equation 
modelling framework, a latent ‘drug use’ variable at each time point can be 
measured based on the responses given to the seven available substance use 
items. Similarly, a latent ‘recovery capital’ variable can represent the responses 
to employment and housing problems at each assessment and a latent ‘health’ 
variable can represent the physical health, psychological health and quality of life 
items. These three latent variables can then be used for the cross-lagged 
modelling and enabled the exploration of 




(2) whether or not poorer recovery capital leads to worsening drug use and 
health; 
(3) whether or not higher levels of health leads to improvements in drug use and 
recovery capital; 
(4) whether or not bidirectional effects exist between two or more of these 
variables. 
6.8 FINAL CONCLUSIONS 
The studies presented in this thesis investigated the long-term treatment 
response in a national cohort of heroin addicts in England. Sub-populations were 
identified cross-sectionally at treatment admission based on concurrent 
substance use disorders and longitudinally based on the pattern of substance-
specific responses over five years of treatment. Study 1 demonstrated that 
spending at least two-years in treatment substantially increased the likelihood of 
recovering from heroin addiction problems. Study 2 demonstrated that, for some, 
achieving abstinence can take several years and that individuals on trajectories 
tending towards abstinence eventually overcome their addiction. Study 3 
demonstrated that those heroin addicts who make the least improvement in terms 
of continued heroin use are also those individuals for whom crack cocaine poses 
a continued challenge. Taken together, these studies highlight the importance of 
appropriate application of sophisticated statistical techniques in discerning 
obstacles faced by the treatment system and the opportunity this represents to 
identify potential solutions to overcoming those barriers. Although not without its 
limitations, NDTMS is an important resource for all stakeholders involved in the 
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A B S T R A C T
Background: This the first 5-year effectiveness study of publicly funded treatment for opioid use disorder (OUD)
in England.
Methods: All adults initiating treatment in 2008/09 in all 149 local treatment systems reporting to the National
Drug Treatment Monitoring System (n = 54,347). Admission polydrug use sub-populations were identified by
Latent Class Analysis. The treatment outcome measure was ‘successful completion and no re-presentation within
six months’ (SCNR) analysed by multilevel, multivariable logistic regression and funnel plots to contrast outcome
by treatment system.
Results: SCNR was achieved by 21.9%. Heroin and crack cocaine users were significantly less likely to achieve
this outcome than patients who used heroin only (adjusted odds ratio [AOR] 0.90; 95% confidence interval [CI]
0.85–0.95). Older patients (AOR 1.09; CI 1.07–1.11), those employed (AOR 1.27; CI 1.18–1.37) and those
enrolled for longer treatment were more likely to achieve the outcome measure. After risk adjustment, the local
treatment systems that achieved substantially better outcome performance (14/149) had a lower rate of opiate
prevalence in the local population at time of study initiation (incidence rate difference [IRD] 4.1; CI 4.0–4.2),
fewer criminal offences per thousand (IRD 28.5; CI 28.1–28.8) and lower drug-related deaths per million (IRD
5.9; CI 5.9–5.9).
Conclusions: In an English national study, one fifth of patients successful completed treatment for OUD and did
not present for further treatment within six months. Longer time in treatment increases the probability of
achieving and maintaining clinical benefit from treatment. After risk-adjustment, an important minority of
treatment systems achieve substantially better outcome performance.
1. Introduction
Heroin and non-medical opioids are associated with a substantial
global burden of disease (Degenhardt et al., 2013). In the United States
(US), it is estimated that 2.6 people per 1000 aged 12 and above used
heroin in the past year (Jones et al., 2015). In Europe, the estimated
annual heroin use prevalence is 4 per 1000 aged 15–64 (EMCDDA,
2015) and 7.3 per 1000 among people aged 16–64 in England (Hay
et al., 2014).
Opioid use disorder (OUD), and the conceptually identical ‘opioid
dependence’, is a debilitating and often chronic bio-behavioural
disorder (DSM-5; American Psychiatric Association, 2013; ICD-10;
WHO, 2016). People with OUD typically use illicit heroin and/or
non-medical opioid pharmaceutical products, developing physiologi-
cally dependence and strong motivational urges. Around one quarter of
opioid users develop OUD (Gable, 1993; Anthony et al., 1994). Left
untreated, OUD typically follows a chronic course causing substantial
health, social and economic problems (Hser et al., 2001; Grella and
Lovinger, 2011; Hser et al., 2015). In the classic Grella and Lovinger
study, half of the sample died and a quarter did not experience any
sustained improvement in their drug use (Grella and Lovinger, 2011).
The OUD population is far from homogenous. Several behaviours
are associated with increasing severity of the disorder (Marsden et al.,
2014) and treatment effectiveness may vary between sub-populations.
For example, drop-out is more likely among patients with comorbid
psychiatric conditions and more criminal justice involvement in the
year before treatment, and less likely among those living with
dependent children (Evans et al., 2009). Ethnic minority populations
http://dx.doi.org/10.1016/j.drugalcdep.2017.03.013
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have been reported to have a lower rate of treatment episode comple-
tion (Mennis and Stahler, 2016). An important sub-population are
polydrug users, typically involving concurrent use of one or more of the
following: alcohol, cocaine powder, smokeable (crack) cocaine and
benzodiazepines (Darke and Hall, 1995; Monga et al., 2007; Harrell
et al., 2012; Kuramoto et al., 2011). Heroin smokers who use crack
cocaine are substantially less likely to be infected with Hepatitis C virus
than those who inject heroin (Harrell et al., 2012). Opioid-polydrug
users have been observed to have greater health and social problems
(Leri et al., 2003) and a relatively poorer response to OUD treatment
(Williamson et al., 2006; Marsden et al., 2011, 2009).
The majority of countries with a high prevalence of OUD have an
array of well-developed treatment services. The opioid medications
methadone and buprenorphine are front-line, randomised-controlled
trial supported pharmacotherapies (Mattick et al., 2014, 2009). Some
OUD patients may receive psychosocial interventions without opioid
psychotherapy. Interventions are typically provided by specialist com-
munity, primary care and hospital providers. Inpatient withdrawal
management and drug-free residential rehabilitation services are also
available. In addition to case management, national clinical guidelines
recommend psychosocial interventions to address cognitive and beha-
vioural symptoms of OUD (e.g., National Institute for Clinical
Excellence, 2007).
Internationally, there have been several longitudinal cohort studies
of the effectiveness of these interventions as delivered under routine
conditions by public treatment systems (e.g., Simpson and Sells, 1990;
Stewart et al., 2002; Darke et al., 2007; Marsden et al., 2009; White
et al., 2015). Taken together, these studies conclude that treatment is
associated with reduced opioid use, drug injecting, and offending
behaviour, and improvements in health (including a substantially
reduced risk of fatal overdose), social functioning and employment.
Longitudinal cohort studies are time consuming and expensive.
Public accountability means that the commissioners of publicly funded
services need information on the effectiveness of treatment as it is
delivered. Various proxy measures of outcome have been used in
treatment systems research, including unsanctioned discharge (drop-
out) from treatment and retention (Brorson et al., 2013; Stark, 1992;
Faggiano et al., 2003). A commonly used measure is the proportion of
patients treated who complete treatment successfully (Alterman et al.,
2001). This indicator is associated with reduced drug use (Evans et al.,
2009; Kornør and Waal, 2005), increased employment (Lang and
Belenko, 2000; Zarkin et al., 2002; Evans et al., 2009; Sung and Chu,
2011; The TOPPS-II Interstate Cooperative Study Group, 2003), lower
arrests and incarceration (Campbell et al., 2007; Evans et al., 2009;
Gifford et al., 2014; Finnigan, 1996), and a reduced likelihood of
readmission to treatment services (Luchansky et al., 2000). In the US,
substantial inter-state (Arndt et al., 2013) and regional variation in
completion rates have been reported (Hawkins et al., 2014), and this is
now monitored at the federal/government level (Stahler et al., 2016).
The ‘successful completion’ indicator has a key limitation − it does
not capture the extent to which treatment benefit is enduring. This is
important because relapse is common, affecting 50–60% of people
within six months after leaving treatment (McLellan et al., 2005). The
process of achieving stable recovery from OUD may involve several
cycles of treatment over a decade or more (Dennis et al., 2005; Hser
et al., 1997).
To fully assess the effectiveness of treatment systems, national
administrative databases need to be able to capture this process, yet the
requirements of such systems are difficult to implement. In the US, the
absence of a patient consent prevents linkage across consecutive
treatment episodes. At the national level, the impact of this is twofold:
it is not possible to objectively assess whether an individual has
previously engaged in treatment (an indicator of patient-level complex-
ity (Marsden et al., 2012; Siguel and Spillane, 1978). It is also not
possible to determine whether a patient’s successful completion status
is enduring.
England has a well-developed public treatment system for drug use
disorders with service delivery involving specialist clinics in the
National Health Service (NHS) and non-governmental sector. Services
are commissioned by 149 local treatment systems across the country
aligned to local government geographical boundaries. All public
providers report clinical and effectiveness data to the National Drug
Treatment Monitoring System (NDTMS). NDTMS is operated by Public
Health England and provides outcome monitoring and performance
benchmarking for each local system (see Marsden et al., 2009 for an
operational description). The latest national report shows that 28% of
people treated for OUD complete treatment successfully (Public Health
England, 2016a).
With temporal linkage of episodes, NDTMS can record re-presenta-
tion to treatment as a proxy remission indicator. To our knowledge, a
‘successful completion and no re-representation’ outcome measure has
not been used in previous OUD treatment systems research.
Accordingly, the aim of this study was to estimate the effectiveness of
OUD treatment in England for OUD using this indicator and contrast the
effectiveness of local treatment systems.
2. Methods
2.1. Design
This was an English national, five-year, prospective, observational
cohort study of publicly-funded, specialist treatment services for OUD
reporting to the NDTMS, and reported following the STROBE guideline
for observational research (Elm et al., 2007). The population for the
study was all adults (≥18 years) diagnosed with OUD who presented
for treatment in England between 1 April 2008 and 31 March 2009.
The study included all local treatment systems and all operational
specialist community agencies in the NHS and third-sector providing
pharmacotherapies, psychosocial interventions and adjunctive support
services for OUD in community, inpatient (short-term medically
supervised withdrawal), and residential (drug-free rehabilitation) set-
tings.
2.2. NDTMS database
NDTMS captures a core dataset of all clients entering the treatment
system, and is designed to record key information at each stage of the
treatment process. An initial triage assessment is conducted by clinical
staff at each treatment service during the first face-to-face meeting
following referral to treatment which can, in the case of self-referrals
for example, take place on the same day. Where a treatment need is
clinically indicated, the substance(s) and patient demographics are
recorded on NDTMS and an appointment for a treatment intervention is
arranged. The mean waiting time to initiate this intervention is 2.2 days
for OUD patients, and 98% start treatment within three weeks (Public
Health England, 2016a). Each treatment intervention received is
recorded on NDTMS (Section 2.2.1). Treatment is not time-limited:
patients are maintained in treatment for as long as clinically indicated
(Section 2.2.2).
2.2.1. OUD treatments
The opioid pharmacotherapies included methadone, buprenorphine
and also naltrexone. Psychosocial interventions such as contingency
management and motivational interviewing complement pharma-
cotherapy and target underlying psychological aspects of dependence.
In addition to opioid pharmacotherapy and/or psychosocial interven-
tions, a patent’s treatment programme could include adjunctive ‘re-
covery support’ services, including: facilitated access to mutual aid;
complementary therapies; and family, housing, employment, education
and training supports.
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2.2.2. Treatment episodes and journeys
Following the NDTMS reporting protocol, each patient-level ‘treat-
ment journey’ comprised: a single episode of pharmacotherapy or
psychosocial intervention provided by a clinic; enrolment in concur-
rently delivered medication and psychosocial interventions (from one
or more clinics); or a continuing care package in which an intervention
was followed by one or more further interventions. Episodes commen-
cing after 21 days are classified as a new treatment journey (Public
Health England, 2015). Recovery support services are offered concur-
rently or following a treatment episode. Patients are regularly re-
viewed, treatment provision changes, and at the end of the ‘treatment
journey’, patients who overcome their dependence are successfully
discharged from the treatment system.
When a patient was discharged from treatment, one of the following
exit reasons was recorded: successful completion; drop-out (patient left
treatment without discussion or before completing their care plan);
unsuccessful transfer (patient was referred to another treatment service
but does not enter treatment within 21 days); incarceration (treatment
is prematurely terminated due to criminal justice action); or patient
died. After this point, further treatment was classified as a new
treatment journey.
2.3. Outcome measure
The outcome measure for the study combined two components:
successful completion and no re-presentation. Successful completion
was assigned to each patient that was reported by the clinic as meeting
the following criteria within five years (ending 31 March 2014):
• in remission from OUD;
• abstinent from all opioids and crack cocaine;
• completed all opioid pharmacotherapy and psychosocial interven-
tions;
• met all care plan goals, with mutual agreement to exit treatment.
For the ‘no re-presentation’ element of the outcome measure, we
judged that a six-month period was reasonable (ending 30 September
2014). Therefore, the effectiveness measure was assigned to those
patients who met the above criteria at exit from treatment and did not
re-present for any treatment within six months (‘successful completion,
no re-representation’, SCNR for economy herein).
2.4. Covariates
We followed an integrated variable-centred and person-centred
approach to evaluate treatment effectiveness for OUD using the
following patient demographic, clinical information and previous
treatment exposure (all recorded at initial assessment):
2.4.1. Demographic
Sex; age (centred at 18 years and grouped in five-year increments);
Black and Minority Ethnicities (BME: a legal monitoring requirement
(Race Relations (Amendment) Act, 2000)); employed; housing problems
(defined primarily as having no fixed abode, but can also include
squatting, short-term hostel/Bed and Breakfast, staying with friends/
relatives; [(homeless, herein]).
2.4.2. Social deprivation
Local area deprivation was measured by the Indices of Multiple
Deprivation (IMD; (Department for Communities and Local
Government, 2007)). IMD data were linked to NDTMS based on the
patient’s residential postcode district or the location of their first
treatment provider in instances of missing postcode information.
2.4.3. Injecting status
Three levels of injecting status are recorded at the start of treatment:
never injected; lifetime history of injecting, and current injector
2.4.4. Career length
The number of years between first initiating opioid use and
enrolment in the index treatment journey (length of the substance-
using career). This measure was mean centred and coded in five-year
increments.
2.4.5. Treatment history
Referral route into treatment was categorised into whether the
patient was self-referred, referred via the criminal-justice system or
other (e.g., referral from health service or substance abuse service).
Whether an individual had previously accessed treatment was also
included.
2.5. Statistical analysis
All analyses were done in Mplus (version 7.11) and Stata (version
13.1).
2.5.1. Drug use sub-populations
Given anticipated heterogeneity in drug use profile of the OUD
population at presentation to treatment (Monga et al., 2007; Public
Health England, 2016a), we used latent class analysis (LCA) in Mplus to
identify discrete sub-populations of OUD patients who presented for
treatment with concurrent disorder with one or more of the following 6
substances: crack cocaine; cannabis; alcohol; non-medical opioids;
stimulants (powder cocaine and d-amphetamine) and benzodiazepines.
The LCA was iterative with an unconditional 1-class model initially
fit to the data and sequentially increased to a 6-class model. Each model
used 5000 random sets of starting values to guard against convergence
on local maxima (McLachlan and Peel, 2000) and a minimum class size
of 5% of the cohort was set for utility (Willey et al., 2016; Borders and
Booth, 2012). Class identification was informed by posterior fit
statistics, including the Bayesian and Akaike information criteria and
entropy. A multinomial logistic regression was then used to characterise
the latent classes on the patient-level characteristics. Given the
hierarchical structure of the study, with patients clustered in treatment
services and services clustered in local treatment systems, confidence
intervals (CI) were calculated using robust standard errors.
2.5.2. Outcome analysis
A three-level, multivariable logistic regression was used for the
analysis of the outcome measure (Stata command: meqrlogit). The
complete-case model contained the following random intercepts:
patients (level one); treatment services (level two); and local treatment
system (level three). Model discrimination and variation (at level two
and three) was estimated by c-index (Hanley and McNeil, 1982), and
intra-cluster correlation (ICC), respectively.
Reflecting the hierarchical design of the study (Hofmann, 1997; Heo
and Leon, 2008) and with alpha, statistical power and a medium effect
size on the outcome measure pre-set (0.05, 0.90 and f2 = 0.15,
respectively (Cohen, 1988)), we ensured that there were at least 15
cases per covariate in the regression analysis to minimise overfitting
(Green, 1991; Babyak, 2004).
With no contrary evidence that data loss was missing-at-random
(Little and Little, 2002), a multiply imputed dataset was computed by
chained equations (Stata command: mi: impute chained). An all-case
multivariate logistic model was run to check on potential bias and loss
of precision (Sterne et al., 2009). To achieve a relative efficiency above
98% (Rubin, 1987), and to ensure that reduction in power was less than
1% (Graham et al., 2007), 20 datasets of probabilistic values were
created, each analysed separately, and then combined using Rubin’s
rules.
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2.5.3. Analysis of local treatment systems
A fixed-effects approach was used to determine the relative effec-
tiveness of each local treatment system because random intercepts
could mask real variation in achieving the outcome (Marsden et al.,
2012). For each treatment system, predicted outcome probabilities
were summed across patients and divided by the number of patients
treated in the area. A risk-adjusted outcome rate was then calculated by
dividing the expected rate by the observed rate and multiplying this by
the national average.
A funnel plot with 95% control limits (Spiegelhalter, 2005) then
identified areas where outcome performance was better or worse than
expected (where the area was located above or the control limit,
respectively). Local treatment systems rates of opiate prevalence,
offending and drug-related deaths were contrasted by incidence-rate
ratio.
Outcome performance was contrasted using pooled estimates of the
rate of opiate users per thousand inhabitants (Hay et al., 2010),
incidence of drug related deaths per million inhabitants (Public
Health England, 2016b) and the criminal offence rate per thousand
inhabitants (Office for National Statistics, 2016) The offending rate was
based on the local area population estimates used in the development of
the opiate prevalence estimates (Hay et al., 2010).
3. Results
3.1. Study cohort and follow-up
The population for the study was all adults (≥18 years) diagnosed
with OUD who presented for treatment in England between 1 April
2008 and 31 March 2009 (N = 56,156). As 1799 (3.2%) people did not
commence treatment by 31 March 2014, they were removed from
further analyses.
Patients in the cohort (n = 54,357) commenced treatment for OUD
in 1421 specialist clinics and primary care teams in the National Health
Service (NHS) and the non-governmental sector (median of 12 patients
per service; IQR 3–45), and in all 149 local treatment systems in
England (median 302 patients per area; interquartile range [IQR]
184–470]).
At the end of the five-year period, 7890 people (14.5%) were
continuously enrolled in treatment for OUD. Given the aims of the
present study, this group was removed. Among the final all-case cohort
(n = 46,467), 9007 patients (19.4%) had missing observations on one
or more covariates, yielding a complete-case cohort of 37,460. The
covariate with the highest level of missing data was length of heroin use
career (11.4%), followed by employment status (9.1%), housing status
(3.4%) and injecting (3.4%).
3.2. Drug use sub-populations
At clinical assessment, 67% of patients had a concurrent substance
use disorder, as follows: crack cocaine (44.1%), cannabis (14.1%),
alcohol (13.3%), other illicit opioids (11.4%), benzodiazepines (9.4%)
and other stimulants (8.8%).
Table 1 displays the results of the LCA models. The value of each
information criterion (Akaike, Bayesian and adjusted Bayesian) reduced
as the number of classes increased, indicating successively better fitting
models. The bootstrapped likelihood ratio test confirmed that each
model was a statistically better fit than the preceding one. Entropy was
high (> 0.8) for all except the 3-class solution, which reflected relative
uncertainty in the assignment of individuals to the third class. The 5-
class and 6-class solutions resulted, however, in at least one class with
less 5% of the cohort. Accordingly, we judged that a 4-class solution
best identified the heroin and other drug use sub-populations at
treatment admission, and labelled these as follows:
• Class 1 (n = 30,339, 56%: heroin low level concurrent drug use
disorders);
• Class 2 (n = 2794, 5%: heroin, crack, alcohol);
• Class 3 (n = 17,907, 33%: heroin, crack);
• Class 4 (n = 3257, 6%: heroin, crack, cannabis).
3.3. Characteristics of the cohort
Table 2 shows the demographic and clinical characteristics of the
cohort and the results of the multinomial logistic regression analysis of
the profile of the drug problem classes on socio-demographic, injecting,
heroin career and treatment referral characteristics (with the heroin
and low concurrent drug use disorders [class 1] as the referent).
There were relatively less employment and more homelessness
among the members of classes 2, 3 and 4. Class 4 was also relatively
more likely to be referred to treatment from the criminal justice system
(35.3%) and have previous OUD treatment (50.4%).
3.4. Treatment exposure and status at exit
Patients in the cohort received a median of 31.0 weeks of treatment
(IQR 12.6–80.3) and 13,360 (28.8%) successfully completed their
treatment journey (Table 3). One-third (32.1%) of discharged patients
were readmitted for further treatment for substance use disorders
within six months.
Readmission was more likely for those who were incarcerated (re-
admission rate 45.2%; odds ratio [OR] 2.67; 95% CI 2.50–2.82),
dropped out (re-admission rate 34.8%; OR 1.72; 95% CI 1.63–1.81),
or transferred unsuccessfully to another SUD treatment service (re-
admission rate 28.3%; OR 1.27; 95% CI 1.20–1.35) compared with
those who completed treatment successfully (re-admission rate 23.7%).
Relative to Class 1, patients assigned to Class 2 and Class 4 were less
likely to have received opioid pharmacotherapy, Class 4 was more
likely to have received psychosocial interventions, and Class 2 received
more in-patient services. Class 1 received the least amount of residen-
tial services and was retained in treatment longer than any other class.
Class 3 reported more incarceration, unsuccessful transfers and drop-
outs, but less deaths, while Class 2 had fewer incarcerations but more
drop outs. There were relatively fewer deaths in Class 4.
3.5. Successful completion of treatment and no re-presentation within six
months
Overall, 21.9% of the cohort (10,194) attained the SCNR outcome
(Table 3). Class 3 were less likely to achieve the outcome. After
negative multi-collinearity screening for all covariates, the results of
the unadjusted, covariate adjusted complete-case (n = 37,460) and
multiply-imputed, all-case (n = 46,467) analyses are shown in Table 4.
The complete- and all-case models yielded very similar covariate
estimates. In the all-case model, with statistically significant adjustment
for clustering effects associated with treatment agency and local
treatment system (ICC 0.13 and 0.17, respectively) there was satisfac-
tory discrimination between patients who achieved the SCNR outcome
(c-index 0.74; 95% CI 0.74-0.75).
There was an increased likelihood of positive outcome among older
patients, those with pre-treatment employment, and those who with
longer time enrolled in treatment (particularly for more than 2 years;
adjusted odds ratio [AOR] 2.60; 95% CI 2.43–2.78).
A negative outcome was associated with men, patients who were
homeless before admission and in areas of greater social deprivation
(gradient with likelihood lowest at highest quintile; AOR 0.77; 95% CI
0.70–0.85); drug injectors; those referred from the criminal justice
system; those with previous treatment for OUD; those with shorter
heroin using career; and members of class 3.
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3.6. Comparison of local treatment systems
Following risk-adjustment, 14 of 149 local treatment systems were
classified as achieving performance that was better than expected on
the SCNR outcome, and 38 local treatment systems achieved perfor-
mance that was worse than expected (Fig. 1). In comparison to the
better performing areas, these 38 areas were characterised with a
higher estimated level of opiate use in the local population (an extra 4.1
(95% CI 4.0–4.2) opiate users per thousand population), a higher level
of drug-related offences (an extra 28.5 (95% CI 28.1–28.8) offences per
thousand population), and more drug-related deaths (an extra 5.9 (95%
CI 5.9–5.9) deaths per thousand population) (Table 5).
Table 1
Unconditional latent class analysis of drug use at presentation to treatment (n = 54,347).
Modela
Parameter Class 1 Class 2 Class 3 Class 4 Class 5 Class 6
No. of parameters 6 13 20 27 34 41
AIC 266,371.29 264,740.91 262,525.26 261,201.63 260,527.17 260,033.40
BIC 266,424.71 264,856.65 262,703.32 261,442.02 260,829.88 260,398.43
aBIC 266,405.65 264,815.33 262,639.76 261,356.22 260,721.83 260,268.13
aBIC change (%) – −0.60 −0.82 −0.49 −0.24 −0.17
Entropy – 0.999 0.718 0.830 0.861 0.857
BLRT – −133,179.65 −132,357.45 −131,242.63 −130,573.82 −130,229.58
BLRT reduction (%) – – 0.62 0.84 0.51 0.26
Class (probability)
1 1.00 (1.00) 0.44 (1.00) 0.06 (0.99) 0.56 (0.83) 0.29 (0.99) 0.01 (0.71)
2 – 0.56 (1.00) 0.38 (1.00) 0.05 (0.99) 0.04 (0.97) 0.55 (0.79)
3 – – 0.56 (0.69) 0.33 (0.99) 0.05 (0.99) 0.04 (0.99)
4 – – – 0.06 (0.99) 0.06 (0.99) 0.06 (0.99)
5 – – – – 0.56 (0.84) 0.29 (0.99)
6 – – – – – 0.05 (0.98)
AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; aBIC, sample-size adjusted BIC; BLRT, bootstrapped likelihood ratio test (all P < 0.00005).
Classification based on most likely latent class membership.
a For the following drugs: crack cocaine, cannabis, alcohol, other opioids, benzodiazepines and other stimulants.
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Male 41,099 (75.6) (76.5) (74.9) (73.0) (82.0)
Agea 32.9 (7.8) 32.9 (7.9) 34.2 (7.9) 33.0 (7.5) 31.9 (7.9)
Black/Minority Ethnic 7342 (13.5) (10.9) (15.8) (15.9) (22.4)
Employed 6222 (12.5) (14.7) (8.1) (9.7) (11.4)
Homeless 17,343 (32.9) (29.5) (43.1) (36.8) (35.1)
Social deprivation:
Quintile 1 (lowest) 10,857 (20.0) (21.6) (19.9) (17.1) (20.4)
2 10,922 (20.1) (19.9) (21.9) (20.1) (20.3)
3 10,823 (19.9) (19.9) (23.3) (19.3) (20.2)
4 10,859 (20.0) (19.8) (18.9) (20.3) (20.6)
Quintile 5 (highest) 10,896 (20.0) (18.7) (16.0) (23.2) (18.5)
Clinical
Heroin careera 11.4 (7.5) (7.6) (8.3) (7.2) (7.4)
Drug injecting:
Never 17,715 (33.6) (32.8) (32.5) (33.1) (44.5)
Lifetime 18,004 (34.2) (34.9) (35.4) (33.5) (30.4)
Current 16,996 (32.2) (32.3) (32.1) (33.4) (25.0)
Referral Source:
Other 17,453 (32.1) (35.0) (35.1) (27.6) (27.2)
Self 20,570 (37.8) (39.4) (37.6) (35.2) (37.5)
Criminal justice 16,334 (30.0) (25.6) (27.3) (37.1) (35.3)
Previous OUD treatment: 30,212 (55.6) (55.6) (52.4) (57.0) (50.4)
<6 months 20,835 (38.3) (35.3) (45.1) (41.4) (44.1)
6 months to< 1 year 8917 (16.4) (16.1) (16.4) (16.9) (17.0)
1 year to< 2 years 8014 (14.7) (15.4) (14.3) (13.6) (14.9)
2 years to 5 years 16,591 (30.5) (33.2) (24.3) (28.1) (24.0)
Class 1: Heroin and low likelihood of problem substance use.
Class 2: Heroin, problem crack cocaine and alcohol use.
Class 3: Heroin and crack cocaine use.
Class 4: Heroin and crack and cannabis use.
Figures in parentheses in table are percentages unless otherwise stated.
Emboldened percentages and means are statistically significant (P < 0.05) from multivariable, multinomial logistic regression (Class 1: referent).
a Year (SD).
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4. Discussion
Over the five-year observation period, we observed that nearly one
in three patients successfully completed treatment for OUD. Reinforcing
previous research (Luchansky et al., 2000), patients who successfully
completed treatment were least likely to be re-admitted to treatment
within a subsequent six-month period. In our national population of
patients accessing publicly-funded treatment, one in five achieved a
sustained benefit from treatment.
Other studies have noted two (Shand et al., 2011), three (Harrell
et al., 2012; Monga et al., 2007), five (Kuramoto et al., 2011), or eight
(Patra et al., 2009) latent class structures. Our analysis of polydrug
dependence in patients seeking treatment for OUD in England revealed
a four-class structure. Crack cocaine was a defining characteristic in
three of these classes, with one class being further classified with
alcohol dependence and another classified with cannabis dependence.
It is interesting to note that the only crack cocaine class without alcohol
or cannabis dependence had worse outcomes than the heroin with low
polydrug class.
4.1. Integration with the literature
Unlike other large-scale studies on treatment completion (Arndt
et al., 2013; Mennis and Stahler, 2016), in our unadjusted models
patients from Black and Minority Ethnicities (BME) were more likely to
recover. After controlling for other socio-economic factors, however,
this disparity no longer held, highlighting the importance controlling
for employment and stable housing (Saloner and Lê Cook, 2013;
Hawkins et al., 2014). Our findings provide general support for the
construct of ‘physical capital’ (Cloud and Granfield, 2008) playing a
major role in recovery from heroin use disorder, as employment and
stable housing were found to significantly affect the likelihood of
recovery. The finding that increased time spent engaged in treatment
increases the likelihood of successful completion aligns with previous
research (Hubbard et al., 2003; Simpson and Sells, 1990) and provides
evidence that OUD treatment should not be time-limited (Advisory
Council on the Misuse of Drugs, 2014).
After controlling for patient-level and area-level deprivation pre-
dictors of outcome, local treatment systems that were performing
significantly below the expected rate also appeared to have a much
larger opiate using population and, presumably as a result of this, a
higher rate of both offending and drug-related deaths. We are not able
to determine a mechanism for this association. There may be social
network influences in operation. For example, social networks can
influence both a transition to injecting heroin (Neaigus et al., 2006) and
the decision to share injecting equipment (De et al., 2007). Heroin users
who have achieved abstinence often cite moving away from drug-using
social networks and receiving support from non-using friends as a
contributory factor to their success (Best et al., 2008).
4.2. Strengths and limitations
The main study strength is the national, large scale, long-term
follow-up of all individuals accessing treatment for heroin use disorder
in England and the utilisation of the national administrative database to
monitor relapse. Unlike other comprehensive administrative datasets
(Sahker et al., 2015; Alterman et al., 2001; Stahler et al., 2016), NDTMS
has patient-level identifiers that enable cross-referencing with subse-
quent treatment admissions. This utility provides not only an objective
summative measure of the sustainability of recovery in this population,
it also enables national administrative systems to objectively capture
whether patients had previously accessed treatment services, which is
an important negative predictor of treatment outcome (Siguel and
Spillane, 1978; Marsden et al., 2012).
Several study limitations are also acknowledged: firstly, our analysis
of OUD sub-populations is based on clients entering the treatment
system in 2008/09. It is possible that since this period, with the rise of
novel psychoactive substances for example, a different class structure
would emerge for clients currently accessing treatment. Second, we
were not able to access data from the national deaths registry or the
national prisons system, and there remains a concern that at least some
of our patients who did not re-present to treatment were simply unable
to. Third, while all available covariates in NDTMS were screened in the
present analysis, other covariates could further elucidate the likelihood
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Exposure − interventions received
Opioid pharmacotherapy, n (%) 36,122 (77.7) 20,377 (80.0) 1602 (64.2) 12,082 (77.6) 2061 (70.2)
Psychosocial interventions, n (%) 25,742 (55.4) 13,682 (53.7) 1537 (61.6) 8694 (55.9) 1829 (62.3)
In-patient withdrawal management, n (%) 3010 (6.5) 1546 (6.1) 275 (11.0) 1021 (6.6) 168 (5.7)
Residential rehabilitation, n (%) 1620 (3.5) 711 (2.8) 167 (6.7) 617 (4.0) 125 (4.3)
Median weeks to discharge
Successful completion (IQR)* 39.5 (15.3–109.9) 46.0 (16.6–119.7) 30.9 (14.9–79.1) 34.1 (14.0–99.3) 31.9 (14.6–90.4)
Died, (IQR) 81.0 (32.0–147.9) 83.4 (35.7–150.0) 51.4 (16.4–177.2) 81.1 (32.0–140.3) 65.3 (11.0–142.1)
Incarcerated, (IQR) 35.4 (14.7–82.6) 38.4 (16.0−85.9) 33.9 (13.3–87.0) 32.3 (13.3–79.0) 34.4 (13.0–73.9)
Unsuccessful transfer, (IQR) 32.4 (12.9–79.3) 35.0 (13.3–84.3) 27.1 (10.3–74.9) 30.7 (12.3–75.6) 27.6 (11.1–66.3)
Dropped out, (IQR) 22.9 (9.9–57.7) 25.1 (10.7–61.9) 19.1 (9.1–46.7) 20.9 (8.9–52.7) 20.3 (9.7–55.9)
Total, (IQR) 31.0 (12.6–80.3) 34.3 (13.3–87.0) 25.6 (11.8–67.9) 28.0 (11.6–73.4) 27.0 (11.9–69.9)
Treatment exit status
Successful completion, n (%) 13,360 (28.8) 7675 (30.1) 718 (28.8) 4066 (26.1) 901 (30.7)
Died, n (%) 684 (1.5) 435 (1.7) 52 (2.1) 182 (1.2) 15 (0.5)
Incarcerated, n (%) 7425 (16.0) 3820 (15.0) 299 (12.0) 2845 (18.3) 461 (15.7)
Unsuccessful transfer, n (%) 8385 (18.1) 4498 (17.7) 449 (18.0) 2922 (18.8) 516 (17.6)
Dropped out, n (%) 16,613 (35.8) 9041 (35.5) 978 (39.2) 5551 (35.7) 1043 (35.5)
Treatment outcome
Successful completion and no re-
presentation within six months, n (%)
10,194 (21.9) 5882 (23.1) 566 (22.7) 3063 (19.7) 683 (23.3)
Emboldened percentages and means are statistically significant (P < 0.05) from multinomial logistic regression (Class 1: referent).
* IQR = interquartile range.
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of sustaining recovery, including treatment motivation (Simpson and
Joe, 1993), engagement (Simpson et al., 1995) and other recovery
strengths (Gossop et al., 2002). Fourth, it is possible that other
interventions were experienced by the patients in this cohort, such as
privately-funded residential treatment or attending Alcoholics Anon-
ymous, but these interventions are not captured by NDTMS and it is not
possible to assess the potential impact these may have had.
4.3. Conclusions
Relapse requiring treatment is relatively common in the six months
following treatment completion. This study highlights the importance
of including re-presentation to treatment as a summative measure of the
effectiveness of local treatment systems. We note a sizeable proportion
of individuals, nearly one in seven, who have been continuously
engaged in treatment throughout the five-year observation period.
The next questions for our research group are whether, and to what
degree, heroin and other drug use changes throughout this time period;
how change in heroin use relates to change in other drugs; whether
five-year in-treatment change predicts subsequent successful comple-
tion of treatment, and to examine the longitudinal inter-relationship
between substance use, employment and housing.
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Table 4












Male 0.87 (0.82, 0.92) 0.88 (0.83, 0.94) 0.88 (0.83, 0.93)
Age 1.07 (1.06, 1.09) 1.09 (1.07, 1.11) 1.09 (1.07, 1.11)
BME 1.11 (1.03, 1.20) 1.05 (0.97, 1.14) 1.02 (0.94, 1.09)
Employed 1.46 (1.36, 1.58) 1.24 (1.15, 1.34) 1.27 (1.18, 1.37)
No fixed abode 0.74 (0.70, 0.79) 0.85 (0.80, 0.91) 0.86 (0.81, 0.91)
Deprivation:
Quintile 2 0.88 (0.80, 0.96) 0.93 (0.84, 1.02) 0.94 (0.86, 1.02)
Quintile 3 0.82 (0.74, 0.90) 0.91 (0.82, 1.00) 0.91 (0.83, 1.00)
Quintile 4 0.79 (0.71, 0.87) 0.84 (0.76, 0.93) 0.86 (0.78, 0.94)
Quintile 5
(highest)





0.81 (0.76, 0.86) 0.87 (0.81, 0.93) 0.86 (0.81, 0.91)
Currently
injector
0.59 (0.55, 0.63) 0.64 (0.60, 0.69) 0.64 (0.60, 0.69)
Referral route:
Self 0.95 (0.88, 1.01) 0.96 (0.90, 1.03) 0.97 (0.92, 1.04)




0.92 (0.81, 1.03) 1.02 (0.90, 1.15) 0.97 (0.87, 1.08)
Class 3:
Heroin & crack




0.99 (0.89, 1.11) 1.08 (0.97, 1.20) 1.02 (0.92, 1.12)
Previously treated 0.64 (0.61, 0.67) 0.66 (0.62, 0.69) 0.66 (0.63, 0.70)
Heroin career 0.99 (0.97, 1.00) 0.97 (0.95, 0.99) 0.97 (0.95, 0.99)
Time in index treatment journey:
6 months
to< 1 year
1.28 (1.19, 1.39) 1.28 (1.19, 1.38) 1.32 (1.23, 1.41)
1 year
to< 2 years
1.43 (1.33, 1.55) 1.40 (1.29, 1.51) 1.39 (1.30, 1.49)
2 years to 5 years 2.70 (2.51, 2.90) 2.59 (2.41, 2.79) 2.60 (2.43, 2.78)
Model statistics















– 0.13 (0.11, 0.15) 0.13 (0.11, 0.15)
SCNR, ‘successful completion of treatment journey and no representation to treatment
within six months’; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; d.f.,
degrees of freedom; ICC, intra-class correlation coefficient.
Emboldened percentages and means are statistically significant (P < 0.05).
Fig. 1. Funnel plot of outcome performance (SCNR rate) by local treatment system.
NB: The horizontal line is the national average for the SCNR outcome. The curved lines
are the upper and lower 95% confidence interval. Each black dot represents a local
treatment system. Local systems lying above the upper CI have an SCNR outcome
performance that is better than average after risk-adjustment. Local systems lying below
the lower CI have an SCNR outcome performance that is worse than average after risk-
adjustment.
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A B S T R A C T
Background: This is the first national study in England of continuous long-term opioid substitution treatment
(OST).
Methods: All adults were admitted to community OST for opioid use disorder (OUD) in 2008/09 with continuous
enrolment to 2013/14 (n= 7719). Heroin use trajectories were identified by multilevel Latent Class Growth
Analysis. In Year 6 and 7 of follow-up, the outcome measure (analysed by multilevel, multivariable logistic
regression) was ‘successful completion and no re-presentation’ (SCNR) to community treatment within six
months.
Results: Five heroin use trajectory classes were identified: ‘gradual decreasing’ (20.9%), ‘decreasing then increasing’
(21.7%), ‘continued low-level’ (17.0%), ‘rapid decreasing’ (25.6%), and ‘continued high-level’ (14.8%). At the end of
Year 7, 4616 people (60.3%) remained in OST. Of those discharged, 28.8% achieved the SCNR follow-up out-
come. SCNR was more likely in the ‘gradual decreasing’ (adjusted odds ratio [AOR] 2.40; 95% confidence interval
[CI] 1.77–3.26), ‘continued low-level’ (AOR 2.46; CI 1.78–3.40), and ‘rapid decreasing’ (AOR 3.40; CI 2.43–4.37)
classes relative to the ‘continued high-level’ class. SCNR was more likely among patients employed at admission
(AOR 1.45; 95% CI 1.15–1.83) and those receiving adjunctive psychosocial interventions (AOR 1.44; 95% CI
1.03 to 2.02).
Conclusions: Among English patients in OST for 5 years, heroin use trajectories were clearly delineated with a
gradient of response on the study outcome. Successful completion and no re-presentation was achieved by 28.8%
of discharged patients. The rapid decreasing trajectory had the greatest likelihood of positive outcome.
Adjunctive psychosocial intervention during OST was associated with positive outcome.
1. Introduction
Oral methadone or buprenorphine are the first-line medical thera-
pies for opioid use disorder (OUD). These opioid substitution treat-
ments (OST) are consistently associated with abstinence from illicit
opioid use (e.g., Hubbard et al., 2003; Gossop et al., 2003; Teesson
et al., 2006), a lowered risk of opioid overdose (White et al., 2015), and
reductions in criminal behaviour (Gossop et al., 2005). Aggregate sta-
tistical results may, however, mask differential clinical response among
sub-populations. For example, in an English national study of ongoing
OUD treatment, 37% of patients were abstaining from heroin during the
28 days before six-month follow-up; a further 31% were using heroin
less often, but 29% continued to use heroin at the same frequency as at
admission, and 3% had deteriorated (Marsden et al., 2009).
Longer follow-up studies have identified distinct sub-populations of
people who share a similar heroin use trajectory. In a US cohort study of
471 heroin users followed-up over 16 years, Hser and colleagues
identified three classes: nine per cent were ‘early-quitters’, 32%
achieved improvements at a later stage in follow-up (‘late-decelerated
users’), and 59% were labelled ‘stably high-level’ heroin users with no
identifiable improvement (Hser et al., 2007). In a recent 4.5-year
follow-up of study of 795 participants in a treatment trial, Hser’s group
identified the following classes: ‘low use’ (42.0%), ‘high use’ (22.3%),
‘decreasing use’ (18.6%), and ‘increasing use’ (17.1%), with people in
the ‘decreasing use’ class spending more time in treatment than those in
the ‘high use’ class (Hser et al., 2017). Comparable findings have been
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reported in Australia (Teesson et al., 2017).
Recently, we estimated the likelihood of successfully completing
OUD treatment within five years among a national cohort of adult pa-
tients admitted to public treatment services in 2008/09 (N=54,357;
Eastwood et al., 2017). Approximately 1:7 patients were continuously
enrolled in OST at the end of the five-year observation period. In the
present study, we report on the follow-up outcomes of this cohort over
the next two years. This is the first national outcome study of long-term
continuous OST in England. To our knowledge, there has been no na-
tional study of OST over this time-frame reported elsewhere.
In this report, we aim to: (1) identify heroin use response trajec-
tories during five years of OST and estimate associations with patient-
level characteristics and treatment exposure and (2) estimate whether
heroin use response trajectories predict positive outcome during the
sixth and seventh year of follow-up.
We hypothesised that: (a) patients with trajectories demonstrating
positive response to ongoing OST would be more likely to exit treat-
ment successfully, and (b) adjunctive psychosocial, in-patient, and re-




This was a seven-year, prospective, observational cohort study of all
publicly-funded specialist community-setting treatment services pro-
viding OST in England reporting to the National Drug Treatment
Monitoring System (NDTMS). The study is reported following the
RECORD guidelines for observational research using routinely collected
health data (Benchimol et al., 2015).
The study cohort is all adults (≥18 years; n= 7877) diagnosed with
OUD (almost all relating to use of heroin) who initiated treatment be-
tween 1 April 2008 and 31 March 2009, were continuously enrolled in
OST for the next five years (ending 31 March 2014), and then followed-
up to 30 September 2016. Following the NDTMS reporting protocol,
‘continuous enrolment’ was defined as either a single unbroken episode
of OST or two or more linked (continuing care) episodes in which there
was no more than 21 days between the end of one methadone or bu-
prenorphine prescribing intervention and the start of another (Public
Health England, 2015).
2.2. Measures
2.2.1. Developmental trajectory indicator
The Treatment Outcomes Profile (TOP; Marsden et al., 2008) is the
English national standard tool for substance use disorder treatment
outcomes monitoring. The TOP is a structured clinical interview that is
completed at admission, every six months thereafter, and at the com-
pletion of treatment. In this study, we used the number of days of
heroin use in the 28 days prior to each TOP interview conducted be-
tween Year 1 (2008/09) and Year 5 (2013/14).
2.2.2. Outcome measure
‘Successful completion’ of treatment has been widely used as an
outcome measure in effectiveness studies. Definitions vary, but this
typically denotes satisfactory resolution of primary clinical problems
and agreement between the clinician and patient to exit treatment (e.g.,
Luchansky et al., 2000; Alterman et al., 2001; Stahler et al., 2016).
The outcome measure in the present study combined two compo-
nents: successful completion and no re-presentation (SCNR). SCNR is
the English national proxy remission measure for OUD treatment out-
come monitoring (Public Health England, 2015). The ‘successful com-
pletion’ component was measured in Year 6 and Year 7 (ending 31
March 2016). It was defined as a clinician-verified report of a patient
who had completed OST, was in remission from OUD, was abstinent
from heroin (and any other non-medical opioids) and cocaine, and had
attained their care plan goals. The ‘no re-presentation’ element captures
the extent to which the successful completion is sustained by linking
patients with a successful completion to the community-based and
prison-based treatment databases, as well as the Office for National
Statistics’ fatal drug-poisoning database over the subsequent six-month
period (ending 30 September 2016), and removing all cases of re-pre-
sentation to treatment or fatal overdose from the summative effec-
tiveness measure.
2.2.3. Baseline covariate measures
The following patient demographic, clinical, and previous treatment
exposure variables (all recorded at initial assessment) were included as
potential confounders in the analysis.
2.2.3.1. Demographics. Demographics measured were: sex; age (centred
at 18 years and utilised in five-year increments); Black and Minority
Ethnicities (BME: a legal monitoring requirement (Race Relations
(Amendment) Act, 2000); whether employed; housing problems
(defined primarily as having no fixed abode, but can also include
squatting, short-term hostel/B and B, staying with friends/relatives
[homeless, herein]).
2.2.3.2. Social deprivation. Local area deprivation was measured by the
English Indices of Multiple Deprivation (IMD; Department for
Communities and Local Government, 2007). IMD data were linked to
NDTMS based on the patient’s residential postcode district or the
location of their first treatment provider in instances of missing
postcode information.
2.2.3.3. Treatment admission drug use latent class. Four heroin-based
latent classes from admission data were used: (1) heroin low level with
concurrent drug disorder, (2) heroin, crack and alcohol, (3) heroin and
crack, and (4) heroin, crack and cannabis. These classes were identified
in Eastwood et al. (2017).
2.2.3.4. Injecting status. Recorded at the start of treatment as (1) never
injected, (2) lifetime history of injecting, and (3) current injector.
2.2.3.5. Duration of heroin use ‘career’. This was defined as the number
of years between first initiation to heroin use and initiating OUD
treatment. In the models, this variable was mean centred and utilised in
five-year increments.
2.2.3.6. Treatment history. The patient’s referral route into treatment
was categorised as (1) self-referred, (2) criminal-justice system, or (3)
other. Whether a patient had previously accessed OUD treatment was
also included.
2.2.3.7. Adjunctive treatment exposure. Together with OST, NDTMS
records the following interventions: psychosocial interventions, in-
patient detoxification, and residential rehabilitation.
2.3. Statistical analysis
Data management was done with SPSS (version 21). We used
multilevel Latent Class Growth Analysis (LCGA) to identify discrete,
non-overlapping heroin use change trajectories across five years of OST
(MPlus; version 7). Management of missing data by multiple imputation
and all regression analyses were done with Stata (version 13).
2.3.1. Heroin use trajectories
In a longitudinal latent analysis of behaviour change, trajectory
membership can be influenced by inclusion of covariates and distal
outcomes (Huang et al., 2010). Following recommendation by Nagin
(2005), 1-class through 6-class models were fit to the data. Each model
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assumed a Poisson distribution, and 5000 random sets of starting values
were used to guard against convergence on local maxima (McLachlan
and Peel, 2000). A minimum class size of 5% was set for utility (Borders
and Booth, 2012; Willey et al., 2016).
Trajectory identification was informed by posterior fit statistics. As
patients were nested within different local treatment systems, we used
multilevel LCGA models, and an intra-class correlation coefficient (ICC)
was computed for each class (Asparouhov and Muthén, 2007). Multi-
nomial logistic regression then regressed trajectory classes on patient-
level characteristics. Robust standard errors were utilised to calculate
95% confidence intervals (CI) to account for clustering of patients in
each treatment system.
2.3.2. Outcome analysis
A multilevel, multivariable logistic regression model was used to
estimate the likelihood of SCNR (Stata command: meqrlogit), and the
ICC was estimated to assess intercept variation. As a sensitivity analysis,
we calculated the E-value from the adjusted odds ratios of the LCGA
trajectories and the estimate of its uncertainty from the CIs closest to
the null. In this application, the E-value is the minimum strength
needed by an unmeasured confounder to account for any significant
association between trajectory membership and outcome conditional
on the included covariates (VanderWeele and Ding, 2017).
2.3.3. Missing data
LCGA is implemented by full-information maximisation likelihood
and can assign patients with at least one measurement to a latent class.
However, a complete case analysis may yield biased estimates due to
missing covariate data. With no evidence that either the predictors or
outcome variables were not missing-at-random (Little and Little, 2002),
we created a multiply imputed dataset (Stata command: MI impute
chained). Logistic regression, multinomial regression, and predictive
mean matching were utilised, respectively, for binary, multinomial, or
continuous covariates with missing data. Twenty probabilistic datasets
were imputed, resulting in a relative efficiency of over 98% (Rubin,
1987) and a reduction in power of less than 1% (Graham et al., 2007).
3. Results
3.1. Study cohort
Patients were recruited from all 149 local treatment systems in
England (median 41; interquartile range [IQR] 23–71).
The flow of the 7877 participants continuously enrolled in OST for
five years is shown in Fig. 1. Two percent of the cohort (n= 158) had
no TOP data and were removed. Therefore, LCGA was undertaken on
7719 cases. A median of 10 TOP interviews were completed (IQR
8–11), and 2211 patients (28.6%) completed all 11 TOP assessments. A
further 58 people (0.7%) were removed, as their follow-up status could
not be determined.
At the end of Year 7, 4616 (60.3%) were still enrolled in OST.
During Year 6 and 7, 1987 (25.9%) exited treatment unsuccessfully,
and 1058 (13.8%) successfully completed treatment. Among those
successfully completing treatment, 16.5% (n=175) were re-admitted
to community treatment in the next six months, five were incarcerated,
and one person died from opioid-related poisoning.
The ‘successful completion and no re-presentation’ (SCNR) outcome
was achieved by 877 (28.8%) of those discharged from OST
(n=3045).
3.2. Heroin use during five years of OST
Heroin use was reported by 85.8% of the cohort during the 28-days
before the start of treatment (Table 1). Proportionately, the greatest
reduction in heroin was in the first six months of OST, at which point
62.7% were still using. Overall, 39.6% of the cohort were using heroin
at Year 3, and there was a slight increase at each six-monthly assess-
ment to Year 5 (43.2%). The mean number of days used reduced from
19.5 days at intake to 7.4 days at six months and did not exceed four
days after 2.5 years in treatment. Correlations over follow-up are shown
in Supplementary Material (Table S11).
3.3. Heroin use trajectories
Table 2 displays the results of the multilevel LCGA models. Model
indicators pointed to a 6-class solution. However, two classes had
consistently low heroin use over the five years. Accordingly, we judged
a parsimonious 5-class model to be optimal. The ICC for classes 1, 2, 4
and 5 ranged between 0.46 and 0.49 and was 0.04 for class 3.
We labelled the heroin use trajectory classes as follows (Fig. 2):
• Class 1 (n= 1617, 20.9%: ‘gradual decreasing’)
• Class 2 (n= 1673, 21.7%: ‘decreasing then increasing’)
• Class 3 (n= 1310, 17.0%: ‘continued low-level’)
• Class 4 (n= 1973, 25.6%: ‘rapid decreasing’)
• Class 5 (n= 1146, 14.8%: ‘continued high-level’)
3.4. Patient-level characteristics
Patient-level characteristics are shown in Table 3 together with the
results of the all-case multinomial logistic regression of the heroin use
trajectory classes on patient-level characteristics. Compared to the poor
response (‘continued high-level’) class, participants in the other classes
had less previous OUD treatment exposure, and the ‘decreasing then
increasing’, ‘continued low-level’, and ‘rapid decreasing’ classes were
less likely to be currently injecting at admission.
The ‘decreasing then increasing’ heroin use class had more men, and
they were less likely to reside in an area of high social deprivation. The
‘continued high-level’ heroin use class were more likely to be exposed
to psychosocial, in-patient, and residential treatments during their en-
rolment in OST.
3.5. Treatment status at the end of year 7
Continued enrolment in OST at the end of Year 7 was not associated
with heroin use trajectory (Table 4). Among the treatment leavers, the
‘continued high-level’ heroin users were most likely to have an un-
successful discharge. There was an outcome response gradient by class
among those who left treatment successfully: successful completion of
treatment was recorded for 8.6% of the ‘continued high-level’ class
compared to 18.7% of the ‘rapid-decreasing’ class. Patients who con-
tinuously enrolled at Year 7 were removed from further analysis at this
point.
Compared to the ‘rapid decreasing’ heroin use class (re-admission
rate 11.2%), re-presentation within six months for community treat-
ment was more likely among the ‘continued high-level’ heroin use class
(22.4%; odds ratio [OR] 2.29; 95% CI 1.29–4.08); this was followed by
the ‘decreasing then increasing’ class (22.2%; OR 2.26; 95% CI
1.38–3.71), the ‘gradual decreasing’ class (17.3%; OR 1.72; 95% CI
1.08–2.73), and the ‘continued low-level’ class (17.8%; OR 1.66; 95%
CI 1.01–2.72).
3.6. Impact of trajectory membership on outcome
The poor responding ‘continued high-level’ heroin using class had
the lowest proportion achieving SCNR (16.2%), followed by the ‘de-
creasing then increasing’ group (19.6%). The ‘continued low-level use’
and ‘gradual decreasing use’ groups had similar levels of SCNR (31.2%
1 Supplementary material can be found by accessing the online version of this paper at
http://dx.doi.org and by entering doi:...
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and 31.7%, respectively), while SCNR was most likely to be attained by
the ‘rapid decreasing’ class (39.7%).
The multiply imputed, multilevel logistic regression analysis
(Table 5) indicated that three trajectory groups (i.e., ‘gradual de-
creasing’, ‘continued low-level’, and ‘rapid decreasing’) were more likely to
achieve SCNR compared to the ‘continued high-level’ class (adjusted
odds ratio [AOR] 2.40 [95% CI 1.77–3.26]); AOR 2.46 [95% CI 1.78 to
3.40]; AOR 3.26 [95% CI 2.43 to 4.37]), respectively.
The E-value estimate for the ‘gradual decreasing use’ class was 4.23
(with an uncertainty estimate of 2.94 for the minimum risk ratio needed
to shift the CI to the null), E= 4.36 (uncertainty estimate= 2.96) for
the ‘continued low-level use’ class, and E= 5.97 (uncertainty
estimate= 4.29) for the ‘rapid decreasing use’ class. There was also an
increased likelihood of achieving SCNR among those with pre-admis-
sion employment (AOR 1.45; 95% CI 1.15 to 1.83) and those who re-
ceived adjunctive psychosocial treatment during OST (AOR 1.44; 95%
CI 1.03 to 2.02) and a positive association for increasing age (AOR 1.07;
95% CI 1.00 to 2.14). Longer heroin using career, lifetime history of
injecting, and referral from the criminal justice system was associated
with a decreased likelihood of achieving SCNR.
3.7. Post-hoc analysis
Finally, we created a binary ‘non-response’ measure by combining
the ‘continued high-level use’ and ‘decreasing then increasing use’
trajectory groups against the remaining three trajectory groups. This
measure was then collapsed at the local treatment system level resulting
in a range of non-response from 0 to 70%. Also available at local area
level were the prevalence of opiate users per 1000 population in 2008/
09 (Hay et al., 2010), the rate of offending per 1000 population (Office
for National Statistics, 2016), and the rate of drug-related deaths per
million population (Public Health England, 2016). Non-response was
regressed on these three measures in a linear regression. The offending
rate and the drug-related death rate were not associated with non-re-
sponse. However, for every extra opiate user per 1000 population there
was an increase in non-response by almost two percentage points (1.97;
95% CI 0.76 to 3.17).
4. Discussion
In a time of increased focus on recovery (Home Office of the United
Kingdom Government, 2017; Laudet and Humphreys, 2013), a greater
Fig. 1. Study profile.
Table 1
Heroin use during five years of continuous OST (n= 7719).
TOP
assessment
Responses (n) No. (%) using heroin Mean days used (SD)*
Admission 5,567 4,775 (85.8) 19.5 (11.6)
Year 0.5 5,774 3,622 (62.7) 7.4 (9.7)
Year 1 6,409 3,796 (59.2) 6.0 (8.7)
Year 1.5 6,449 3,673 (57.0) 5.9 (8.6)
Year 2 6,567 3,498 (53.3) 5.4 (8.3)
Year 2.5 6,649 2,899 (43.6) 4.0 (7.5)
Year 3 6,670 2,639 (39.6) 3.5 (6.9)
Year 3.5 6,713 2,729 (40.7) 3.7 (7.1)
Year 4 6,733 2,821 (41.9) 3.6 (730)
Year 4.5 6,743 2,873 (42.6) 3.9 (7.2)
Year 5 6,748 2,913 (43.2) 4.0 (7.4)
TOP=Treatment Outcomes Profile.
SD= standard deviation.
* Mean days of opioid use in past 28 days.
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understanding of the heterogeneous response to treatment is required
by policy makers, treatment purchasers, and clinicians to inform their
decision-making processes. This report extends our previous study
(Eastwood et al., 2017) by estimating heroin use change trajectories
over long-term enrolment in OST. We identified five heroin use tra-
jectory groups and found that the trajectory groups tending towards
abstinence at Year 5 were significantly more likely to achieve a sus-
tained benefit from treatment (SCNR follow-up outcome).
4.1. Integration with the literature
In the treatment literature, several demographic and patient-level
characteristics have been linked to developmental trajectories asso-
ciated with relatively poor treatment response, including: males, people
from some ethnic minorities, lower educational achievement, earlier
onset of drug use, and involvement with the criminal justice system
(Grella and Lovinger, 2011; Hser et al., 2008, 2007).
Our ‘continued low-level’, ‘continued high-level’, and ‘decreasing
then increasing’ classes are similar to the ‘low use’, ‘high use’, and
‘increasing use’ response groups identified by Hser’s group (Hser et al.,
2008). Other studies have also highlighted a sub-population that does
not exhibit substantial reduction in drug use as well as a group de-
monstrating rapid reductions (Grella and Lovinger, 2011; Teesson et al.,
2017). This points to a degree of phenotypic similarity across different
countries, settings, and cohort characteristics. Similar to the Australian
study (Teesson et al., 2017), we note that few baseline covariates pre-
dict trajectory membership, although higher deprivation, currently in-
jecting, and previous treatment were associated with relative non-
response to treatment.
The validity of person-centred latent trajectory modelling has been
criticised (Sher et al., 2011). Our finding that more favourable trajec-
tory memberships are associated with sustained benefit provides sup-
port for the predictive validity of the approach. It also extends previous
work documenting associations with decreased mortality and better
employment, substance use, and mental health outcomes (Hser et al.,
2007; Teesson et al., 2017; Hser et al., 2017) and highlights the im-
portance of incorporating independent outcomes in person-centred re-
search design.
Our findings also highlight the positive role of employment in re-
covery, although it is interesting that stable housing did not affect the
likelihood of recovery as in other studies (e.g., Cloud and Granfield,
2008). Injecting and criminal justice referrals were, as expected
(Marsden et al., 2012), negatively associated with positive outcome.
4.2. Clinical implications
In our study, we estimate that one in seven patients demonstrate
sustained non-response over significant periods of time, and a further
fifth of patients exhibit a tendency to deteriorate after three years of
treatment. Continued illicit opioid use on top of an opioid prescription
is a recognised problem (Clinical Guidelines on Drug Misuse and
Dependence Update 2017). It is important for clinicians to identify non-
response at an early stage and to review and optimise the treatment
care package. Several clinical responses are available, including: in-
creasing the dose, dividing the dose into smaller daily doses in the case
of faster metabolism, offering to change the OST medication, and re-
introducing daily supervised consumption (ibid). Service user views on
medication should be taken into account, as a quarter consider the OST
dose to be ‘poor or bad’ (Advisory Council on the Misuse of Drugs,
2015). In the US, around a quarter of patients also receive methadone
doses too low to be effective (D’Aunno et al., 2014).
4.3. Policy implications
Our finding that more than 40% of patients continue to use illicit
opioids after five years of continuous treatment supports the conclusion
that a blanket time limit on prescribing would not be clinically ap-
propriate (Advisory Council on the Misuse of Drugs, 2014). National
drug treatment administrators should make available performance
monitoring reports for clinics and treatment purchasers focused on
long-term use of illicit opioids, which could aid local planning and re-
source allocation and improve outcomes. Further, incorporation of
prescription dose into the NDTMS would help estimate whether, and to
what degree, sub-optimal dosing is associated with continued use on
top of that dose.
Table 2
Unconditional multilevel latent class growth analysis of heroin use over five years (n=7719).
1-Class 2-Class 3-Class 4-Class 5-Class 6-Class
AIC 886002.87 671087.82 610578.39 580090.68 553248.75 537428.48
BIC 886023.73 671136.50 610654.88 580194.97 553380.86 537588.40
aBIC 886014.20 671114.25 610619.92 580147.31 553320.48 537515.31
Entropy – 0.975 0.971 0.964 0.950 0.956
Class (probability)
Class 1 1.00 (1.00) 0.58 (0.99) 0.42 (0.99) 0.24 (0.97) 0.21 (0.97) 0.12 (0.96)
Class 2 – 0.42 (0.99) 0.21 (0.99) 0.37 (0.99) 0.22 (0.97) 0.25 (0.97)
Class 3 – – 0.37 (0.99) 0.23 (0.97) 0.17 (0.97) 0.18 (0.97)
Class 4 – – – 0.16 (0.99) 0.26 (0.94) 0.14 (0.98)
Class 5 – – – – 0.15 (0.98) 0.17 (0.96)
Class 6 – – – – – 0.15 (0.95)
VLMR – <0.01 0.12 < 0.01 < 0.01 < 0.01
BLRT – <0.01 <0.01 < 0.01 < 0.01 < 0.01
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; aBIC: sample-size adjusted BIC; VLMR: Vuong-Lo-Mendel-Ruben test; BLRT: bootstrapped
likelihood ratio test.
Fig. 2. Heroin use trajectories over 5 years of continuous OST.
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Our finding that psychosocial interventions, received by most but
not all patients, are advantageous for sustaining recovery underscores
the importance of comprehensive interventions being made available in
the treatment of OUD. More frequent or personalised psychosocial in-
terventions may also be beneficial (Marsden et al., 2017). Treatment
clinics may benefit from an audit of clinical practices, as it has been
suggested that interventions are ‘front-loaded’, and less intensive sup-
port is available to those in treatment over longer periods (Finch,
2003).
In the current study, it appears that areas with a greater degree of
non-response are also affected by a larger opiate-using population.
Although we are unable to determine a precise mechanism, there may
be social network influences in operation to explain this association.
For example, heroin users who have achieved abstinence often cite
moving away from drug-using social networks as a factor in their suc-
cess (Best et al., 2008). Greater integration of treatment services with
local recovery groups may help mitigate this influence.
4.4. Strengths and limitations
A major study strength is the national, large-scale, long-term follow-
up of all individuals accessing treatment for opioid use disorder in
England. In addition, the consent model supporting NDTMS enables
cross-referencing with subsequent treatment admissions and drug-poi-
soning databases, providing the utility to examine an objective sum-
mative measure of sustained recovery from OUD.
Several limitations are also acknowledged. First, while all available
covariates in NDTMS were screened in the present analysis, other
covariates could further elucidate the likelihood of sustaining recovery,
including treatment motivation (Simpson and Joe, 1993), engagement
(Simpson et al., 1995), and other recovery strengths (Gossop et al.,
2002). Second, it is possible that other interventions, such as attending
Narcotics Anonymous, were experienced by the patients in this cohort.
These interventions are not, however, captured by NDTMS, and it is not
possible to assess the potential impact these may have had. We note
that the E-value parameter suggests such a variable would need to have
an adjusted odds ratio of at least 2.9 to mitigate the association between
trajectory membership and outcome.
4.5. Conclusions
This study highlights the importance of research analytical methods
that capture longitudinal trajectories. Within a cohort of patients con-
tinuously enrolled in treatment for five years, diverse treatment-re-
sponse trajectories emerge. The differential association between tra-
jectory membership and subsequent outcomes has real application and
could be important to clinicians and treatment purchasers, as it in-
dicates a substantial proportion of patients exhibit chronic or relapsing
opioid use in response to treatment and may require more intensive
interventions over a longer period.
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Table 4
OST status at Year 7, by heroin use trajectory (n= 7661).
Heroin use trajectory class Still enrolled Unsuccessful discharge Successful completion
Continued high-level (n= 1142) 678 (59.4) 366 (32.1) 98 (8.6)
Decreasing then increasing (n= 1660) 1016 (61.2) 482 (29.0) 162 (9.8)
Continued low-level (n= 1298) 803 (61.9) 304 (23.4) 191 (14.7)
Gradual decreasing (n= 1604) 975 (60.8) 388 (24.2) 241 (15.0)
Rapid decreasing (n=1957) 1144 (58.5) 447 (22.8) 366 (18.7)
Total 4616 (60.3) 1987 (25.9) 1058 (13.8)
Numbers in parentheses are percentages.
Table 5
Unadjusted and multi-level, all-case multivariable logistic regression of SCNR
outcome (n= 3045).




Male 0.90 (0.75, 1.07) 0.95 (0.79, 1.15)
Age 1.03 (0.98, 1.08) 1.07 (1.00, 1.14)
Black/Minority Ethnic 1.03 (0.78, 1.36) 0.94 (0.70, 1.26)
Employed 1.61 (1.29, 1.99) 1.45 (1.15, 1.83)
Homeless 0.79 (0.66, 0.96) 0.88 (0.72, 1.08)
Social deprivation
Quintile 1 (lowest) 1.06 (0.84, 1.35) 1.07 (0.83, 1.37)
Quintile 2 0.78 (0.60, 1.00) 0.84 (0.64, 1.09)
Quintile 3 0.86 (0.67, 1.10) 0.94 (0.73, 1.22)
Quintile 4 0.82 (0.62, 1.09) 0.89 (0.67, 1.20)
Quintile 5 (highest) – –
Heroin career 0.95 (0.90, 1.01) 0.93 (0.87, 1.00)
Drug injecting:
Never – –
Lifetime 0.71 (0.58, 0.86) 0.79 (0.64, 0.97)
Current 0.65 (0.53, 0.80) 0.80 (0.64, 1.00)
Referral source:
Other – –
Self 0.92 (0.77, 1.10) 0.94 (0.78, 1.14)
Criminal justice 0.62 (0.50, 0.79) 0.68 (0.54, 0.87)
Previous OUD treatment 0.73 (0.62, 0.86) 0.87 (0.73, 1.03)
Drug use classification:
Heroin low level concurrent drug
disorder
– –
Heroin, crack and alcohol 1.05 (0.72, 1.54) 1.02 (0.69, 1.51)
Heroin and crack 1.01 (0.85, 1.20) 0.99 (0.83, 1.19)
Heroin, crack and cannabis 0.93 (0.65, 1.33) 0.87 (0.60, 1.25)
Treatment exposure:
Psychosocial 1.26 (0.91, 1.75) 1.44 (1.03, 2.02)
In-patient 0.70 (0.52, 0.95) 0.79 (0.57, 1.11)
Residential 0.84 (0.43, 1.64) 1.34 (0.65, 2.76)
Heroin use trajectory class:
Gradual decreasing 2.37 (1.75, 3.21) 2.40 (1.77, 3.26)
Decreasing then increasing 1.28 (0.93, 1.76) 1.23 (0.89, 1.70)
Continued low-level 2.48 (1.81, 3.40) 2.46 (1.78, 3.40)
Rapid decreasing 3.47 (2.60, 4.64) 3.26 (2.43, 4.37)
Continued high-level – –
Model statistics
Constant – 0.16 (0.09, 0.29)
Wald χ2 (d.f.= 25) – 159.6 - 163.8
LR test χ2 (d.f.= 1) – 12.0 - 12.7
Intra-class correlation – 0.03 - 0.03
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A B S T R A C T
Background: English national prospective, observational cohort study of patients continuously enrolled for five
years in opioid substitution treatment (OST) with oral methadone and sublingual buprenorphine. This is a
secondary outcome analysis of change in use of alcohol and other drug use (AOD) following identification of
heroin use trajectories during OST.
Methods: All adults admitted to community OST in 2008/09 and enrolled to 2013/14 (n= 7717). Data from 11
sequential, six-monthly clinical reviews were used to identify heroin and AOD use trajectories by multi-level
Latent Class Growth Analysis. OST outcome in the sixth and seventh year was ‘successful completion and no re-
presentation’ (SCNR) to structured treatment and was assessed using multi-level logistic regression.
Results: With 'rapid decreasing' heroin use trajectory as referent, ‘continued high-level’ heroin use predicted
‘continued high-level’ crack cocaine use (relative risk ratio [RRR] 58.7; 95% confidence interval [CI]
34.2–100.5),‘continued high-level’ alcohol use (RRR 1.2; 95% CI 1.0–1.5), ‘increasing’ unspecified drug use
(RRR 1.7; 95% CI 1.4–2.1) and less ‘high and increasing’ cannabis use (RRR 0.5; 95% CI 0.4–0.6). 'Increasing’
crack use was negatively associated with SCNR outcome for the ‘decreasing then increasing’ and 'gradual de-
creasing' heroin use groups (adjusted odds ratio [AOR] 0.5; 95% CI 0.3–0.9 and AOR 0.2; 95% CI 0.1–0.7,
respectively).
Conclusions: Continued high-level heroin use non-response during long-term OST is associated with high-level
crack cocaine and alcohol use, increasing unspecified drug use, but less high and increasing cannabis use.
Increasing use of crack cocaine is negatively associated with the likelihood that long-term OST is completed
successfully.
1. Introduction
Opioid substitution treatment (OST), with oral methadone or sub-
lingual buprenorphine, is the first-line maintenance intervention for
opioid use disorder (OUD). Observational studies have consistently
reported OST to be associated with suppression of illicit opioid use (e.g.
Hubbard et al., 2003; Mattick et al., 2014, 2009; Simpson et al., 1982;
Teesson et al., 2006), a lower risk of opioid overdose (White et al.,
2015), and reductions in crime (Russolillo et al., 2018).
Many people with OUD present for treatment with problems asso-
ciated with several substance classes. Darke and Hall (1995) reported
that 99% of heroin users had used another drug class in the six-months
before treatment and reported using an average of 5.2 other substances.
In England, national statistics demonstrate that crack cocaine is the
most prevalent of concurrent substance use disorders and has increased
in those starting treatment from 42% to 54% in the four years to 2017/
18 (Public Health England [PHE], 2018a, 2017, 2016, 2015). Crack
cocaine use during treatment for OUD is associated with poorer sup-
pression of illicit opioid use, worse acquisitive crime and psychological
health outcomes and a lowered likelihood of completing treatment
successfully (Eastwood et al., 2017; Gossop et al., 2002a; Heidebrecht
et al., 2018; Marsden et al., 2012, 2009). Concurrent alcohol use dis-
order has been reported to affect around a third of OUD patients in
treatment, although in England the prevalence is somewhat lower at
17% (Nolan et al., 2016; Public Health England, 2018a).
There have been mixed findings from observational follow-up
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studies of change in concurrent alcohol and other drug use (AOD)
during OUD treatment. Brecht et al. (2008) observed an aggregate re-
duction in use, while Gossop et al. (2003) reported a return to baseline
levels following a temporary reduction, and others have reported a
worsening state in a subset of non-users at treatment admission (Gossop
et al., 2002b; Weiss et al., 2015). A two-year study of heroin users
enrolled in the Australian Treatment Outcomes Study reported that
reductions in heroin use were not associated with increases in the use of
cocaine, amphetamine, cannabis, benzodiazepines and other opioids
(Darke et al., 2006). A longer 11-year follow-up study reported the use
of alcohol was to be consistent across waves, ranging between 49% and
56% (Darke et al., 2015). Similar reductions in alcohol and other drug
use has been reported in Ireland over a 3-year follow-up period
(Comiskey et al., 2009).
Aggregated findings may, however, mask differential clinical re-
sponse among sub-populations. In their classic 30-year study of heroin
and other drug use, Grella and Lovinger (2011) reported that a quarter
of those followed up tracked a ‘rapid decrease’ heroin use trajectory and
over half of these reported an early increase in AOD (although specific
non-opioid substance classes were not reported). Recently, Teesson
et al. (2017) identified six heroin use trajectory groups over 11-years.
They reported that those following the ‘no decrease’ track were more
likely to have been incarcerated and to be currently affected by un-
stable housing and to be using benzodiazepines, but did not examine
longitudinal patterns of concurrent substance use.
In a recent report in this journal, we identified five heroin use tra-
jectories in a national cohort of patients who were continuously en-
rolled in OST for five years (n= 7719; Eastwood et al., 2018). We
showed that patients following a positive treatment response trajectory
towards abstinence were more likely to successfully complete treatment
in the subsequent two-year period.
To inform clinical practice and treatment policy, studies are needed
to determine specific substance use change trajectories during long-
term OUD treatment. Accordingly, in this related article, we determined
the strength of evidence:
(1) for a trajectory of patients characterised by increasing use of al-
cohol, cannabis, crack cocaine, cocaine powder, amphetamines and
any unspecified drug use;
(2) that positive and negative change in heroin use is associated with
an increase in alcohol and other drug use; and




Using data from the English National Drug Treatment Monitoring
System (NDTMS), this was a national, seven-year, prospective cohort
study reported following the RECORD guidelines for observational re-
search using routinely collected health data (Benchimol et al., 2015).
The study cohort has been described in two previous reports in the
journal where a detailed description of measures is presented
(Eastwood et al., 2018, 2017).
The present analysis concerns all patients who initiated OST be-
tween 1 April 2008 and 31 March 2009 and were enrolled for five
years, ending 31 March 2014 and followed-up to 30 September 2016
(7719 [14.2%] of 54,357). Following the NDTMS reporting protocol, all
members of the cohort were either continuously enrolled in OST (i.e.
they had a single unbroken episode of OST), or there was no more than
21 days between the end of one prescribing episode and the initiation of
another (i.e. in the context of a transfer of a patient from one OST
prescribing service to another).
2.2. Measures
2.2.1. Developmental trajectory indicators
The Treatment Outcomes Profile (TOP; Marsden et al., 2008) is a
structured, clinical interview for substance use disorder treatment
monitoring. Using a recall period of the past 28 days, the TOP is
completed by the clinician at the patient’s admission; then as part of a
clinical review conducted every six months, and at treatment comple-
tion. There were 11 TOP interviews conducted between Year 1 (2008/
09) and Year 5 (2013/14) recording the number of days the patient
reported using alcohol, cannabis, crack cocaine, cocaine powder, am-
phetamines, and any unspecified drug. The latter drug category is
known only at the level of the treatment clinic. However, annual ag-
gregate data suggest it is likely to involve benzodiazepines rather than
anti-depressants, hallucinogens, volatile solvents, or major tranquilli-
sers (10% prevalence versus< 1%, respectively; Public Health
England, 2018a).
For the present analysis, we used the following five heroin use
trajectory classes identified by Eastwood et al. (2018; Fig. 1)1:
• Class 1 (n= 1,617, 20.9%: ‘gradual decreasing’)
• Class 2 (n= 1,672, 21.7%: ‘decreasing then increasing’)
• Class 3 (n= 1,310, 17.0%: ‘continued low-level’)
• Class 4 (n= 1,973, 25.6%: ‘rapid decreasing’)
• Class 5 (n= 1,145, 14.9%: ‘continued high-level’)
2.2.2. Outcome measure
The OST outcome was the national summative measure of treatment
effectiveness defined as successful completion and no re-presentation
(SCNR) for further treatment within six months (Public Health England,
2018b). ‘Successful completion’ was recorded in Year 6 and Year 7
(ending 31 March 2016) by a clinician-verified report indicating: (1)
abstinence from heroin (and any other non-medical opioids) and co-
caine; (2) remission from OUD; (3) attainment of personal care plan
goals and (4) completion of OST. For this summative measure of OST
effectiveness, we removed all individuals to 30 September 2016 who
were re-admitted to community-based or prison-based treatment, or
were recorded on the Office for National Statistics’ fatal drug-poisoning
database.
Fig. 1. Heroin use trajectories over 5 years of continuous OST.
1 Due to two individuals with no AOD data, the ‘decreasing then increasing’
and ‘continued high-level’ classes were each reduced by one individual for the
present analysis.
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2.2.3. Baseline covariate measures
Patient-level variables in the analysis included demographics (sex,
age, ethnicity, employment, homelessness); social deprivation (linked
to NDTMS based on the patient’s residential postcode district or the
location of their first treatment provider in instances of missing post-
code information; Department for Communities and Local Government,
2007); treatment admission latent drug use class from Eastwood et al.
(2017); drug injecting status; duration of heroin use ‘career’; referral
route; other interventions (psychosocial; in-patient detoxification; or
residential rehabilitation); and previous treatment for OUD.
2.3. Statistical analysis
Data management was done with SPSS (version 21). Given the
clustering of patients within local treatment systems, we used multi-
level Latent Class Growth Analysis (LCGA) to identify discrete, non-
overlapping AOD use change trajectories across the five-years of OST
(MPlus; version 7). Management of missing data (by multiple imputa-
tion) and all regression analyses was done with Stata (version 15.1).
2.3.1. AOD use trajectories
Sequentially, 1-class through 6-class models were fit to the data to
identify unconditional trajectory membership. A Poisson distribution
was assumed for all models and 5000 random sets of starting values
were used to guard against convergence on local maxima (McLachlan
and Peel, 2000). Trajectory identification was informed by the Aikaike
and Bayesian information criteria, entropy and the Vuong-Lo-Mendel-
Ruben and bootstrapped likelihood ratio tests. A minimum class size of
5% of the cohort was pre-specified for utility (Borders and Booth, 2012;
Willey et al., 2016).
2.3.2. Missing data
As LCGA is implemented by full-information maximisation like-
lihood, all patients with at least one measurement could be assigned to
a latent class, but a complete case sample may yield biased estimates
due to missing covariate data. As such, and with no evidence that
missing data was not missing-at-random, a set of twenty multiply im-
puted datasets was created using logistic regression, multinomial re-
gression, and predictive mean matching for missing binary, multi-
nomial or continuous data, respectively (Stata command: MI impute
chained).
2.3.3. Analysis of heroin and AOD use trajectories
A series of multiply imputed, multivariable, multinomial logistic
regressions regressed AOD use trajectory classes on heroin use trajec-
tory groups, controlling for patient-level characteristics (Stata com-
mand: mlogit). Robust standard errors were utilised to calculate 95%
confidence intervals (CI) to adjust for clustering of patients in each
treatment system. Multiply imputed, multilevel, multivariable logistic
regression models were used to estimate the likelihood of SCNR (Stata
command: meqrlogit). As the likelihood of SCNR varied by heroin use
trajectory, we estimated the association between AOD use trajectory
groups and SCNR for each group.
3. Results
3.1. Study cohort
The study cohort includes 7719 patients for which heroin use tra-
jectories were identified (sample details in Eastwood et al., 2018).
These patients were recruited from all 149 local treatment systems in
England (median 41; interquartile range [IQR] 23–71). Two patients
did not complete a TOP assessment across all 11 assessment periods and
were removed. Multilevel LCGA models were undertaken on 7717 pa-
tients. A further 58 patients (0.8%) were subsequently removed as their
original treatment records from 2008/09 were no longer available on
NDTMS when assessing their follow-up status.
Table 1
Heroin, alcohol and other drug use during five years of continuous OST (n= 7717).
Treatment Outcomes Profile assessment
Substance Admission Year 0.5 Year 1 Year 1.5 Year 2 Year 2.5 Year 3 Year 3.5 Year 4 Year 4.5 Year 5
Heroin
Responses (n) 5567 5774 6409 6449 6567 6649 6670 6712 6733 6742 6746
% using 85.8 62.7 59.2 57.0 53.3 43.6 39.6 40.6 41.9 42.6 43.2
Mean days using (SD) * 19.5 (11.6) 7.4 (9.7) 6.0 (8.7) 5.9 (8.6) 5.4 (8.3) 4.0 (7.5) 3.5 (6.9) 3.7 (7.1) 3.6 (7.0) 3.9 (7.2) 4.0 (7.4)
Alcohol
Responses (n) 5496 5758 6407 6450 6569 6652 6675 6716 6737 6748 6739
% using 41.7 43.3 43.3 42.5 41.9 42.5 42.3 41.2 40.9 40.2 39.0
Mean days using (SD) * 5.4 (9.3) 5.2 (8.9) 5.3 (9.0) 5.2 (9.0) 5.3 (9) 5.3 (9.1) 5.5 (9.3) 5.3 (9.2) 5.4 (9.2) 5.3 (9.3) 5.3 (9.3)
Crack
Responses (n) 5511 5761 6401 6444 6565 6642 6667 6708 6728 6738 6740
% using 40.3 25.1 20.4 20.3 20.3 19.6 19.2 19.2 19.1 19.2 19.7
Mean days using (SD) * 4.5 (8.5) 2.0 (5.4) 1.5 (4.4) 1.5 (4.5) 1.5 (4.7) 1.4 (4.5) 1.5 (4.6) 1.4 (4.3) 1.4 (4.3) 1.4 (4.4) 1.4 (4.5)
Cannabis
Responses (n) 5463 5741 6391 6434 6555 6643 6670 6709 6721 6735 6731
% using 27.2 24.3 23.5 22.3 21.2 22.3 22.4 22.1 21.3 21.8 20.5
Mean days using (SD) * 3.8 (8.4) 3.5 (8.3) 3.5 (8.4) 3.4 (8.1) 3.2 (8.0) 3.4 (8.2) 3.5 (8.3) 3.5 (8.4) 3.4 (8.3) 3.5 (8.3) 3.2 (8.0)
Unspecified drug
Responses (n) 5395 5684 6356 6407 6554 6627 6654 6695 6713 6710 6703
% using 19.7 9.5 8.3 7.3 7.4 6.9 7.1 7.3 7.2 7.9 7.7
Mean days using (SD) * 3.3 (8.1) 1.7 (6.3) 1.3 (5.6) 1.2 (5.4) 1.2 (5.2) 1.1 (5.0) 1.1 (4.9) 1.0 (4.9) 1.1 (5.0) 1.1 (5.0) 1.1 (5.1)
Cocaine powder
Responses (n) 5438 5736 6391 6435 6559 6635 6655 6686 6700 6705 6701
% using 4.7 3.2 2.5 2.3 2.3 2.7 2.4 2.6 2.4 2.6 2.6
Mean days using (SD) * 0.2 (1.8) 0.1 (0.9) 0.1 (0.8) 0.1 (0.9) 0.1 (0.9) 0.1 (0.9) 0.1 (1.1) 0.1 (0.9) 0.1 (0.8) 0.1 (1.0) 0.1 (0.9)
Amphetamines
Responses (n) 5434 5734 6390 6434 6559 6637 6660 6692 6700 6708 6705
% using 4.1 2.7 2.5 2.8 2.6 2.5 2.8 2.3 2.3 2.5 2.6
Mean days using (SD) * 0.4 (2.6) 0.1 (1.4) 0.2 (1.5) 0.2 (1.6) 0.2 (1.6) 0.2 (1.7) 0.2 (1.8) 0.2 (1.5) 0.2 (1.7) 0.2 (1.8) 0.2 (1.9)
SD= standard deviation * Mean days of opioid use in past 28 days.
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3.2. Heroin and AOD use during five years of continuous OST
Heroin use was reported by 85.8% of the cohort during the 28-days
preceding treatment admission (Table 1). The most prevalent sub-
stances reported in the pre-admission month were alcohol (41.7%),
crack cocaine (40.3%), cannabis (27.2%) and unspecified drugs
(19.7%). Less than 5% reported using cocaine powder or an ampheta-
mine.
At the end of Year 5, the prevalence of heroin use fell by almost half
to 43.2%. The largest reduction in AOD use was observed for crack
cocaine (20.6%), unspecified drugs (12.0%) and cannabis (6.7%). The
prevalence of alcohol use was reduced by 2.7%. Although cocaine
powder and amphetamines were reduced by 2.1% and 1.5%, respec-
tively, this represented a reduction of over a third (36.6%) for am-
phetamines and nearly a half (44.7%) for cocaine powder. Due to the
marginal prevalence of amphetamines and cocaine powder use in the
cohort, these substances were not included in the models.
3.3. AOD use trajectories
Table 2 displays the results of the multilevel LCGA models for al-
cohol, crack cocaine, cannabis and unspecified drug. For each sub-
stance, AIC, BIC, aBIC, entropy and BLRT indicators all pointed to six-
class solutions. However, based on the model indicators, as well as the
longitudinal separation between trajectory groups, we judged that al-
cohol, crack cocaine, cannabis and unspecified drug were best de-
scribed by a more parsimonious four, five, three and three class model,
respectively.
Fig. 2 (charts A–D) show the following trajectory classes:
Alcohol (Fig. 2A: Class 1 [n=1,323, 17.1%: ‘continued high-level];
Class 2 [n=3,810, 49.4%: ‘continued low-level]; Class 3
[n= 123,015.9%: ‘increasing’]; Class 4 [n= 1,354, 17.6%: ‘de-
creasing’]).
Crack cocaine (Fig. 2B: Class 1 [n= 735, 9.5%: ‘gradual de-
creasing’]; Class 2 [n=924, 12.0%: ‘increasing’]; Class 3 [n=4,576,
59.3%: ‘continued low-level’]; Class 4 [n= 407, 5.3%: ‘continued high-
level’]; Class 5 [n= 1,075, 13.9%: ‘rapid decreasing’]).
Cannabis (Fig. 2C: Class 1 [n= 4,565, 59.2%: ‘continued low-level’],
Class 2 [n=1,834, 23.8%: ‘low and decreasing], Class 3 [n=1,318,
17.1%: ‘high and increasing’].
Unspecified drug use (Fig. 2D: Class 1 [n= 1,047, 13.6%: ‘in-
creasing’], Class 2 [n=5,490, 71.1%: ‘continued low-level’], Class 3
[n=1,180, 15.3%: ‘decreasing’].
3.4. AOD trajectories regressed on heroin use
The distribution of AOD trajectory groups within each of the heroin
use trajectory classes is shown in Table 3. Relative risk ratios (RRR) and
95% confidence intervals (CI) from the multiply imputed multivariable
multinomial regression analyses of the relationship between heroin and
AOD use are displayed in Supplementary Tables 1–4.
For brevity, we focused on the ‘rapid decreasing’ heroin class as the
referent (Model 4, Supplementary Tables 1–4). Members of the ‘con-
tinued high-level’ heroin use class were:
• more likely to be members of the ‘continued high-level’ alcohol class
(21.7% vs 15.5%: RRR 1.24; 95% CI 1.01–1.53), and less likely to be
members of the ‘decreasing’ alcohol use class (12.1% vs 20.4%: RRR
0.57; 95% CI 0.45-0.71);
• more likely to members of crack cocaine ‘continued high-level’
(23.7% vs 0.8%; RRR 58.66; 95% CI 34.23–100.54), ‘increasing’
(17.3% vs 4.5%; RRR 6.45; 95% CI 4.89–8.51), ‘gradual decreasing’
(10.9% vs 3.4%; RRR 5.65; 95% CI 4.09–7.79) classes, were less
likely to be members of the ‘rapid decreasing’ class (8.9% vs 22.3%;
RRR 0.66; 95% CI 0.52–0.84);
• less likely to be members of the ‘high and increasing’ cannabis group
Table 2
Unconditional multilevel latent class growth analysis of alcohol and other drug use over five years (n= 7717).
Post-hoc criteria Class proportion (probability of assignment)
Substance AIC BIC aBIC Entropy VLMR BLRT 1 2 3 4 5 6
Alcohol
Class 1 1035730.70 1035751.55 1035742.02 – – – 1.00 (1.00)
Class 2 596761.37 596810.03 596787.78 0.994 < 0.0001 <0.0001 0.67 (1.00) 0.33 (1.00)
Class 3 518637.67 518714.13 518679.18 0.985 0.293 < 0.0001 0.29 (0.99) 0.51 (1.00) 0.20 (0.99)
Class 4 488513.21 488617.47 488569.81 0.980 0.135 < 0.0001 0.17 (0.99) 0.49 (1.00) 0.16 (0.98) 0.18 (0.98)
Class 5 466197.73 466329.81 466269.43 0.971 0.650 < 0.0001 0.11 (0.97) 0.14 (0.99) 0.12 (0.98) 0.24 (0.97) 0.40 (0.99)
Class 6 450851.39 451011.27 450938.18 0.967 0.200 < 0.0001 0.12 (0.99) 0.11 (0.97) 0.15 (0.95) 0.09 (0.97) 0.14 (0.96) 0.40 (0.99)
Crack cocaine
Class 1 521547.29 521568.15 521558.61 – – – 1.00 (1.00)
Class 2 317093.91 317142.57 317120.33 0.988 < 0.0001 <0.0001 0.27 (1.00) 0.73 (1.00)
Class 3 272328.31 272404.78 272369.82 0.979 0.057 < 0.0001 0.10 (0.99) 0.26 (0.98) 0.64 (1.00)
Class 4 252515.88 252620.15 252572.48 0.974 < 0.05 < 0.0001 0.15 (0.96) 0.08 (0.99) 0.63 (1.00) 0.14 (0.97)
Class 5 241212.70 241344.77 241284.40 0.965 0.210 < 0.0001 0.10 (0.96) 0.12 (0.96) 0.59 (0.99) 0.05 (0.98) 0.14 (0.94)
Class 6 233444.82 233604.70 233531.61 0.958 0.536 < 0.0001 0.05 (0.98) 0.07 (0.96) 0.14 (0.93) 0.09 (0.90) 0.56 (0.99) 0.09 (0.97)
Cannabis
Class 1 938291.53 938312.38 938302.85 – – – 1.00 (1.00)
Class 2 535324.30 535372.95 535350.71 0.994 < 0.0001 <0.0001 0.28 (1.00) 0.72 (1.00)
Class 3 464870.58 464947.04 464912.09 0.988 0.319 < 0.0001 0.59 (1.00) 0.24 (0.99) 0.17 (0.99)
Class 4 432664.99 432769.26 432721.59 0.986 < 0.05 < 0.0001 0.13 (0.98) 0.14 (0.98) 0.60 (1.00) 0.13 (0.99)
Class 5 412930.72 413062.79 413002.41 0.982 0.305 < 0.0001 0.57 (1.00) 0.11 (0.98) 0.09 (0.99) 0.13 (0.97) 0.10 (0.98)
Class 6 397768.05 397927.93 397854.84 0.983 0.103 < 0.0001 0.56 (1.00) 0.07 (0.99) 0.08 (0.98) 0.11 (0.97) 0.11 (0.97) 0.08 (0.98)
Unspecified drug
Class 1 539800.54 539821.40 539811.86 – – – 1.00 (1.00)
Class 2 348344.25 348392.91 348370.66 0.991 < 0.0001 <0.0001 0.27 (0.99) 0.73 (1.00)
Class 3 297333.74 297410.20 297375.25 0.986 0.217 < 0.0001 0.14 (0.99) 0.71 (1.00) 0.15 (0.98)
Class 4 269356.09 269460.36 269412.70 0.985 0.623 < 0.0001 0.69 (1.00) 0.07 (0.99) 0.10 (0.99) 0.14 (0.97)
Class 5 246710.61 246842.68 246782.31 0.981 0.409 < 0.0001 0.68 (1.00) 0.09 (0.98) 0.98 (0.96) 0.99 (0.99) 0.98 (0.98)
Class 6 230945.90 231105.78 231032.69 0.980 0.0187 <0.0001 0.05 (0.99) 0.68 (1.00) 0.05 (0.99) 0.10 (0.95) 0.05 (0.97) 0.06 (0.97)
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; aBIC: sample-size adjusted BIC; VLMR: Vuong-Lo-Mendel-Ruben test; BLRT: bootstrapped
likelihood ratio test.
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(11.0% vs 19.2%: RRR 0.49; 95% CI 0.39–0.62); and
• more likely to be members of the ‘increasing’ unspecified drug class
(17.6% vs 9.7%: RRR 1.70; 95% CI 1.36–2.12).
3.5. Probability of membership in the heroin use trajectory group
Table 4 shows the probability of membership in the heroin use
trajectory group conditional on AOD classes. Among patients classified
as members of ‘decreasing’ alcohol use trajectory, 10% were members
of ‘continued high-level’ heroin non-response class, and 30% were
members of the ‘rapid decreasing’ heroin good response class.
In the ‘gradual decreasing’ crack cocaine use class, 43% were
members of the ‘gradual decreasing’ heroin use class, and among ‘rapid
decreasing’ crack cocaine group, 41% were members of ‘rapid de-
creasing’ heroin use class. Only 1% of the ‘continued high-level’ crack
cocaine use group were members of the ‘continued low-level’ heroin use
class while 67% of this non-responding crack cocaine class were in the
‘continued high-level’ heroin use class. For cannabis, only 10% of the
patients in the ‘high and increasing’ class up were members of the
‘continued high-level’ heroin use class. For the unspecified drug, only
Fig. 2. AOD trajectories over 5 years of continuous OST.
Table 3
Alcohol and other drug use trajectory group membership conditional on heroin use trajectory group.
AOD use trajectory
groups












Continued high-level 283 (17.6) 284 (17.1) 197 (15.2) e 304 (15.5) e 247 (21.7) c,d 1315 (17.2)
Continued low-level+ 769 (47.9) 800 (48.2) 677 (52.2) 965 (49.3) 566 (49.6) 3777 (49.3)
Increasing 247 (15.4) c 312 (18.8) c,d 184 (14.2) a,b,e 288 (14.7) b 190 (16.7) c 1221 (15.9)
Decreasing 305 (19.0) e 263 (15.9) d,e 240 (18.5) e 400 (20.4) b,e 138 (12.1) a,b,c,d 1346 (17.6)
Crack cocaine
Gradual decreasing 317 (19.8) b,c,d,e 197 (11.9) a,c,d 25 (1.9) a,b,d,e 67 (3.4) a,b,c,e 124 (10.9) a,c,d 730 (9.5)
Increasing 169 (10.5) b,c,d,e 368 (22.2) a,c,d 94 (7.2) a,b,e 87 (4.5) a,b,e 197 (17.3) a,c,d 915 (11.9)
Continued low-level+ 793 (49.4) 837 (50.5) 1107 (85.3) 1352 (69.1) 448 (39.3) 4537 (59.2)
Continued high-level 51 (3.2) c,d,e 64 (3.9) c,d,e 5 (0.4) a,b,e 15 (0.8) a,b,e 270 (23.7) a,b,c,d 405 (5.3)
Rapid decreasing 274 (17.1) b,c,e 193 (11.6) a,c,d 67 (5.2) a,b,d,e 436 (22.3) b,c,e 102 (8.9) a,c,d 1072 (14.0)
Cannabis
Continued low-level+ 930 (58.0) 969 (58.4) 760 (58.6) 1133 (57.9) 737 (64.6) 4529 (59.1)
Low and decreasing 391 (24.4) 433 (26.1) c,e 271 (20.9) b 448 (22.9) 279 (24.5) b 1822 (23.8)
High and increasing 283 (17.6) e 257 (15.5) c,e 267 (20.6) b,e 376 (19.2) b, e 125 (11.0) a,b,c,d 1308 (17.1)
Unspecified drug
Increasing 245 (15.3) c,d 248 (15.0) d 159 (12.3) a,e 189 (9.7) a,b,e 201 (17.6) c,d 1042 (13.6)
Continued low+ 1075 (67.0) 1189 (71.7) 934 (72.0) 1464 (74.8) 781 (68.5) 5443 (71.1)
Decreasing 284 (17.7) b,e 222 (13.4) a 205 (15.8) 304 (15.5) 159 (13.9) a 1174 (15.3)
Figures presented in table are number of participants (percentages).
+Represents the base outcome in the from all-case, multiply imputed, multivariable multinomial logistic regression models.
a,b,c,d,e Represent significant statistical differences when different heroin use trajectory groups are used as referent categories (c.f.
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14% of the continued low-level class were members of the ‘continued
high-level’ heroin class and 27% were in the ‘rapid decreasing’ heroin
group.
3.6. Treatment status at the end of Year 7
At the end of Year 7, 4615 (60.3%) were still enrolled in OST.
During Year 6 and 7, 1986 (25.9%) exited treatment unsuccessfully,
and 1058 (13.8%) successfully completed treatment. Among this group,
16.5% (n=175) were re-admitted to treatment in the next six months,
five were incarcerated and one person died from opioid-related poi-
soning. The SCNR outcome was therefore achieved by 877 of 3044
patients discharged from OST (28.8%).
SCNR was most likely to be attained by the ‘rapid decreasing’ heroin
class (39.7%). The ‘continued high-level’ heroin use trajectory group
was least likely to achieve the SCNR (16.2%), followed by the ‘de-
creasing then increasing’ group (19.6%). The ‘continued low-level use’
and ‘gradual decreasing use’ groups had similar levels of SCNR (31.2%
and 31.7%, respectively).
3.7. Impact of AOD trajectory membership on outcome
Table 5 shows the results of the multiply imputed, multivariable,
multilevel logistic regression analyses. Within the ‘continued high-level’
heroin use class, patients with a ‘rapid decreasing’ crack cocaine tra-
jectory had an increased likelihood of achieving SCNR (adjusted odds
ratio [AOR] 1.70; 95% confidence interval [CI] 1.04–2.77). Member-
ship of the ‘increasing’ unspecified drug class was associated with a
decreased likelihood of achieving SCNR (AOR 0.47; 95% CI 0.27–0.81).
Among the ‘decreasing then increasing’ heroin trajectory group, a
decreased likelihood of achieving SCNR was associated with ‘continued
high-level’ alcohol use (AOR 0.43; 95% CI 0.21-0.88), ‘gradual de-
creasing’ crack use (AOR 0.42; 95% CI 0.18–0.96), ‘increasing’ crack
use (AOR 0.50; 95% CI 0.27–0.93) and ‘low and decreasing’ cannabis
use (AOR 0.50; 95% CI 0.28–0.92).
There was a decreased likelihood of achieving SCNR for patients in
the ‘increasing’ crack cocaine class within the ‘gradual decreasing’
heroin use class (AOR 0.22; 95% CI 0.07–0.66) and an increased like-
lihood of achieving SCNR for patients in the ‘rapid decreasing’ heroin
class who were members of the ‘low and decreasing’ cannabis class
(AOR 2.39; 95% CI 1.29–4.40).
4. Discussion
Over long-term continuous OST, we identified five trajectory classes
for use of crack cocaine, four for alcohol, three for cannabis and three
for unspecified drug use. In relation to our aims, each of these four
substances contained an ‘increasing’ trajectory class. We found that the
‘rapid decreasing’ heroin trajectory group was less likely to be re-
presented in both the ‘increasing’ crack cocaine and ‘other drug’ classes
(although there was an increased likelihood of being represented in the
‘high and increasing’ cannabis use group). Membership of the ‘in-
creasing’ crack cocaine class was associated with a decreased likelihood
of achieving the study outcome measure for two of the five heroin
classes, while membership of the ‘increasing’ unspecified drug class was
also associated with a decreased likelihood of achieving the outcome, at
least for the ‘continued high-level’ heroin trajectory group.
4.1. Integration with the literature
Similar to other group based trajectory modelling studies (Grella
and Lovinger, 2011; Teesson et al., 2017), we identified a sub-popula-
tion of OUD patients who do not report a substantial improvement in
drug use. In our study, we demonstrate that these patients are also more
likely to use crack cocaine and alcohol at a higher frequency than other
subpopulations, and the pattern of alcohol and other drug use has a
detectable and negative influence on eventual successful completion of
treatment. Grella and Lovinger (2011) reported that their ‘no decrease’
group was more likely to be represented in the ‘late-onset increase’ of
alcohol and other drug use while Teesson et al (2017) noted that their
‘no decrease’ trajectory group were more likely to live in unstable ac-
commodation, to be imprisoned and to have injection-related health
problems. Taken together, this seems to indicate a subpopulation for
whom multiple problems emerge across several domains.
The increased likelihood of ‘rapid decreasing’ and ‘continued low-
level’ heroin trajectory groups being represented in the ‘high and in-
creasing’ cannabis trajectory group may reflect the potential for use of
cannabis to be associated with a pathway away from use of heroin
during OST (Sifaneck and Kaplan, 1995). Daily cannabis use has also
been associated with less severe heroin dependence, a lowered like-
lihood of daily heroin use and an increasing likelihood of never in-
jecting heroin (Valdez et al., 2008). It is notable, however, that the
increased use of cannabis in these two heroin groups did not confer any
advantage in terms of completing OST successfully. If cannabis use does
Table 4
Probability of heroin use trajectory group conditional on AOD use trajectory group.
AOD use trajectory
groups












Continued high-level 283 (0.22) 284 (0.22) 197 (0.15) 304 (0.23) 247 (0.19) 1315 (1.00)
Continued low-level 769 (0.20) 800 (0.21) 677 (0.18) 965 (0.26) 566 (0.15) 3777 (1.00)
Increasing 247 (0.20) 312 (0.26) 184 (0.15) 288 (0.24) 190 (0.16) 1221 (1.00)
Decreasing 305 (0.23) 263 (0.20) 240 (0.18) 400 (0.30) 138 (0.10) 1346 (1.00)
Crack cocaine
Gradual decreasing 317 (0.43) 197 (0.27) 25 (0.03) 67 (0.09) 124 (0.17) 730 (1.00)
Increasing 169 (0.18) 368 (0.40) 94 (0.10) 87 (0.10) 197 (0.22) 915 (1.00)
Continued low-level 793 (0.17) 837 (0.18) 1107 (0.24) 1352 (0.30) 448 (0.10) 4537 (1.00)
Continued high-level 51 (0.13) 64 (0.16) 5 (0.01) 15 (0.04) 270 (0.67) 405 (1.00)
Rapid decreasing 274 (0.26) 193 (0.18) 67 (0.06) 436 (0.41) 102 (0.10) 1072 (1.00)
Cannabis
Continued low-level 930 (0.21) 969 (0.21) 760 (0.17) 1133 (0.25) 737 (0.16) 4529 (1.00)
Low and decreasing 391 (0.21) 433 (0.24) 271 (0.15) 448 (0.25) 279 (0.15) 1822 (1.00)
High and increasing 283 (0.22) 257 (0.20) 267 (0.20) 376 (0.29) 125 (0.10) 1308 (1.00)
Unspecified drug
Increasing 245 (0.24) 248 (0.24) 159 (0.15) 189 (0.18) 201 (0.19) 1042 (1.00)
Continued low-level 1075 (0.20) 1189 (0.22) 934 (0.17) 1464 (0.27) 781 (0.14) 5443 (1.00)
Decreasing 284 (0.24) 222 (0.19) 205 (0.17) 304 (0.26) 159 (0.14) 1174 (1.00)
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increase the likelihood of OUD recovery, it would be expected to be
associated with treatment completion, though improved treatment
outcomes have not been reported elsewhere (Budney et al., 2002;
Epstein and Preston, 2003). While outside the scope of this paper, it is
interesting to note the emerging evidence base of cannabinoid-opioid
interactions within noradrenergic neural circuitry and the potential for
cannabinoids to influence opioid withdrawal symptoms (Scavone et al.,
2013).
4.2. Strengths and limitations
A key study strength is the national, large-scale follow-up of all
individuals accessing treatment for opioid use disorder in England and
the utilisation of the national outcomes monitoring system to measure
change in heroin and concurrent substance use throughout patients’
long-term enrolment in treatment. This ‘concurrent recovery mon-
itoring’ system (McLellan et al., 2005) is a powerful platform for policy
makers and researchers to efficiently evaluate the effectiveness of
community-based treatment under routine conditions. In addition, un-
like other comprehensive administrative databases (Sahker et al., 2015;
Stahler et al., 2016), the consent model supporting NDTMS enables
linkage with subsequent treatment admissions to provide a measure of
sustained recovery from OUD in patients exiting the treatment system.
Several limitations are also acknowledged: first, while the frequency
of use is captured by the Treatment Outcomes Profile, NDTMS does not
capture the quantity of heroin and other drugs being consumed. It is
possible that analysis of composite frequency by quantity metrics would
yield different substance use trajectories, or that the ‘continued high-
level’ groups do in fact demonstrate improvements in terms of quantity
consumed. Second, NDTMS is a ‘core dataset’ and does not capture
several covariates that may affect trajectory membership, including
treatment motivation (Simpson and Joe, 1993), engagement (Simpson
et al., 1995) and other recovery strengths (Gossop et al., 2002c). Third,
the observational design of this study does not allow inference of
causality. It is not possible to determine whether low-level or reducing
heroin use was caused by increased use of cannabis (or vice versa), or
whether a complex set of causal factors are involved. Finally, it is un-
fortunate that illicit benzodiazepine use is not captured by the TOP.
This remains an important clinical issue in the treatment of OUD and is
reported by a sizeable minority in the English treatment system.
4.3. Clinical implications
Findings from this study and earlier reports underscore the chal-
lenge for OST services to support engagement and recovery for patients
with illicit OUD. If OST does not supress a patient’s heroin use to any
clinically meaningful extent, then there is a likelihood that approxi-
mately 40% will use alcohol or crack cocaine at a consistently high or
increasing level and 1 in 7 will report increasing use of other un-
specified drugs. Helping a patient with heroin and poly-substance use
may be very challenging, but this should be a high priority because of
immediate health needs and because the success of OST is diminished.
Screening for AOD use is recommended at treatment admission and at
regular clinical reviews, which can be a rapid assessment (Ali et al.,
2013), and the assessment of other important aspects of personal and
social functioning should not be overlooked (Marsden et al., 2014).
If there is an unsatisfactory response to flexible dosing, it may be
appropriate to suggest a change in medication (e.g. switching from
methadone to buprenorphine), reinstate supervised administration
(Clinical Guidelines on Drug Misuse and Dependence Update 2017
Independent Expert Working Group, 2017), or offer a targeted psy-
chosocial intervention for opioids (Marsden et al., 2017), alcohol
(Nolan et al., 2016) or cocaine (Marsden et al., 2018) from the service if
there are resources or by referral. Although it may be discouraging that
some patients continue to alcohol and other drugs, treatment may still
offer provide important harm reduction benefits by reducing the risk of
opioid poisoning (Cornish et al., 2010; White et al., 2015) and, taking a
wider societal perspective, there is an overall economic benefit-cost
ratio from investing in OST (Zarkin et al., 2005).
Table 5












Rapid decreasing (n= 813;
SCNR=39.7%)
Alcohol
Continued low-level – – – – –
Continued high-
level
0.47 (0.27,0.82) 0.43 (0.21,0.88) 0.66 (0.33,1.30) 0.75 (0.47,1.20) 1.29 (0.65,2.55)
Increasing 0.59 (0.34,1.01) 0.97 (0.53,1.76) 0.65 (0.34,1.23) 1.31 (0.82,2.08) 0.94 (0.43,2.08)
Decreasing 0.75 (0.46,1.22) 1.06 (0.57,1.97) 0.90 (0.51,1.59) 1.13 (0.76,1.69) 1.00 (0.42,2.39)
Crack cocaine
Continued low-level – – – – –
Gradual decreasing 0.98 (0.60,1.61) 0.42 (0.18,0.96) 0.22 (0.02,2.04) 0.49 (0.18,1.33) 1.15 (0.43,3.04)
Increasing 0.58 (0.29,1.16) 0.50 (0.27,0.93) 0.58 (0.23,1.44) 0.22 (0.07,0.66) 1.13 (0.53,2.41)
Continued high-
level
1.18 (0.47,2.97) 0.86 (0.29,2.55) - a - b 1.23 (0.61,2.50)
Rapid decreasing 1.70 (1.04,2.77) 1.03 (0.54,1.97) 0.59 (0.20,1.77) 1.18 (0.81,1.71) 1.16 (0.41,3.30)
Cannabis
Continued low-level – – – – –
Low and decreasing 0.90 (0.57,1.43) 0.50 (0.28,0.92) 1.15 (0.68,1.95) 1.31 (0.90,1.90) 2.39 (1.29,4.40)
High and increasing 1.30 (0.80,2.12) 1.53 (0.84,2.76) 1.04 (0.59,1.83) 1.44 (0.96,2.17) 1.43 (0.59,3.42)
Unspecified drug
Continued low-level – – – – –
Increasing 0.47 (0.27,0.81) 1.04 (0.55,1.96) 0.70 (0.34,1.43) 0.88 (0.49,1.57) 0.97 (0.47,2.00)
Decreasing 0.84 (0.52,1.34) 1.28 (0.69,2.37) 1.02 (0.54,1.91) 0.70 (0.45,1.11) 0.92 (0.41,2.07)
Adjusted odds ratios for baseline covariates are not shown.
a There were only 3 patients from the ‘continued low-level’ heroin trajectory group who were also in the ‘continued high-level’ crack cocaine trajectory, and these
were removed from analysis.
b There were only 5 patients from the ‘gradual decreasing’ heroin trajectory group who were also in the ‘continued high-level’ crack cocaine trajectory, and these
were removed from analysis.
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4.4. Conclusions
This study highlights the importance of concurrent monitoring of
adjunctive substance use in the treatment of opioid use disorder as a
sizeable minority of patients either increase or maintain a high level of
concurrent drug use and increasing drug use trajectories have a nega-
tive impact on positive outcome. These findings reinforce the concep-
tion of OUD as a complex and chronic condition. The next task for our
research group is to examine the longitudinal inter-relationship be-
tween substance use, employment and housing.
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